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The identification of relevant pathogenetic processes is crucial for the developement of rational 
therapy in rheumatoid arthritis. Several aspects of the function of CD4+ T-cells in the 
rheumatoid synovial compartment remain largely unknown, including the nature of the T-cell 
stimulus, the role and regulation of CD4+ T-cell mediated antigen-specific cytotoxicity, and the 
potential modulatory effects of eicosanoids, present in significant concentrations in the 
rheumatoid synovial compartment, on T-cell effector functions . The aim of this study was to 
address these aspects of T-cells in the immunopathogenesis of rheumatoid arthritis and identify 
novel targets for the therapeutic modulation of CD4+ T-cell effector functions . 
Antigen-induced proliferation and antigen-specific cytotoxic function of peripheral blood and 
synovial fluid mononuclear cells were investigated in a total of 20 patients with seropositive 
rheumatoid arthritis using purified protein derivative of Myocbacterium tuberculosis (PPD) as 
the antigen. Proliferation was determined in a standard in vitro tritiated thymidine incorporation 
assay and cytotoxicity measured in a 5 lchromium release assay, confirmed as a specific 
indicator of CD4+ T-cell cytotoxic function . In vitro findings were correlated with clinical 
data. A significant positive linear relationship between proliferation and cytotoxicity was 
demonstrated in cells from both compartments . Patients were classified according to their 
synovial fluid mononuclear cell proliferative and cytotoxic responses : low or absent 
proliferation and cytotoxicity was associated with significantly longer disease duration, while 
moderate to high levels of both parameters was associated with non-steroidal anti-inflammatory 
drug monotherapy. A novel finding of intact proliferation but impaired antigen-specific 
cytotoxicity was observed in the synovial fluid mononuclear cells of 5 out of 6 patients 
receiving disease modifying therapy. This observation was confined to cells from the synovial 
compartment in these patients, with moderate to high levels of proliferation and cytotoxicity 
demonstrated in autologous peripheral blood mononuclear cells . 
The potential mechanisms for these findings were explored by investigating the in vitro effects 
of several disease modifying agents and prostaglandin E2 on proliferation and cytotoxicity of 
peripheral blood mononuclear cells from normal controls . In addition, prostaglandin E2 
production by CD 14+ synoviocytes from the patients was quantified in cell supematants using 
a commercial radioimmunoassay and correlated with proliferative and cytotoxic reponses 
demonstrated previously. The data obtained indicate that impaired synovial CD4+ T-cell 
mediated cytotoxicty in the setting of intact proliferative responses may be due to the 
suppressive effects of prostaglandin E2. Thus, in addition to providing functional evidence of 
the cytotoxic potential of the CD4+ T-cell infiltrate in rheumatoid synovium, these findings 
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highlight potential regulatory mechanisms of this function, with clinical and therapeutic 
correlations. 
The mechanism of prostaglandin E2 inhibition of CD4+ T-cell cytotoxicity and the effects of 
this agent and other eicosanoids on CD4+ T-cell effector functions and phenotypic expression 
were investigated further. Studies were performed in vitro using bulk peripheral blood 
mononuclear cells from normal individuals, and panels of CD4+ T-cell clones from the 
synovium of three patients with inflammatory synovitis and the circulation of a healthy control. 
CD4+ T-cell clones were isolated by limiting dilution cloning of T-cell lines generated from 
synovial explants of the patients or the peripheral blood mononuclear cells of the healthy 
control. Cloning was performed using both specific and non-specific stimuli . Prostaglandin E2 
inhibition of antigen-specific cytotoxicity was demonstrated in polyclonal peripheral blood 
mononuclear cell effectors and in the panel of CD4+ T-cell clones . Misoprostol (a 
prostaglandin El analogue) and forskolin (a cyclic AMP agonist) also displayed inhibitory 
effects on the clones . Inhibition of both binding and post-binding events by PGE2 was indicated 
by data from lectin-dependent and antigen-specific cytotoxicity assays . Conversely, moderate 
but significant augmentation of cytotoxicity by leukotriene B4 and C4 was observed in the 
clones . Modulation of CD4+ T-cell cytotoxicity by the eicosanoids tested was mainly due to 
effects on calcium-dependent pathways of cytotoxicity. Reciprocal effects of prostaglandin E2 
and leukotrienes on interferon-y production by the clones was also demonstrated . This study 
provides a novel illustration of the regulatory effects of eicosanoids on CD4+ T-cell 
cytotoxicity and confirms and e>..1:ends previous reports of the regulatory effects of these agents 
on cytokine production. In addition, the findings indicate the potential to modulate CD4+ T-cell 
function at a chronic inflammatory site by therapeutic manipulation of local eicosanoid 
synthesis . 
The observation of dissociated proliferation and cytotoxicity (proliferation in the absence of 
cytotoxicity) in synovial fluid mononuclear cells of a subset of rheumatoid arthritis patients, 
and in normal peripheral blood mononuclear cells assayed in the presence of prostaglandin E2, 
suggested that these functions of CD4+ T-cells may be independently regulated . This 
hypothesis was tested by measuring a range of morphologic, phenotypic and functional 
parameters of a panel of 6 CD4+ T-cell clones as a function of time following a single 
initiating stinmlus. Morphologic, phenotypic and cell cycle analyses were performed by flow 
cytometry, and cytokine concentrations of cell supematants quantified using commercial kits . 
Dissociation of functions was noted, with maintenance of cytolytic potential independently of 
other parameters . These findings provide evidence, at a clonal level, of the separate regulation 
of cytotoxicity in CD4+ T cells and demonstrate that CD4+ T-cells retain cytolytic potential 
irrespective of their size, activation status, cell cycle progression or cytokine production. Based 
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on these in vitro observations, it is possible that the rheumatoid synovial CD4+ T-cell infiltrate 
may retain cytolytic potential in vivo, despite their small size and paucity of cytokine 
production. In addition, the different kinetics of effector pathways in CD4+ T-cells suggests the 
possibility of independent therapeutic modulation of effector functions . 
Previous reports have suggested that mycobacterial antigen reactivity of synovial fluid 
mononuclear cells in rheumatoid arthritis may have aetiological significance. In this study, the 
specificity of mycobacterial antigen reactivity in rheumatoid arthritis was investigated in 
patients and controls drawn from a population where tuberculosis has been endemic for several 
decades . The data demonstrate that in this population, mononuclear cell reactivity to purified 
protein derivative of Mycobacterium tuberculosis is a non-specific phenomenon, observed with 
similar frequency in rheumatoid arthritis patients and the control non-rheumatoid inflammatory 
synovitis patient group, and with similar kinetics of proliferation in both patient groups . In 
addition, PPD-specific cytotoxicity was also demonstrated in synovial fluid mononuclear cells 
and CD4+ T-cell clones from the control patient group. Interestingly, the frequency of 
peripheral blood mononuclear cell reactivity to a recombinant 65kDa heat shock protein of 
Mycobacterium bovis (HSP65) in PPD-responsive rheumatoid arthritis patients was 
significantly lower than that found in PPD-responsive healthy controls, and specific localisation 
of HSP65 reactive T-cells to the site of acute synovial inflanm1ation was found in a patient 
with gout. Given current theories on the potential immunoregulatory role of HSP65 reactive T-
cells, these observations may have pathogenetic significance for rheumatoid arthritis . 
Explants of synovial membrane from patients with rheumatoid arthritis and other arthritides 
were cultured under conditions that favour the growth of in vivo activated T-cells . Prolonged 
out-growth of T-cells from synovial explants passaged repeatedly in the presence of 
recombinant interleukin-2 (lOOiu/ml) was confined to rheumatoid synovium. Phenotypic and 
functional characterisation of the synovial explant-derived T-cell lines was perfonned. Synovial 
membrane was subject to SDS-polyacrylamide gel electrophoresis and proliferative responses 
of synovial T-cell lines to autologous synovial constituents investigated using a T-cell 
immunoblot technique. Clustering of responses to a 114-142 kDa component of autologous 
synovium was found in 5 out of 6 patients with rheumatoid arthritis , but not in control patients . 
Components of extracellular matrix proteins, including collagen and fibronectin, were 
demonstrated in the stimulatory fraction of synovium by western blotting, and cross reactivity 
between this fraction and type I collagen found in a T-cell line from a single patient. 
This study therefore contributes to the understanding of the function and regulation of CD4+ T-
cells at the site of pathology in rheumatoid arthritis and indicates novel targets for the 
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Chapter 1 Literature Review 
1. INTRODUCTION 
Identifying the aetiological agent(s) and the pathogenetic mechanisms involved are critical for 
the development of rational therapy for rheumatoid arthritis (RA). Recent progress in the 
comprehension of fundamental mechanisms in immunology may have considerable implications 
for RA and herald the advent of a new generation of anti-rheumatic agents . This review 
encompasses a spectrum of clinical and scientific publications that provide the background and 
indicate recent developments in the understanding of the immunological processes involved in 
the pathogenesis of RA, and their potential therapeutic relevance. 
2. CLINICAL FEATURES 
2.1. Epidemiology 
The global prevalence of rheumatoid arthritis is estimated to be in the order of l % of the adult 
population, affecting females predominantly1. Geographical variations in the prevalence and 
severity of disease have been reported2; with particular relevance to southern Africa, there has 
been a perception that RA is rare in black Africans3. Earlier reports , on which this perception 
is based, may have failed to take into account the lack of accessible clinics or hospitals for 
many disabled patients. More recent epidemiological surveys have revealed that the prevalence 
of RA in urban black African populations is similar to that reported from the northern 
hemisphere4; however, considerable variation in prevalence rates have been reported in studies 
of rural African populations (0.1 % to 3.0%)5,6,7 . Higher prevalence rates associated with 
urbanisation may reflect increased population densities and suggest a transmissible aetiological 
agent. Historical record and studies of skeletal remains of native North Americans also indicate 
the possibility of an infectious agent as the cause of RA 8. 
2.2 Morbidity and mortality 
RA can affect any diarthrodial joint, but typically presents as a symmetrical polyarticular 
inflammatory arthritis involving joints of the hands, wrists, knees and feet9. Extra-articular 
manifestations occur with variable frequencies and may include abnormalities of virtually 
every major organ system9. There is now considerable evidence that the severity of rheumatoid 
arthritis has been underestimated, largely due to the application of diagnostic criteria in the 
past that failed to distinguish between different fonns of the disease in population studies 1° . In 
clinical settings, the application of the revised criteria in studies performed shows that 
rheumatoid arthritis is associated with significant mortality and rare spontaneous remissionsll . 
Accelerated mortality rates in patients with RA have been noted in several studies and are 
similar to mortality rates in patients with triple vessel coronary artery disease or Hodgkin's 
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lymphomal2 _ Maximal joint destruction occurs early, within the first two years of disease 
onsetl3 . Hospital-based studies from southern Africa have shown similar disease severity 
among black RA patients when compared to patients of other race groups in other settings14,15 . 
The disease has substantial economic impact; in addition to the high costs of medical care, fifty 
per cent of those working at the time of diagnosis will be unemployed within 10 years 16. 
Several markers that predict a particularly poor outcome in patients with RA are known, and 
include: high titres of rheumatoid factor, subcutaneous nodules, early bone erosions, 
polyarticular onset of the disease, older age onset and level of formal education17. Recent 
studies have shown that the combination of HLA DR4 (DRl), positive rheumatoid factor and 
persistent elevation of CRP indicate a poor prognosis in patients who satisfy the revised ARA 
classification criteria 1 s, 19 . 
3. PATHOLOGY 
The pathogenic processes in RA are essentially, but not exclusively, centred in the synovial 
membrane and surrounding structures of diarthroidal joints . Normal diarthroidal joints are 
lined by a superficial layer of synvoiocytes l - 3 cells deep, in a bed of loose vascular 
connective tissue20 . Synoviocytes have been classified into types A and B according to their 
appearance, phenotypic characteristics and suggested function and lineage. Type A 
synoviocytes have an appearance suggestive of phagocytic function and are thought to be bone-
marrow derived cells of macrophage lineage21 . Type B synoviocytes contain a rough 
endoplasmic reticulum and Golgi appartus, suggestive of a secretory function, and are thought 
to be specialised mesenchymal cells of fibroblastic origin22. 
Synovial membrane undergoes dramatic changes during the course of RA. Early disease is 
characterised by synovial hypertrophy with a predominant increase in type A synoviocytes, 
although local proliferation of type B synoviocytes may also occur23,24. These changes are 
accompanied by neovascularisation, a range of vascular abnormalities, and subintimal 
infiltration of lymphocytes which typically form perivascular aggregates25,26,27,28 _ At the 
junction of synovial membrane and cartilage a wedge-shaped tongue of synovial tissue 
extending over cartilage has been described and termed pannus20 . Synoviocytes in this area, 
particularly those of fibroblastic origin, have a transformed appearance typified by expression 
of ras and myc oncoproteins29,30 . In addition, clusters of immature polyhedral cells with large 
folded nuclei may be found at the site of synovial attachment20. As the disease progresses, 
cartilage and subchondral bone is progressively invaded and destroyed, with increasing villus 
hypertrophy of synovial membrane31 . Other cells present in synovium include natural killer 
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(CD16/CD57+) and dendritic cells (CD14/CD44+); the latter cell type may appear similar to 
classical follicular dendritic cells found in lymphoid follicles and germinal centres and have 
enhanced antigen processing functions27,32 . Polymorphonuclear neutrophils (PMN) are rarely 
found in synovial membrane in established disease but are the predominant cellular constituent 
of synovial fluid31 . End stage rheumatoid arthritis is characterised by loss of cartilage and bone 
with progressive fibrous ankylosis, accompanied by reduction in vascularity and cellularity31 . 
3 .1 Cellular products 
A wide range of enzymes, cytokines, growth factors and inflammatory mediators have been 
described in the rheumatoid synovial compartment (TABLE 1.1). 
TABLE 1.1. Cellular products identified in rheumatoid synovial compartments* 
CELLULAR CYTOKINES & GROWTH FACTORS ENZYMES I 
SOURCE OTHER 
Monocyte/macrophage or ILi, IL6, IL8, 1NFa, CSF-1 / MCSF, IFNa, GM-CSF, Eicosanoids, Collagenase, neutral 
type A synoviocyte EGF, acidic and basic FGF, Insulin-like growth factor, proteinases, MMP -I -2 -3, 
PDGF, TGFP , stromelysin, TIMP, collagen 
Fibroblast or type B ILi, IL6, IL8, GM-CSF, MCSF, TGFp, Collagenase, neutral proteinases, MMP 
synoviocyte -I -2 -3 , stromelysin, TIMP, collagen 
Endothelial cells ILi , IL8, GM-CSF, MCSF, FGF, PDGF, TGFp heparinase, plasmin, tissue plasminogen 
activator 
Platelets FGF, PDGF 
I-lymphocyte IL2, IL6, 1NFa, IFNy, GM-CSF, TGFp perforin, granzymes 
B-lymphocyte / IL6, Inununoglobulin 
plasma cell 
* Table adapted from refs 27,33,34,35 
IL(n) - interleukin(n); lNFa - tumour necrosis factor a ; CSF-1 - colony stimulating factor; MCSF - macrophage 
colony stimulating factor; IFNa - interferon a; GM-CSF - granulocyte macrophage colony stimulating factor; 
EGF - epidermal growth factor; FGF - fibroblast growth factor; PDGF - platelet-derived growth factor; TGFP -
transforming growth factor p; MMP (n) - matrix metalloproteinase (n); TIMP - tissue inhibitor of matrix 
metalloproteinase. 
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3 .2 Lymphocytic infiltrate 
The lymphocytic infiltrate in the subintimal layer of synovium includes CD4, CD8 and y8 T-
cells and B-cells and plasma cells28,36 . CD4 T-cells with memory phenotype (CD29+ and 
CD45RO) predominate and are typically described as clustered around monocyte/macrophages 
or dendritic cells37,38,39,40. Significant quantities of CD4 T-cells are also found in synovial 
fluid, although the proportion of CD4:CD8 T-cells may differ from that found in synovial 
membrane41 . Cytolytic mediators, granzymes and perforins, within the cytoplasm of synovial 
CD4 and CD8 T-cells have been described in RA 42,43 . Evidence of CD4 T-cell activation 
include upregulated expression of HLA DR, soluble IL2 R, VLA -1 , VLA-4 and CD69 and 
down-regulated expression of CD2 and CD3 28,44,45 ,46,47,48,49 . The presence of CD4 T-cell 
derived cytokines or messenger RNA, although often difficult to detect and somewhat 
controversial, has also been cited as evidence of CD4 T-cell activation50,5 i , 52. Oligoclonality 
ofT-cell receptor expression in RA synovium is also controversial. Preferential usage of VP 14 
and VP 2 have been reported, but may reflect in vitro manipulation of cells53,54,55,52 _ 
Histological appearances of RA synovial membrane similar to a secondary lymphoid organ or 
indistinguishable from tuberculosis have been described, and, in the case of the latter, led to the 
use of gold therapy in RA 56,57_ 
4. AETIOPATHOGENESIS 
It is widely accepted that the cause of RA is multi-factorial, and that a variety of events and 
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4 .1 . Infectious agents 
There is evidence from epidemiological studies that suggests a transmissible agent as the cause 
of RA (see section 2.1). In addition, investigation of RA in monozygotic twins has indicated 
that genetic factors contribute in the order of 30% to the development of the disease, thereby 
implying an important role for environmental factors in its pathogenesis58 . A wide variety of 
micro-organisms can indeed cause inflammatory arthritis [TABLE 1. II]; in some cases the 
arthritis may closely resemble RA. 
TABLE l.II. Infectious aetiological agents of arthritis* 
MULTIPLY LOCALIZE TO JOINT OUTSIDE DIRECT TOXIC 
WITHIN JOINT JOINT EFFECT 
Pyogenic bacteria Borrelia burdorferi Rheumatic fever / Arbovirns 
streptococci 
Mycobacteria Mycoplasma Shigella 
Fungi Rubella Salmonella 
Virnses: small pox Herpes Yersinia 
Hep. B (in inunune complex) 
Mycoplasma (in inunune complex) 
? Reactive arthritis 
* Table adapted from59 
Several infectious agents have been implicated in the pathogenesis of RA [TABLE 1.111] . 
These associations have resulted from either the isolation of the organism, its antigens or DNA 
from joints (or other sites, including blood and stool) of RA patients, or the identification of 
elevated or persistent immune responses to the organism or its components . In some studies 
control samples from the joints of OA patients have also yielded evidence of foreign antigens60 . 
Thus the presence of a foreign microorganism or its antigens at the site of pathology are not 
necessarily indicative of a causative association in the disease process . Shared clinical and 
laboratory features of infections by slow-growing microorganisms and RA have also been cited 
as evidence for a role of infectious agents in the aetiology of the disease6 1. 
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Mycoplasma66 Epstein-Barr Virus67 
Mycobacteria68 Parovirus69 
Streptococci 70 Retroviruses 7 l 
Rubella 72,73 
In order to define a causative association between a microorganism and a disease, fulfilment of 
Koch's postulates is required. These postulates include: (i) isolation of the microbe from an 
infected host, (ii) identification of the microbe by culture or direct methods and (iii) transfer of 
the microbe to a susceptible host, human or animal, results in similar symptoms of disease74 . 
The difficulty in fulfilling these postulates to define a causative association between Borrelia 
burdorferi and Lyme arthritis may have implications for identifying an infectious cause of 
RA 75 . In particular, the causative agent of Lyme arthritis remained undetected for several 
decades, and B. burgdoferi is infectious only in the minority of cases. 
4 .1.1 Current models of infectious agents in the pathogenesis of RA 
Several models have been proposed to address the potential pathogenic mechanisms involved in 
the association between infectious agents and RA. [Figure 1.2) Although indicated as separate 
models, a combined mechanism involving aspects of persistent local infection, molecular 




• Persistent Infection ! 
~ secondary immune 
phenomena 
FIGURE 1.2 
Current paradigms of the 
cross-reactive T-cells infectious aetiopathogenesis 










of rheumatoid arthritis. 
(References indicated in text) 
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a) Persistent infection: the persistent presence m the synovial compartment of a foreign 
microbe, either actively replicating or in a latent phase of growth, may result in persistent local 
immune activation and chronic inflammation. Lyme arthritis and possibly reactive arthritis, 
where the antigens of microorganisms can be identified within the synovial compartment, are 
examples of this 'permanent hit' modeI74,76 . At present there is no consistent evidence of 
microbes in RA joints, although limitations of isolation techniques may partly be responsible. 
It has been suggested that PCR technology will contribute considerably to the identification of 
infectious agents, particularly viruses, in RA 77. Retroviral-like particles have been identified in 
synovial fluid samples of a small number of RA patients71 . Their discovery has led to the 
suggestion that retroviral activation of fos and myc oncogenes in synoviocytes may be an 
important initiating event in RA, leading to the transformation of synoviocytes into an 
aggressive invading component of pannus, and giving rise to a secondary immune response34. 
b) Molecular mimicry: this paradigm invokes triggering of an immune response by an initial 
infection, which may subsequently be cleared. However, the activated immune response may be 
maintained by the recognition of self components with similar (cross-reactive) antigenic 
structures to the initiating pathogen or its products 78. Cross-reactivity between bacterial 65kDa 
heat shock proteins (HSP65) and human 60 kDa heat shock proteins or between EBY 
glycoprotein and HLA DR4 have been proposed as important pathogenic mechanisms that 
conform to this paradigm of RA79,67. The role of HSP65 in RA is controversial and is 
discussed in the review on mycobacteria and RA (pg. 11) and in chapter 5 (pg. 126) . A short 
sequence of homology between HLA DR4 and EBY glycoprotein gpl 10 has been identified, 
but its potential role in the pathogenesis of RA, particularly activation of CD4 T-cells, requires 
further delineation 74. 
c) Superantigen stimulation: Given the ability of superantigens to activate a large proportion 
of T-cells in a non-specific manner (figure 1.3), a potential role for these bacterial and viral 
products in the pathogenesis of RA has been suggested&o. Stimulation of quiescent but 
potentially autoreactive T-cells, which clearly exist in normals, may give rise to persistent 
autoimmune T and B-cell responses81 ,82,83 . Restricted TCR YP usage has been reported in 
synovial T-cells in RA, and suggested to be indicative of prior superantigenic stinmlation84,53 . 
However, the fmding of restriced TCR YP usage in RA synovium is not universal54_ In 
addition, the effect of prior superantigenic stimulus on subsequent antigen-specific responses 
by T-cells is unclear; anergy or unresponsiveness may be the result85,86_ Conversely, evidence 
from an animal model of autoimmune disease indicates that a superantigen is capable of 
causing disease relapse, thereby implying intact in vivo function of post superantigen-
stimulated T-cells83. 
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FIGURE 1.3 B cell 
Superantigenic stimulation of T 
cells. Binding of a specific region 
of the V/3 chain, distinct from the 
peptide binding groove, may 
activate a population of T cells 






(figure reproduced from 80) Tcell 
4.1.2. Reactive arthritis : implications for RA 
Classical reactive arthritis is usually defined as inflammatory arthritis that occurs 
approximately four weeks following infection by a specific microorganism, with a typical 
pattern of involvement, systemic features and strong HLA class I association87 . Wider 
definitions have included rheumatic fever and Lyme disease, and reactive arthritis shares 
several conunon features with other spondarthropathies including psoriatic arthritis and 
ankylosing spondylitis88. Indeed, it has been suggested that ankylosing spondylitis is a form of 
reactive arthritis caused by Klebsiella89_ 
TABLE I.IV. Differences between RA and reactive arthritides* 
RA Reactive Arthritis 
Microbiological organisms recognised No Yes 
Peripheral joint destruction Typical Rare 
Sacroiliac involvement None Frequent 
Association with skin infections None Frequent 
rheumatoid factor production Frequent None 
Response to antibiotic treatment None Yes 
HLA linkage Class II, DR4 Class I, HLA B-27 
Clinical course upon HIV infection Remission Severe 
*Table reproduced from 74 
While there are several distinct differences between classical reactive arthritis and RA 
(TABLE I.IV), similarities in the histological appearance of synovium have been noted90 . In 
common with RA, the pathogenesis of reactive arthritis would appear to involve an 
environmental trigger in individuals with a genetic predisposition (HLA association), leading to 
cellular and humoral inunune activation and the development of chronic inflammatory 
10 
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arthritis88 . Earlier theories invoked antibody cross-reactivity between microbes and HLA-B27 
as a mechanism for the persistent immune activation, although this does not explain 
localisation to synovial joints91 _ Recent studies have indicated the presence of inciting 
organisms in the joints, usually in low numbers and perhaps latent forms92 . The distinction 
between reactive and septic arthritis may thus be a function of the intra-articular pathogen load 













Reactive and septic arthritis 
may represent extremities of 
a continuum that reflects 
the rate of intra-articular 
multiplication of the 
initiating infectious agent 
Mycobacteria and RA have had a long and complex association. Historically gold therapy was 
first used to treat RA based on similarities in histological appearance of RA and tuberculous 
tissue, and its perceived beneficial effects when used to treat RA patients with tuberculosis57 . 
Mycobacteria are capable of causing inflammatory arthritis in both experimental animal 
models and in humans . Immunization of susceptible strains of laboratory rodents with dead 
Mycobacterium tuberculosis in oil (Freund's adjuvant) causes progressive polyarthritis of 
small joints of extremities and extra-articular phenomena, an experimental disease tem1ed 
adjuvant arthritis93,94. Although there are some important differences, adjuvant arthritis has 
been widely accepted as a laboratory model of RA. Transfer of the disease to naive rats can be 
achieved using T-cell clones specific for aminoacids 180-188 of the HSP65 of M tuberculosis 
that cross-react with cartilage proteoglycan95 . Interestingly, prior inmmnisation with this 
peptide or the whole HSP65 , can also confer protection against the development of adjuvant 
arthritis or other animal models of autoimmune diseases96,97 ,98 . 
In humans, Mycobacterium tuberculosis infection can cause septic arthritis, with bacilli 
readily identifiable in affected joints, usually axial skeleton or single peripheral joints99. Rarely 
a reactive-type polyarticular inflammatory arthritis, without identifiable intra-articular bacilli 
11 
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and similar to RA can occur in individuals with tuberculosis, and has been termed Poncet's 
diseaseIOo,101,102_ BCG immunization or therapy for bladder cancer has also been associated 
with the development of inflammatory arthritis 103 . 
Several features shared by RA and the mycobacterioses have been cited as evidence for a 
causative association [TABLE 1. V]. Further evidence has included proliferative and cytotoxic 
responses of RA synovial T-cells to mycobacterial antigens, including HSP65 , and the 
identification of mycobacterial antigens in synovial joints1o4,1os,106,107,68 _ In addition, yo T-
cells specific for HSP65 have also been identified in RA synovial fluid 108. Thus it was 
suggested that T-cells activated by mycobacterial HSP65 may cross-react with the human 
homologue, present in significant amounts in affected joints, thereby leading to a persistent 
autoimmune response 109. However, the role of mycobacteria in the pathogenesis of RA is not 
clear; recent evidence has indicated that mycobacterial antigen-reactivity is not specific to RA, 
but is a feature of chronic inflammatory sites of diverse aetiology110. It has also been suggested 
that lower than normal responses to HSP65 in RA, found in a recent study, may be relevant to 
the immunopathogenesis of the disease111 . 
TABLE l.V. Shared features of rheumatoid arthritis and the mycobacterioses* 
Lesions Systemic illness 
Synovitis 
Skin nodules with eosinophilic necrosis 
Abnonnal alveolar lavage 
Inununogenetics Partly genetic, some HLA links 
Possible restricted usage of I-cell receptor Vj3 sequences 
Different incidences in males and females 
Serology f rheumatoid factor 
f autoantibodies 
tagalactosyl IgG 
f antibody to mycobacterial HSP65 
Serological changes in spouses 
Epidemiology Transmission of disease more to children than to spouse 
Cause is about 70% environmental (ca 30% genetic) 
Skin-test responses .J..response to conunon mycobacterial antigens 
iresponse to tuberculin in DR4+ (RA and leprosy) 
Endocrinology Improvement in pregnancy and worsening post partum 
Defective cortisol response 
Table reproduced from 111 
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4.2. Genetic Predisposition 
Classical genetic studies have indicated that a genetic component is relevant in the pathogenesis 
of RA. One third of the overall inherited risk has been ascribed to sex and an equal proportion 
to HLA haplotype112 . 
4.2.1 HLA and RA 
A strong association between RA and HLA-DR4/DR1 subtypes has been found in most 
populations studiedll3,ll4,115,116_ In addition, DR4 homozygosity has been associated with 
juvenile RA, Felty's syndorme and severe adult RA117,118,119. The molecular basis for the 
association has been addressed in the shared epitope hypothesis120. DR4, DRl and DR6 
subtypes associated with RA share a common pentapeptide in the third hypervariable region of 
the HLA-DR-P-1 chain, a region that lines the peptide binding cleft of the HLA molecule, and 
may thus influence the nature of the peptide being presented to CD4 T-cells121 ,122. Additional 
functions of class II HLA in shaping the T-cell repetoire and as a ligand for superantigens may 
have relevance in the association of HLA-DR4 and RA123,124,125 . However, DR subtypes with 
the shared epitopes are found in 45% of caucasian populations without RA and the short arm 
of chromosome 6 contains approximately 70 other genes, in addition to HLA genes, which may 
exhibit linkage disequilibrium with DR4 subtypesl26,127. In particular, transporter proteins 
encoded by the T AP2 gene localised to this region may have relevance in RA 112. Cytokine gene 
polymorphism may also contribute to the inherited risk for the development of RA 128. 
4.3 Angiogenesis 
Cartilage in normal diathroidal joints is avascular129. In early RA neovascularisation is a 
prominent feature in pannus tissue, and may contribute to the maintenance of the chronic 
inflammatory state by several mechanisms29 . These mechanisms include the ability of 
endothelial cells to regulate the inflammatory cell influx and produce several soluble factors 
that have local effects on these cells130,rn ,132,133, 134. Normally angiogenesis is tightly 
regulated by a dominance of inhibitory over stimulatory factors . The neovascularisation that 
occurs in RA pannus may represent a shift in favour of stimulatory factors that include 
heparin-binding growth factors , angiogenin, ILl , IFNa and TGFpm. It has been suggested 
that a cartilage-derived matrix metalloproteinase inhibitor that is responsible for the inhibition 
of angiogenesis in nom1al cartilage may have therapeutic relevance in RA 136. 
4.4 Cytokine-hypothalamic-piturity-adrenal axis (C-HPA axis) 
The endocrine and immune systems have complex interactions that combine to regulate the 




inflammatory cytokines may be important in the control of an acute inflam
matory response 
(FIGURE 1.5) . Evidence for endocrine involvement in the pathogenesis of
 RA includes the 
female preponderance of the disease and the influence of pregnancy and post
partum period on 
disease activity, although the precise role of sex hormones remains unclear
138. Small animal 
models of autoimmune diseases are uniformly associated with abnorm
alities in HP A 
function 139 . Abnormalities in HPA function in RA have also been noted
, and have been 
ascribed to hypothalamic dysfunction
140. The defect results in subnormal cortisol secretion, 
causing an imbalance favouring the immune stimulatory effects of prolactin 
over the immuno-
suppressive effects of corticosteroids
141 . Given the differential susceptibility of CD4 T-cell 
subsets to cortisol, normal secretion of this hormone favours a Th2 response 
that is capable of 
inhibiting rheumatoid synovitis by IL4 production 1
42 . Subnormal cortisol secretion in response 
to infection or other initiating stimuli may result in prolonged Thi responses .
 A possible role 
for dehydroepiandrosterone (DHEA) in opposing glucocorticoid effects an
d promoting Thi 

































4.5 Other factors that mediate joint damage 
ACTH - adrenocorticotrophic 
hormone; GH growth 
hormone; LH - leutinizing 
hormone; TSH thyroid 
stimulating hormone 
IL1 secretion indicated refers to 
macrophage and fibroblast 
secretion and not T-cell. 
(references indicated in text) 
A state of relative hypoxia can occur within rheumatoid joints. Progressive
 accumulation of 
fluid causes marked intra-articular hypertension, reducing blood flow 
to hypertrophied 
synovium and leading to ischaemia and focal infarction
31. It has been suggested that 
reperfusion injury may contribute significantly to joint damage in RA145,
146. Free radicals 
released by activated macrophages, granulocytes or endothelial cells may m






Earlier models of the pathogenesis of RA focused on the role of rheumatoid factor p
roduction 
by B-cells and invoked immune complex-mediated damage as a prime pathogenetic m
echanism 
in rheumatoid jointsl48. Current paradigms favour complex interactions, mediated b
y a wide 
range of soluble factors, between T-cells, monocyte/macrophages and synoviocytes
20,33,34,35,52 . 
The relative importance of each cell type and its products in initiating and perpetu
ating the 
disease process is the subject of considerable debate20,33,
52,149. 
5.1 . T-cells in RA 
5 .1 .1 Evidence for a role in RA 
There is a substantial body of evidence that supports a role for T-cells in the pathog
enesis of 
RA. CD4+ T-cells are a significant component of the cellular infiltrate in rheumatoid s
ynovium 
and their typical perivascular aggregation and expression of surface markers compatib
le with a 
state of activation (see earlier) have been cited as indications of their role in RA
52 . Further 
evidence includes the strong HLA class II association with RA, especially in view o
f current 
understanding of the role of class II molecules in peptide presentation to CD4 T-ce
lls112,122 . 
The presence of T-cell cytokines is somewhat controversial, although it would appear 
that IFN-
y and IL2 messenger RNA in RA synovium can be detected with the use of the po
lymerase 
chain reaction (PCR)35 . 
Several parallels have been drawn between models of diseases with known antigen-d
riven T-
cell participation and RA35,52,149 . Rheumatoid synovium and tuberculous tissue may
 have 
similar immunohistological appearance
57. In tuberculosis, tuberculoid leprosy and 
leishmaniasis, T-cells specific for the inciting antigen occur in low frequencies at th
e site of 
pathology, such that the detection of oligoclonality by current techniques w
ould be 
difficult150,1s1 ,1s2. In addition, the majority of T-cells from tuberculous effusions ar
e not 
activated, according to IL2-R and HLA-DR status, and are in the GO-G 1 phase of the cel
l 
cycle [P . T. Lukey, personal communication]. The detection of oligoclonality or limited T-
cell 
receptor usage of T-cells from RA joints has yielded conflicting results and in the lig
ht of the 
above would appear unnecessary as evidence of their role in the disease
35. 
Therapeutic manipulation of CD4 T-cells modulates the disease. IL-2 therapy for ma
lignancy 
has been associated with reactivation and flares of RA 
153. Thoracic duct drainage, total 
lymphoid irradiation and lymphocytopharesis cause significant improvement in
 disease 
activity154,155,156 . In addition, Cyclosporin A and monoclonal antibodies directed at v
arious 
antigens on CD4 T-cells may have similar beneficial therapeutic effects in RA157,1
ss. It has 





of the role of CD4 T-cells in the disease although effects of HIV on other immune functions 
may be relevant34. Evidence of T-cell involvement in several experimental animal models of 
arthritis has also been cited in support of a role for T-cells in RA
52,149 . Perhaps the most 
compelling indications come from adoptive transfer experiments in which even small numbers 
of CD4 T-cell clones are capable of transferring adjuvant arthritis to otheiwise healthy 
animalsl59,160. 
5.1.2. The nature of the T-cell stimulus 
Candidate antigens: While there is evidence to support the hypothesis that RA is an antigen-
driven, T-cell mediated disease, the nature of the rheumatoid antigen remains elusive. Locally 
sequestered microbial antigens or persistent infection may implicate foreign antigens as the 
source of the T-cell stimulus (see infectious causes)7
4,161. Alternatively, self-reactive T-cells, 
activated non-specifically or by cross-reactive microbial antigens, may be relevant. While 
clonal deletion may exclude most potentially self-reactive T-cells in the thymus, it is evident 
that many autoreactive cells escape this mechanism. Potentially auto-reactive T-cells to several 
immunologically 'noisy' proteins have been identified in normal individuals, including responses 
to myelin basic protein, heat-shock proteins, acetylcholine receptor and thyroid 
peroxidasel62,163,164,165 . These findings appear to be confined to in vitro studies, and 
autoreactive T-cells may be suppressed in vivo in normals by several potential mechanisms, 
loosely termed peripheral tolerancel65,166. Peripheral tolerance may be the result of anergy or 
apoptosis of autoreactive cells when stimulated by their specific antigen, or may be due to a 
network of complex regulatory pathways167,168,169,170,171 . In any event, activation of T-cells 
that react to self antigens in vivo may require disruption of tolerance mechanisms. Several self-
antigens have been proposed as the rheumatoid auto-antigen, including native type II collagen, 
cartilage proteoglycan and as yet unspecified chondrocyte antigens 172,173,174, I 75 . T-cell 
responses to type II collagen have been demonstrated in RA176 . However, the Jack of DR-
restriction of collagen-reactive T-cells and the suggestion that pepsin contaminants may have 
been responsible for some of the earlier findings raise some doubts about collagen as the 
rheumatoid antigen176,177. The immunologically priveleged nature of cartilage has led to the 
suggestion that the rheumatoid antigen may be a component of cartilage
178. Screening of 
chondrocyte expression libraries for evidence ofT-cell reactivity is currently in progress . 
Clues from antigen processing and presentation: cells of several lineages in rheumatoid 
synovium display marked upregulation of class II HLA expression, possibly as a result of IFN-
y or other cytokine stimulation161 . In addition, the rheumatoid synovium is enriched with 
activated and mature dendritic cells that have enhanced antigen-presenting capabilities3
2. 
Taken together these findings are indicative of active antigen processing and presentation to 




are derived from exogenous protein sources, m contrast to cytoplasmic products that are 
presented in association with class I HLA180. The majority of peptides occupying the groove of 
the MHC molecules are derived from self constituents181 ,182,183 . The molecular basis ofHLA-
DR4 association with RA has suggested that an important region of the peptide binding groove 
may govern the nature of the antigenic peptide being presented to pathogenic CD4 T-cells
120. 
Recent advances in the understanding of peptide-HLA interactions may contribute significantly 
to the identification of the elusive rheumatoid antigen. However, unlike HLA class I bound 
peptides which are of 8-10 amino acids in length with fairly rigid allotype-specific binding 
motifs containing between one and three anchor positions, class II bound peptides are of 
variable length (10-34 amino acids) with a higher degree of allelic promiscuityI80,1s
4,1ss,1s6 . 
The recently-solved DRl structure has indicated that the class II groove is open ended; the 
variation in bound peptide length may be due to portions of the peptide extending beyond the 
edges of the groove 122 . At least three anchor positions have been defined for class II bound 
peptides, although as few as 2 and as many as 6 different amino acids may be found at each 
anchor position1s7,1ss. A fairly conserved and deep hydrophobic pocket binds aromatic or 
aliphatic residues near the amino tenninal of the peptide, fonning the first anchor position. 
Other anchor positions have been defined at residues 4 (hydrophobic) and 6 (small amino acid). 
In addition to variable residues at anchor positions, allelic promiscuity may result from the fact 
that not all anchors need to be used by a specific ligand 189 . Nevertheless, investigation of DR4-
bound peptides in RA patients is currently being actively pursued and may have therapeutic 
relevance, particularly if relevant CD4 T-cell responses can be elicited 190. Recent advances in 
the understanding of the interaction of HLA-DR2 and myelin basic protein-derived peptides in 
patients with multiple sclerosis may have significance for RA 191. 
Non-specific stimulus: It is now well-established in known antigen-specific models of chronic 
inflammation that the vast majority of T-cells at the site of pathology are not specific for the 
inciting antigen150,151 ,152 . Non-specific accumulation of "memory" CD4 T-cells (CD4+ CD45 
RO CD29+) at chronic inflanunatory sites, including RA synovium, may be due to the 
increased expression of adhesion molecules (ICAM-1 , ELAM-1 and VCAM-1) on endothelial 
cells192,193,194. These adhesion molecules bind their specific ligands (LFA-1 ,asylyl Lewis-X, 
VLA-4) which are expressed in increased quantities on memory CD4 Tcells, initiating a 
process that results in transendothelial migration of the T-cells and binding to cellular and 
extracellular components at the inflammatory sitel95,196_ Release of granzymes and other 
proteolytic enzymes by the T-cells may be important in transendothelial migration, resulting in 
cleavage of basement membrane collagen type IV197. Once present at the site of pathology, 
non-specifically recruited memory CD4 T-cells may (i) remain quiescent and not participate in 
the inflammatory process - the so-called bystanders at the fire, (ii) become activated by a 




extra-cellular matrix, and homotypic adhesion, and (iii) exert an
 effect even in their resting 
state33,35,198,199 _ It is also possible that non-specifically recruited
 memory CD4 T-cells may 
encounter their specific or cross-reactive antigen in the joint, thereb
y initiating antigen-specific 
responses 161 . 
5.1.3 . Pathogenetic role ofCD4 T-cells in RA 
The current paradigm invokes a central role for CD4 T-cells in the
 initiation and perpetuation 
of the disease process in RA35,52,149,200_ Stimulation of the pathogen
ic T-cell initiates a cascade 
of events that results in activation of macrophages and synovioc
ytes, the main effector cell 
populations, and the subsequent release of a wide range of soluble 
factors including cytokines, 
growth factors, enzymes and arachidonic acid metabolites (Figure
 1.6). Some of these factors 
combine to promote the formation of pannus and activate osteocla
sts, together contributing to 
erosive destruction of cartilage and bone
20. Several autocrine loops may amplify the responses, 
although there is evidence of potential negative feedback regulatio
n, including the presence of 
an ILl receptor antagonist and the anti-inflammatory effects 
of certain cytokines (see 
5 .3)201,202. It is not yet known whether the pathogenic CD4 T
-cells are activated in the 
circulation and then home to the joints, or are activated in the joints
 themselves35. According to 
the T-cell paradigm of the immunopathogenesis of RA, the persist
ent autoimmune response is 
also centrally controlled by CD4 T-cells, and may include the
 effects of non-specifically 
activated CD4 memory T-cells localised to the chronic inflammator
y site35,I49_ 
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Rheumatoid Arthritis: T-cell 
Centric Paradigm 
(References indicated in text) 
1 T-cell lymphokines: IL-2 , IFN-y, IL4, IL5; 2 Monokines (and growth 
factors): ILi , tumour necrosis factor a , 
granulocyte macrophage colony stimulating factor (GMCSF), IL6, pla
telet derived growth factor, acidic and basic 
fibroblast growth factors, transfonning growth factor (a and P); 3 
Enzymes and other factors : collagenase, 
matrix metalloproteinase, metalloproteinase, stromelysin, tissue 
inhibitor of metalloproteinase, IL1 , IL6, 




CD4 T-cel/ subsets: Three subsets of murine and, more recently, human C
D4 T-cell clones 
have been defined according to their cytokine production profile (TABLE 
l . VI)203 ,204 . Th l and 
Th2 represent reciprocal subsets that are mutually antagonistic. A
dditional functional 
distinctions also exist between these two subsets : Thl cells are p
rimarily involved in 
interactions with members of the phagocytic cell system (monocytes an
d macrophages) and 
Th2 cells with B-cells and antibody production
205 . Important differences in signalling 
pathways between these two subsets have been identified by investigati
ng their responses to 
prostaglandins (see section 5.5)206,207. Macrophage-derived interleukin-12 (IL
 12) is probably 
the most potent stimulus of Thl responses
208. ThO cells are a hetergenous population that may 
have predominant Thl or Th2-like functions or a combination thereo:f2°
6. At present, data of 
CD4 T-cell subset prevalence in RA is somewhat conflicting, although an
alysis of synovial T-
cell clones has indicated a predominant Thl infiltrate209,210,2
11 . Additional evidence in support 
of a role for Th l cells in the pathogenesis of RA includes the presence of 
intracellular perforins 
and granzymes in RA synovial CD4 T-cells (indicating cytolytic pote
ntial that is usually 
confined to Thl cells) and the fact that the predominant Th2 product, 
IL4, actually inhibits 
rheumatoid synovitis42,43,212,213, I 42 . 
TABLE l.VI. CD4 T-cell Subsets: Cytokine profiles* 
THl TH2 THO 
IL-2 IL-4 IL-2 
IFN-y IL-5 IFN-y 
1NFa IL-6 IL-4 
1NFP IL-JO IL-5 
GM-CSF GM-CSF 1NFa 





*Table adapted from 204,2I4,21s,216 
CD4 T-cell mediated cytotoxicity: Although CD4 T-cells are traditionally 
termed helper T-
cells (reflecting their cytokine production) and CD8 cells cytotoxic T-c
ells, it is now well-
established that these functional distinctions are no longer valid. A subs
et of CD4 T-cells is 
capable of mediating antigen-specific, class II HLA-restricted cytotoxic
ity, and CD8 T-cells 
are capable of cytokine production and providing 'help' for B 
cell immunoglobulin 
synthesis212,217,21





cells and exhibits a positive linear relationship with the amount of IFN-y pro
duction208,220. 
Cytotoxic CD4 T-cells are thought to be important in the immune respon
se to intracellular 
pathogens where they mediate cytolysis of infected monocyte/macrophages r
esulting in release 
of the pathogen to alternate defence mechanisms
221 . Two distinct pathways (calcium dependent 
and calcium independent) may be involved in mediating T-cell cytolytic func
tion 222,223,224,225 . 
The calcium dependent pathway is probably effected by perforins and 
granzymes (serine 
protease constituents of cytoplasmic granules)(FIGURE l.7a)
226,227. Following specific 
binding with the target cell , cytoplasmic granules are transported to the b
inding pole in the 
cytotoxic cell by the action of microtubules
228 . The granules are then exocytosed into the 
intercellular space and the released perforin polymerizes in the target cell m
embrane causing a 
series of holes 15nm in diameter, and leading to osmotic rupture of the tar
get cell229 . In 
addition to cytolysis, granule constituents of cytotoxic T cells may a
lso mediate 
apoptosis230,23 I ,232. A calcium independent pathway of T-cell cytotoxicity h
as been described 
and involves the binding of fas antigen, expressed on the surface of the t
arget cell , and its 
ligand on the T-cell (FIGURE l.7b)
223,224. The fas ligand has been cloned and is a type II 
trans-membrane protein of the TNF receptor family
233 . Binding of the fas antigen and its 
ligand results in apoptosis, and subsequently lysis, of the target cell
234. Cytolytic granules have 
been demonstrated within RA synovial CD4 T-cells and an isolated pr
evious report has 
indicated cytolytic function of mycobacterial antigen-reactive CD4 T-cell
 clones from RA 
synovial fluid42,43,107. The current paradigm of CD4 T-cell mediated pathog
enesis of RA does 
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FIGURE 1.7 
Mechanisms of T-cel/ mediated cytotoxicity: 
(a) Granule exocytosis model 
a) Resting T-cell containing cytotoxic granules 
distributed randomly throughout the cytoplasm. 
b )Specific target cell recognition: receptor/ligand 
binding and polarization of cytotoxic granules. 
c) Delivery of the 'lethal hit' . Conjugate fonnation is 
associated with morphological changes. Cytotoxic 
granules are released into the intercellular space. 
Perforin, a constituent of the granules, polymerizes in 
the target cell membrane, creating multiple pores. Other 
components of the cytotoxic granules may mediate 
apoptosis. 
d) Target cell cytolysis occurs due to increased osmotic 








Mechanisms of T-cell mediated cytotoxicity: 
(b) Fas and fas ligand interaction model 
a) Fas antigen is constituitively expressed on potential 
target cells 
b) Specific target cell recognition: receptor/ligand 
binding of adhesion molecules 
c) T-cell fas ligand expression follows specific 
triggering of activation pathways through the T-cell 
receptor 
d) Fas/fas ligand binding results in target cell apoptosis 
prior to cytolysis 
(References are indicated in the text) 
5.2. Macrophage and Synoviocyte centric paradigms of RA 
T-cell independent models of the pathogenesis of RA have been suggested20,33,3
4. These models 
focus on activated synovial macrophages and fibroblastic-origin synoviocytes as the centre of 
complex autocrine and paracrine pathways and suggest that T-cell responses are secondary to 
initial destructive processes . Evidence cited in support of these models include (i) prominent 
macrophage activation compared to T-cell activation status, (ii) abundant macrophage as 
opposed to scarce T-cell derived cytokines in rheumatoid joints, (iii) the ability of GMCSF and 
TNFcx. to upregulate class II HLA expression, independently ofIFN-y, (iv) MRL lpr/lpr mouse 
model of arthritis , where proliferation, attachment and invasion of transformed synoviocytes 
preceeds inflammatory cell infiltrate, and (v) the spontaneous development of erosive arthritis 
in TNFcx. transgenic mice that is associated with markedly increased TNFcx. production and 
cured by anti-TNFcx. monoclonal antibody therapy33,235 ,236,237,238 . The effectiveness of anti-
TNFcx. monoclonal antibody therapy in RA may also support this view239 . It has been 
suggested that retroviral infection may be responsible for initiating the pathogenetic process by 
stimulation of synoviocyte oncogenes that are responsible for transcriptional control of 
collagenase and stromelysin (FIGURE l.8)34_ 
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While it is generally accepted that monocyte/macrophages and s~11oviocytes contribute the 
main effector mechanisms of damage in the rheumatoid joint. in defence of a T-cell centric 
model of RA and in addition to evidence noted above, it has been argued that evidence of 
macrophage activation and monokine production is also prominent in knovm antigen-specific 
T-cell driven chronic inflammatory sites35,149 . In addition, even a few CD4 T -cells secreting 
small amounts of cytokines can be respons ible for a marked inflammatory response and CD4 
T-cells may also be the source of GM-CSF, TNF a and IL6 (see table l. YI) 149 . Impaired T-cell 
acti vation and low levels of T-cell cytokines in the synovial companment may be due to the 
inhibitory effects of macrophage products, including prostaglandins and TNF a 2.io,2
4 1 _ 
FIGlJRE 1. 3 
Oncogene activation in synoviocytes may be the result of rerroviral infection and contribu te 
to local tissue destruction through the effects of collagenase and caihepsin L. 
Figure reproduced from 34 
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A wide range of cytokines, growth factors and their inhib
itors have been identified within 
rheumatoid joints, either in the protein form or at the mRNA
 level (see table l .I ). It is likely 
that these factors play an important role in the pathogenesis o
f RA by a variety of mechanisms . 
A complex network of synergistic and antagonistic inter
actions between cytokines may 
determine their final effects on fibroblast-derived synov
iocytes and local inflammatory 
processes in rheumatoid joints (FIGURE 1.9). 
FIGURE 1.9 
Cytokine network in rheumatoid arthritis. Complex synergistic
 and antagonistic interactions 
of cytokines in the synovial compartment may combine to pr
omote invasive transformation 
or, conversely, maturation of fibroblast-derived (type BJ synov
iocytes. 
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ILl and TNFa are probably the most important cytokines w
ith regard to cartilage and bone 
destruction in RA
247
. Intra-articular injection of either of these cytokines into r
abbit knees 
results in acute inflammatory arthritis with leukocyte infilt
ration and cartilage damage, the 
latter being more marked with ILl than TNFa2




molecule expression on endothelial cells and also stimulates chondrocytes
247 . Correlation of 
ILi levels, DR expression and X-ray evidence of joint damage has been found in RA
250 . In 
addition to ILl-like effects, TNFa activates osteoclasts and upregulates class I and class II 
MHC expression on macrophages and synoviocytes247,251 . ILl and TNFa stimulate the release 
of each other and are found together in several other inflammatory arthritides; a hierachy of 
cytokine production in which TNFa induces production of ILl, IL6, IL8 and GM-CSF has 
been suggested247,252,2s1. Genetic variations in the promoter region of ILl and TNFa genes 
may influence the magnitude of the cytokine response to a particular stimulus and increase the 
risk of autoimmunity128_ 
IL6 in RA is mainly produced by synovial macrophages, although synovial T and B-cells 
sources have also been identified253 . It has been suggested that IL6 is a mediator of the acute 
phase response; in support of this hypothesis correlation between serum levels of IL6 and C-
reactive protein in RA have been reported254. Given the immunoglobulin-inducing activity of 
IL6, it has also been suggested that this cytokine may be an important stimulus for rheumatoid 
factor production255 . 
IL8 is a potent chemoattractant that is present in synovial fluid in RA and correlates with the 
number of neutrophils present256,257. Several growth factors , including epidermal growth 
factor (EGF), acidic and basic fibroblast growth factors (aFGF and bFGF) and platelet-derived 
growth factor (PDGF) have been detected in rheumatoid joints (see Table 1.1). EGF may play a 
role in tissue remodelling and bone resorption258,259 . PDGF is a potent synoviocyte stimulant 
that may be relevant to the development of synovial hypertrophy and pannus formation26
0 . 
The paucity of classical T-cell cytokines in RA synovial fluid and membrane has previously 
been noted. However, soluble IL2 receptor (sIL2-r, p55 chain) is readily detectable in RA and 
has been shown to be a good monitor of disease activity261 . The in vitro inhibitory effects of 
IFNy on rheumatoid synoviocyte production of PGE2 and collagenase provided the rationale 
for use of this cytokine in the treatment of RA, with variable results262,263,264,265 . IL4 is not 
readily demonstrable in rheumatoid synovial fluid but has been shown to have marked 
inhibitory effects on rheumatoid synoviocyte proliferation in vitro213. In addition, in vitro 
inhibitory effects of IL4 on rheumatoid synoviocyte spontaneous production of pro-
inflammatory cytokines (ILi and TNF) and immunoglobulin have also been observed214. 
Recently it has been demonstrated that ILlO produced by T cells and monocytes in the 
rheumatoid synovium may inhibit macrophage production of TNFa and IL1l3 , and T-cell 
production of IFNy266. 
Cytokine inhibitors present in rheumatoid joints include a third member of the ILl gene family, 




addition shed/soluble forms of cytokine membrane-bound receptors, including sIL2-R and TNF 
receptors, may function as specific cytokine antagonists
268,269 . 
5 .4. B cells and rheumatoid factor 
RA synovium contains significant amounts of activated B-cells and plasma cells that 
spontaneously produce large quantities of rheumatoid factor in vitro
270 . Rheumatoid factor 
was first identified nearly 50 years ago and provided the initial indication of an immunological 
process in RA271 . Rheumatoid factor may be detectable in the serum of up to 80% of RA 
patients and high titres of IgM rheumatoid factor may be associated with severe disease and 
extra-articular manifestations27 . However, rheumatoid factor is not specific for RA and may 
occur in a variety of inflammatory conditions and in a significant percentage of healthy normal 
individuals272 . Although IgG and IgM antibodies that recognise antigenic determinants on Fe 
fragments of IgG are the most common forms of rheumatoid factor, IgA, IgD and IgE isotypes 
have also been reported273 . Investigation of rheumatoid factor genes has yielded evidence of 
somatic mutation indicative of a T-cell dependent antigen-driven process2
74. The role of 
rheumatoid factor in the pathogenesis of RA is uncertain . Polyclonal IgM rheumatoid factor 
and immune complexes containing rheumatoid factor can fix and activate the classical 
complement pathway and thereby initiate an inflammatory process2
75,276. However, the fact 
that RA can occur in patients with congenital agammaglobulinaemia has raised doubts about 
the pathogenetic significance of rheumatoid factor277. 
5 .5 Arachidonic acid metabolites 
Arachidonic acid is released from phospholipids of cell membranes by the action of 
phospholipase A2 and further metabolised by two main pathways (FIGURE 1.10). Products of 
both cyclooxygenase (predominantly £-series prostaglandins, PGE) and lipoxygenase 
(predominantly leukotriene B4, LTB4) metabolism of arachidonic acid (AA) are readily 
demonstratable at sites of active rheumatoid synovitis278_ 
Sources of eicosanoids include neutrophils, macrophages, fibroblasts and follicular-dendritic 
cells; although lymphoid cells, including T-cells, B-cells and NK cells, have cyclooxygenase 
and lipoxygenase metabolic potential, their role in the production of eicosanoids is 
controversial279,280,281 ,282,283 ,284,285 . In general, prostanoids (cyclooxygenase products of AA 
metabolism) have diverse immune suppressive and anti-inflan1matory properties, and 
lipoxygenase products, in particular LTB4, are immune stimulatory and pro-inflammatory 
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TABLE I.VIia. Immune modulatory effects of Prostaglandin E2 and other products of 
cycloxygenase metabolism of arachidonic acid. 
TARGET EFFECT PGE2 OTHER 
CELL PROSTANOIDS 
PBMNC ,I, TNF (a. and P); tIFNy 
,/ PGEI, PGE3, MISO, 
PGA2,PGFla.,PGF2a. 
tIFNy ,/ 
tMLR prolif, tHLA-DR, .J..IL2-R ,/ MISO and ENTSO 
tGM-CSF MISO 
CD4 I-CELL tThl (murine)TNFa. 
,/ 
,I, Thlm10 (human) IFNy ,/ MISO 
,I, IhlffhO (murine) GM-CSF ,/ 
t Th2 (human) IL4 ,/ MISO 
CD8 I-CELL ,I, Cytotoxicity ,/ PGEI 
,I, Generation of effectors ,/ 
NKCELL ,I, Cvtotoxicitv ,/ 
BCELL ,I, Prolif, ,I, activation, .J.. IgM ,/ 
t IL4 - induced faE production ,/ 
MONOCYTE/ ,I, ILi, ,I, TNFa. ,/ 
MACROPHAGE t IL6 MISO 
tclass II MHC ,/ 
PMN ,I, activation, ,I, 02 release, ,I, LTB4 ,/ 
MISO - misoprostol ; ENISO - enisoprost; PBMNC - peripheral blood mononuclear cells; 
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TABLE l .VIIb. Immune modulatory properties ofleukotriene B4 (LTB4) 
TARGET CELL EFFECT REF. 
PBMNC 1' lFNy 301 
Necessruv for pha-induced proliferation 302 
CD4 I-CELL 1' lFNy, 1'IL2 303 
CD8 I-CELL 1'IL2-RP 304 
1'PHA-induced responses 305 
1'CD8 expression 306 
NKCELL 1'cytotoxicity 304,307,308 
1'JL2-RB 304 
BCELL 1' lL4 - induced activation 309 
1'antibodv production 309 
MONOCYTE I MACROPHAGE 1'IL6 310 
1'TNFa (IL2 - induced) 311 
1'ILI and TNFa 312 
PMN 1'Chemotaxis and chemokinesis 313 
5.5.1. Prostaglandin E 
PGE has historically been viewed as harmful in RA, mainly due to its potentially deleterious 
effects of vasodilatation, hyperalgaesia and bone resorption299 . Recently, however, the 
significance of these potential deleterious effects and their role in the pathogenesis of RA has 
been questioned299 . Conversely, growing evidence indicates a potential beneficial role of PGE 
in RA (see TABLE 1.Vlla above) . Prostaglandin E2 (PGE2) production by macrophages and 
macrophage-lineage synoviocytes is increased by a variety of stimuli, including ILl , TNFa, 
lipopolysaccharide (LPS), components of the complement cascade and Fe receptor 
engagement314,315,316,317,318. The potent inhibitory effects of PGE2 on ILl and TNFa 
production indicate that PGE2 may function as a negative feedback inhibitor of these pro-
inflammatory cytokines (FIGURE 1.11). It has been suggested that modulation of T-cell 
functions by PGEl-3 and rnisoprostol is mediated by binding to a common cell surface 
receptor resulting in increased intracellular cyclic AMP286 . PGE2 has several other potential 
beneficial effects in RA, including inhibition of lymphocyte adhesion to endothelial cells, 
inhibition of transendothelial migration of T lymphocytes, suppression of synoviocyte 
collagenase production and inhibition of LTB4 production 319,320,321 ,300. PGE2 mediated 
inhibition of in vivo and in vitro models of acute and chronic inflammation, and beneficial 
therapeutic effects on adjuvant arthritis have also been reported322,323. 
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FIGURE 1.11 
Function of PGE2 as a negative feedback inhibitor of proinflammatory cytokines following 
macrophage activation 









An important role for L TB4 in the pathogenesis of RA has been indicated by the effectiveness 
ofreduction of this eicosanoid (pharmacological and dietary) in the treatment of the disease. In 
contrast to PGE, LTB4 is a potent stimulator of diverse immune functions (TABLE l.Vllb) 
which may be mediated by binding to a cell surface receptor with resultant increase in 
intracellular cGMP, or by its action as a calcium ionophore324,325,326 . L TB4 may be important 
in the activation ofNK, Band T-cells285 . In addition to exogenous sources of LTB4, T-cells 
may provide their own source of LTB4 by LT A4-hydrolase metabolism of macrophage-derived 
LT A4327 ,328 . Further evidence of the role of L TB4 in T-cell activation is indicated by the fact 
that inhibition of FHA-induced proliferation of T-cells by a 5 lipoxygenase inhibitor and, most 
interestingly, hydrocortisone, can be abrogated by the addition of exogenous LTB4302,329. It 
has been suggested that L TB4 stimulation (indirectly via IFNy production or directly by 
another mechanism) of PGE2 release may represent an important feed-back regulatory 
mechanism285 . This hypothesis may account for the apparent contradiction in earlier reports 
that noted LTB4, HPETE and HETE actually suppressed mitogen-induced proliferation of 
mixed T-cell and monocyte populations, while in the presence of a cycloxygenase inhibitor 
LTB4 enhanced proliferation330,33I _ 
In addition to LTB4, other 5 lipoxygenase products may be involved in the pathogenesis of 
RA. It has recently been demonstrated that leukotrienes C4 and D4 stimulate angiogenesis via 
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a receptor-mediated interaction, and thus may contribute to the development of pannus332 . 
Immune modulatory properties of 5 HPETE and HETE may also be significant330,333 . 
Lysophosphatidylcholine and platelet activating factor are additional products of phospholipase 
A2 activity that have potent proinflammatory and immune modulatory functions that may be 
relevant at the site of pathology in RA334,335. 
6. THERAPY 
6.1 Current treatment 
Historically a conservative approach to the treatment of RA has been followed, fuelled by the 
perception that the disease was not life-threatening, and was self-limiting in the majority of 
cases. This approach is exemplified by the "therapeutic pyramid" in which non-steroidal anti-
inflammatory drugs (NSAIDs) are used exclusively in the early stages of the disease, while the 
so-called disease modifying anti-rheumatic drugs (DMARDs) were reserved for patients in 
whom NSAIDs failed. In practice this has meant that the time from diagnosis to the use of 
DMARDs has been 7 years or longer336 . With the growing realisation that RA is a severe 
disease with a predictably poor outcome, early and more aggressive therapeutic intervention 
has been recommended336. The goal of such intervention is to induce disease remission early, 
and thereby prevent erosive joint damage, preserve function and improve life expectancy. The 
safety and efficacy of current therapies in achieving these goals is questionabJe337 . 
6.1.1 Non steroidal anti-inflammatory drugs 
NSAIDs are some of the most widely-prescribed pharmacological agents, and are used 
e"'1ensively in the treatment of all forms of arthritis . Aspirin, the prototype NSAID, was the 
cornerstone of RA treatment for many years . Numerous NSAIDs belonging to several different 
chemical classes are now available and share a common inhibitory effect on cyclooxygenase 
metabolism of arachidonic acid, resulting in reduction of prostaglandins in the synovial 
compartment338. Although inhibition of prostaglandin synthesis has been suggested as the 
mechanism of the anti-inflammatory action of these agents, their definitive mode of action 
remains unclear339. Indeed, there is increasing evidence that prostaglandins themselves, 
particularly PGE2, have extensive anti-inflammatory and immune suppressive effects (see 
Table I .Vila) . Scavenging of oxygen radicals and effects on leukocyte function have been 
been proposed as alternative mechanisms of NSAID action340,341 . Systemic inhibition of 
prostaglandin E (PGE) does, however, appear to be responsible for many NSAID-induced side-
effects 299. 
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Inhibition of arachidonic acid metabolism by conventional NSAIDs at standard doses is 
generally confined to the cyclooxygenase pathway, and may result in a compensatory increase 
in lipoxygenase activity342 . Products of this pathway, in particular leukotrienes, have pro-
inflammatory and immune stimulatory properties (see Table l.Vllb) . NSAID therapy has been 
associated with increased accumulation of neutrophils at chronic inflammatory sites in vivo, 
possibly as a result of the chemotactic effects of LTB4343 . Interestingly, combined inhibition of 
cycloxygenase and lipoxygenase by benoxaprofen, a NSAID that is no longer available, 
resulted in reduced migration of leukocytes, particularly monocytes, into sites of experimental 
inflammation344. The disease modifying properties of Tenidap, a new NSAID that inhibits both 
cycloxygenase and lipoxygenase pathways of arachidonic acid metabolism, may be due to 
combined inhibitory effects on leukotrienes and pro-inflammatory cytokines345 . 
While often used to achieve symptomatic improvement in RA, NSAIDs acting only on the 
cycloxygenase pathway of arachidonic acid metabolism do not beneficially affect disease 
progression346 . It has also been suggested that therapeutic reduction in PGE levels may prevent 
remission induction by gold therapy347. NSAID inhibition of proteoglycan synthesis in 
cartilage of osteoarthritis patients has been demonstrated and may have implications for RA348. 
In addition, the significant morbidity and mortality associated with NSAID side-effects would 
suggest that these agents are not as safe as previously thought, and rival the side effect profiles 
of several DMARDs and corticosteroids349. 
Given the accumulated evidence, a reappraisal of the role of cycloxygenase inhibitors in the 
treatment of RA has been suggested336. Apart from a theoretical reduction in systemic side 
effects, new experimental cycloxygenase inhibitors that specifically inhibit inducible isoforms 
of the enzyme (cycloxygenase-2) do not offer additional benefits in the treatment of RA350 . As 
has been suggested for other chronic inflammatory diseases, inhibition of lipoxygenase, alone 
or in combination with cycloxygenase inhibition, may be preferable351 . It has also been 
suggested that the sole use of cycloxygenase inhibitors in the treatment of early RA, as 
promoted by the therapeutic pyramid, is no longer tenable336_ 
6.1.2 Corticosteroids 
Corticosteroids have a lengthy historical association with the treatment of RA352 . Initial 
enthusiasm for their use diminished once the adverse side effects of high dose corticosteroid 
therapy became apparent. The recent resurgence of interest in corticosteroid therapy has 
resulted from reappraisal of data obtained during early clinical trials m RA, which 
demonstrated a significant reduction in the development of new joint erosions using 
comparatively low dose regimens353 ,354_ 
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The precise mechanism of action of corticosteroids in the potential modification of the disease 
process in RA is unknown. Corticosteroids exert a wide range of effects on inflammatory 
mediators and immune functions and, given the fact that they are also endogenously produced, 
represent an important group of natural anti-inflammatory and immune suppressants. Steroid 
receptors can be found in virtually all cell types in every organ system355 . Following binding of 
these cytoplasmic receptors, steroids are transported to the nucleus where they can affect 
transcriptional, translational and post-translational processes concerned with protein synthesis, 
processing and secretion, and cell growth, division and apoptosis356. Some of these effects may 
be modulated by lipocortins or annexins, a group of steroid-inducible proteins357. 
Corticosteroids have diverse effects on immunological cells, including inhibition of IFN-y, IL2, 
IL3 and IL6 production by T-cells and suppression of GM-CSF, ILi and TNF-a. production 
by monocytes358,359,360 _ Inhibition of cytolytic mediators, granzymes and perforins, within 
cytotoxic lymphocytes has also been described361 . Differential effects of corticosteroids on Thl 
and Th2 subsets of CD4 T-cells may be responsible for some of the prior observations143,l44. 
Corticosteroids reduce arachidonic acid metabolites by inhibiting phospholipase, thereby 
impeding arachidonic acid release from phospholipids362. This effect thus occurs at a level 
distinct from that exerted by NSAIDs, and results in reduction of products of both 
cycloxygenase and lipoxygenase pathways, although predominant inhibitory effects on 
lipoxygenase products have been described in a short term study338. 
6.1.3 Disease modifying anti-rheumatic drugs 
The so-called disease modifying anti-rheumatic drugs (DMARDs) constitute a diverse group of 
agents used empirically to modify the outcome of RA. These drugs include gold, penicillamine, 
anti-malarials, sulphasalazine and methotrexate; more recently, immune suppressants and 
cytotoxic drugs including cyclophosphamide, azothiaprine and cyclosporin have been added to 
this list57,363,364,365,366,367,368 . At present there is no consensus whether these agents actually 
influence disease progression in RA369 . Thus, despite growing knowledge of some of their 
effects, including modulation of inflammatory and immune parameters, it is difficult to identify 
any disease-relevant processes modulated by DMARD therapy that could account for a 
mechanism of action in RA370,371 ,372,373 . 
A reappraisal of outcome measures in RA has shifted the focus from short term control of 
inflanunation and symptoms, to long term preservation of function and retardation of joint 
erosions; viewed from this perspective, it has been suggested that methotrexate is the only 
DMARD to have significant beneficial effects374,375 . The reasons for failure of other 
DMARDs may relate to side-effects and lack of efficacy leading to high attrition rates, and the 
practice of reserving their use for well-established disease374 . Although methotrexate may be 
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effective in modifying the outcome in RA, its precise mechanism of action remains unclear. It 
has been suggested that with weekly dose regimens used in the treatment of RA, inhibition of 
its target enzyme, dihydrofolate reductase, is never complete376. Inhibition of other folate-
dependent enzymes, particularly aminoimidazole carboxamide riboside transformylase and, 
secondarily, adenosine deaminase, by polyglutamyl derivatives of methotrexate may be 
relevant to its cytostatic and neutrophil suppressive effects377. Modulation of purine 
biosynthesis by methotrexate has several other effects potentially relevant to its action in RA, 
including inhibition of Ieukotriene synthesis and ILl secretion378,379 . Additional mechanisms of 
action of methotrexate defined in animal models that may have implications for RA include 
increased concentrations of adenosine in inflamed murine air pouches and markedly reduced 
leukocyte accumulation38o. 
6.1.4 Non-pharmacological therapy 
Several studies have demonstrated a short- to medium-term beneficial effect of dietary 
supplementation with omega-3 fatty acids in rheumatoid arthritis381 ,382 . Omega-3 fatty acids 
may competitively inhibit the formation of 2-series prostaglandins and 4-series leukotrienes 
from arachidonic acid, resulting in the formation of compounds with altered and reduced 
biological activity, and indicate a possible mechanism of their action in RA383 . 
6.2 Immunotherapy 
The growing understanding of the immunopathogenesis of RA has led to attempts to intervene 
in the disease process using a variety of methods . The goal of such therapy is to modulate a 
specific pathogenetic process, with minimal side-effects, and induce lasting disease remission 
or cure384. While immunotherapy in RA represents probably the first use of rational therapy in 
the treatment of the disease, efficacy and safety profiles of these new generation anti-
rheumatics vary widely. In addition, most clinical trials to date have been open-label and 
included small numbers of patients with long-standing disease, and focused on short-tem1 
effects . 
6.2 .1. Targets for immunotherapy 
The CD4 T-cell / antigenic peptide / HLN antigen-presenting cell complex has been the focus 
of most immunotherapeutic regimens to date (FIGURE 1.12). Given that specific suppression 
of pathogenetic mono- or oligo-clonal CD4 T-cell populations requires identification of the 
antigenic peptide, current targets fall short of the goal of immunotherapy in RA. However, 





Targets for immunotherapy in rheumatoid arthritis 







* Inununotherapeutic target in RA 
6.2.2. Monoclonal antibody therapy 
Literature Review 
The majority of therapies directed at the targets indicated above have used monoclonal 
antibodies, of murine origin, specific for the target antigen. Binding of the antibody to its 
specific ligand may, in the case of T-cell surface antigens, result in (i) inhibition of T-cell -
APC interaction, (ii) partial/inappropriate activation of the T-cell leading to anergy or 
apoptosis, (iii) complement fixation and cell depletion and (iv) receptor blockade385,386,387,388. 
Anti-CD4 therapy with a range of different monoclonal antibodies is the most extensively 
studied antibody therapy in RA at present, and was based on successful prevention of animal 
models of autoimmune disease389,390. Although early phase I studies yielded promising clinical 
and laboratory results, more recent controlled trials of anti-CD4 therapy have failed to show 
significant efficacy39I ,392,385,393 . Prolonged depletion of circulating CD4 +ve cell populations 
has been noted with chimeric antibody therapy, and there appears to be no correlation between 
CD4 cell numbers and therapeutic efficacy, perhaps due to the persistence of small numbers of 
pathogenetic cells sequestered in the joints394,395 . Modulation of monocyte/macrophage cell 
populations that also express CD4 antigen may result from anti-CD4 therapy385 . In addition to 
CD4 depletion, side-effects of anti-CD4 therapy include a cytokine release syndrome 
immediately following antibody infusion, the development of human anti-mouse antibodies 
(considerably reduced with chimeric or humanised antibodies, although anti-idiotypic responses 
may still limit prolonged therapy), and opportunistic infections396,385,394. The long-term risk of 
malignancy in patients with prolonged CD4 T-cell depletion has not been defined . Given the 
present difficulties of anti-CD4 treatment in RA, alternative treatment protocols have been 




antibodies to induce a state of prolonged inunune tolerance, as has been achieved in murine 
transplant models397 . 
Other monoclonal antibodies directed against cell surface antigens and used in the treatment of 
RA include anti-CDS, anti-CD?, anti-CD25 (IL2-R), and anti-CDw52 (Campath-lH); as with 
anti-CD4 therapy, the studies reported to date have included comparatively small numbers of 
patients over short time periods and have yielded variable results
398,399,400,388,401. 
Improvement on standard monoclonal antibodies has included an immunoconjugate that 
combines a monoclonal antibody with a toxin to increase depleting efficiency
398,399 . Targeting 
activated cells with increased expression of IL2-R is the rationale behind the use of anti-CD25 
therapy; a novel technique to achieve the same goal has been the use of an IL2 fusion toxin that 
couples sequences of human IL2 to components of diptheria toxin and thus avoids the problems 
associated with monoclonal antibody therapy402. 
Monoclonal antibodies against cytokines have also been used to treat RA. Anti-TNFa 
monoclonal antibody therapy has been effective in collagen induced arthritis and, more 
recently, in early phase studies in RA403 ,239,404_ Significant clinical improvement (swollen joint 
count and painful joint count) associated with reduction in acute phase reactants has been 
noted in the clinical trials of anti-TNFa monoclonal antibody therapy, but the requirement of 
shorter dosing intervals on retreatment may limit the application of this form of therapy
405 . 
Reduction of ILl , GMCSF and IL8 has been shown to be an in vitro effect of anti-TNFa, 
suggesting a pivotal role for TNFa in the hierachy of cytokines in RA
251 . A combination of 
anti-TNFa and anti-CD4 monoclonal antibody therapies has a synergistic effect in the 
treatment of collagen induced arthritis, and may have implications for RA395_ Additional 
strategies to inhibit cytokines in RA may include the use of cytokine receptor antagonists and 
soluble cytokine receptors or, in the case of TNFa, metalloproteinase inhibitors that prevent 
the release of biologically active cytokine from the cell membrane 
406,407,408,409,4I0,4I I _Recently, a phase I study in patients with RA using a recombinant human 
TNFa-receptor (p75) linked to the Fe portion of a human IgGl antibody was completed, 
demonstrating considerable improvement in inflanunatory markers and clinical parameters 
(Moreland L, Annals of Rheumatic Diseases 1995 (in press)) . Further trials using similar 
strategies to inhibit TNFa in patients with RA are currently in progress . 
6.2.3 . T-cell vaccination 
T-cell vaccination has been shown to be effective in the prevention and treatment of animal 
models of autoimmunity412,413 . The technique involves the isolation and in vitro expansion of 
known pathogenetic T-cells, followed by activation, attenuation and subsequent subcutaneous 
vaccination of an aliquot of these cells . The vaccine activates anti-clonotypic (presumably 
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anti-T-cell receptor) and anti-ergotypic (anti-activated) T-cells of both CD4 and CD8 
phenotype that may regulate the original pathogenetic T-cell population4' 4,415,4I6 _ T-cell 
vaccination in RA has been essentially unsuccessful, largely due to the difficulty in identifying 
pathogenetic T-cells for use in the vaccine417,418. In the absence of a defined auto-antigen, non-
specific expansion of cells from the site of pathology has been utilised419 . However, given the 
non-specific nature of the T-cell accumulation at chronic inflammatory sites, it is likely that 
such techniques result in only modest enrichment of pathogenic T-cell populations, and may 
cause potentially harmful responses to protective memory T-cells included in the vaccine. 
Additional constraints include the labour- and facility-intensive nature of T-cell vaccination, 
making it impractical for general clinical application41 7. 
6.2.4. Peptide therapy 
Peptide immunotherapy may inhibit APC-T-cell interaction and subsequent activation by three 
distinct mechanisms: (i) activation of regulatory T-cell networks by peptides of disease-
associated TCR families , (ii) induction of selective T-cell anergy or tolerance by modified 
antigenic epitopes with partial TCR agonist or antagonist properties, and (iii) MHC blockade 
using non-antigenic peptide sequences that displace autoantigenic and other epitopes and 
inhibit all T-cell interactions with the particular MHC haplotype l 90,420,421 _ Potential problems 
confound all peptide therapy techniques and include the finding that vaccination with disease 
associated TCR peptides may aggravate the disease190. Determinant spreading during an 
autoimmune response may nullify therapeutic attempts using single peptides, and short half-
lives of infused peptides make prolonged MHC blockade extremely difficult420 . Given the latter 
aspect of MHC blockade, TCR antagonism may have an advantage as a therapeutic option and 
suggest a rational approach to antigen-specific immuno-intervention422 . Apart from early phase 
studies of TCR peptide vaccination in patients with multiple sclerosis, in vivo experience of 
peptide immunotherapy has been confined to animal models of autoimmunity423,424_ For 
specific peptide therapy in RA identification of autoantigenic epitopes and clarity on disease-
associated TCR VP families is requiredl90. 
6.2.5 . Mucosa! tolerance 
It has been recognised for some time that encountering an antigen at a mucosa! surface can 
lead to the development of specific immune tolerance425. In the case of orally ingested myelin 
basic protein in animals, it has been suggested that antigen-specific suppressor T-cells 
activated in the small intestine release TGFP on re-encountering their specific antigen in the 
central nervous system, resulting in suppression of local immune responses426,427,428,429,430_ 
Inhaled peptides may induce tolerance as a result of failure to activate pulmonary dendritic 
cells and local inflammatory responses 190. Oral tolerance therapy has proved successful in the 
prevention and treatment of animal models of autoimmune arthritis431 ,432,433 _ Safety and a 
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degree of efficacy of oral tolerance therapy has also been demonstrated in humans with 
multiple sclerosis (using myelin basic protein) and RA (type II chicken collagen), although 
both studies included comparatively small patient numbers studied over short periods434,435 . 
6.2.6. Antimicrobials 
Based on impressions that RA is the result of an infectious agent, and the degree of success 
achieved in the treatment of lyme disease and some cases of reactive arthritis with antibiotics, 
several studies have investigated the therapeutic effects of antimicrobials in RA436,437,438_ In 
general, significant efficacy has not been demonstrated, even with prolonged treatment. In 
addition, in isolated cases where a therapeutic effect has been observed using antimicrobials, 
this may be a consequence of antiinflammatory and immune modulatory properties of the 
agents, rather than a direct antimicrobial effect439 . 
7. CONCLUSIONS 
Recognition of the severity of rheumatoid arthritis, its in1pact at many levels, and the lack of 
efficacy of most conventional therapeutic agents provides an1ple incentive for the development 
of new therapeutic regimens . The increasing understanding of the immunopathogenesis of the 
disease permits, for the first time, the rational targeting of specific cells, products or processes 
thought to be involved in the disease process . The evidence in support of a role for CD4 T-cells 
in the initiation and perpetuation of RA would suggest that these cells are involved in proximal 
events in the pathogenesis of the disease, and thus may provide important therapeutic potential. 
Several aspects of CD4 T-cell function in RA remain largely unknown, including the nature of 
the inciting 'rheumatoid antigen', the role and regulation of CD4 T-cell mediated cytotoxicity at 
the site of pathology, and the potential modulatory effects of eicosanoids, present in the 
synovial compartment, on T-cell effector functions . The aims and objectives of this thesis, as 
detailed below, encompass investigation of several of these aspects of the immunopathogenesis 
of RA. The findings may have implications for novel therapeutic interventions in the 
immunopathogenetic processes of the disease. 
8. AIM AND OBJECTIVES OF THIS STUDY 
8.1. Aim 
To investigate the effector functions and regulation of CD4 T-cells from the synovial 
compartment of patients with rheumatoid arthritis, and identify novel targets for the therapeutic 
modulation of CD4 T-cell functions . 
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8.2. Objectives 
(i) To investigate the proliferative responses and cytotoxic effector function of CD4 T-cells 
from the site of pathology in patients with RA and other arthritides, and correlate this 
function with clinical parameters . 
(ii) To determine the potential modulatory effects of eicosanoids on the in vitro functions of 
CD4 T-cells. 
(iii) To define the cellular regulation of CD4 T-cell mediated cytotoxicity and its association 
with other cell functions . 
(iv) To investigate the specificity of mycobacterial antigen-reactivity of synovial T-cells in 
patients with RA drawn from a population with high environmental exposure to 
Mycobacterium tuberculosis . 
(v) To identify the source of the T-cell stimulus in the synovial compartment in RA. 
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INTRODUCTION 
The pathology of rheumatoid arthritis (RA) is characterised by an infiltration o
f activated 
CD4+ T-lymphocytes in synovial membrane and synovial fluid
1,2. These cells have been 
thought to have a central function in the immunopathogenesis of the disease
, mediated 
primarily by their cytokine stimulation of B-cells and the mesenchymal react
ion3 . This 
paradigm of RA has recently been disputed, largely due to the absence of T-cell der
ived 
cytokines at the site of pathology4. However, the demonstration that a subset of syno
vial CD4+ 
lymphocytes has cytolytic potential has suggested an alternative role for these c
ells in the 
pathogenesis of RA 5. CD4+ T-cell mediated cytolysis of target cells presenting a class II H
LA-
restricted antigen in the synovial compartment may be an important effector mechani
sm of joint 
destruction. Factors that modulate this function may have therapeutic relevance. 
Although products of cyclooxygenase metabolism of arachidonic acid (prostanoids)
 have been 
associated with several potentially deleterious effects in RA, their therapeutic reduct
ion by non 
steroidal anti-inflammatory drugs (NSAIDs) does not impede disease progression
6 . There is 
evidence from early studies that cyclooxygenase inhibition as the sole form of treatm
ent in RA 
accelerates erosive joint damage7, suggesting that synovial prostanoids may me
diate local 
protective effects. It is now well established in both in vivo and in vitro mode
ls, that 
prostanoids have anti-inflammatory and immune modulatory properties8,9,IO _ In particular,
 E-
series prostaglandins (PGEs) suppress natural killer (NK) and CD8 T-cell 
cytotoxic 
function9,10 . The potential role of prostanoids in modulating antigen-specific clas
s II HLA-
restricted synovial fluid mononuclear cell (SFMNC) cytotoxic function in RA
 has not 
previously been described. 
The results of this study of 20 seropositive RA patients indicate heterogeneity i
n SFMNC 
antigen-specific cytotoxicity that correlates with therapy. Furthermore, evidence i
s provided 
that both synthetic prostaglandin E2 (PGE2) and prostanoids produced by macropha
ge-lineage 
synoviocytes inhibit antigen-specific CD4+ T-cell cytotoxic function in vitro . Taken 
together 
the data may indicate a role for synovial prostanoids in suppressing T-cell mediate
d antigen-
specific cytolysis at the site of pathology in RA. 
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MATERIALS AND METHODS 
1. Patients 
20 patients with seropositive RA, as diagnosed according to the revised ARA criteria
11 , were 
included in this study. Apart from one newly-diagnosed patient who was untreated, all patients 
were receiving either NSAIDs, disease modifying anti-rheumatic drugs (DMARDs) or 
combinations thereof, at the time of study (TABLE 2.1). Paired samples of synovial fluid and 
venous blood, collected into heparinized tubes, were obtained at the time of clinically-indicated 
arthrocentesis and processed simultaneously. Mononuclear cells (MNC) were isolated from 
samples by Ficoll-Hypaque density centrifugation (Lymphaprep - Nycomed, Oslo, Norway) as 
previously describedl2. Cells were washed three times in phosphate buffered saline (PBS) and 
resuspended at l x 106;m1 in tissue culture medium. Tissue culture medium used throughout 
these studies was RPMI 1640 (Flow Laboratories, Mclean, VA) containing l OOU/ml of 
penicillin, lOOµg/ml of streptomycin and 10% pooled AB human serum. PBMNC from 13 age-
matched healthy laboratory staff were used as normal controls . 
2. Proliferation and cytotoxicity assays 
PBMNC and SFMNC proliferation in response to mitogen and antigen was analysed as 
previously described 12 . MNC (105 per well) were stimulated in triplicate wells of a 96-well U-
bottomed sterile tissue-culture plate (Flow Laboratories, Irvine, Scotland) with the rnitogen 
phytohaemagglutin (PHA, Wellcome Research Laboratories, Beckenham, England) and 
purified protein derivative of Mycobacterium tuberculosis (PPD, Central Veterinary 
Laboratory, Weybridge, Surrey, England) in a final volume of 200 µl of culture medium. Wells 
containing cells without antigen or mitogen were used for determining background 
proliferation. Cultures were incubated at 37°C in a humidified atmosphere containing 5% CO2 
for 3 days (rnitogen) or 7 days (antigen) and tritiated thynudine (2µCi/well) incorporation 
(Amersham International, Buckinghamshire, England; specific activity 185 µCi/mmol) over the 
final 18 h of incubation measured. 
Antigen-specific cytotoxicity was measured in a 15 h 5 lchrornium (51 Cr) release assay as 
previously reported 12 . PPD-specific effector cells were generated from PBMNC and SFMNC 
by culturing 6 -10 x 106 MNC at 106/ml in medium with 3µg/ml PPD in 25cm2 tissue 
culture flasks (Becton Dickinson Labware, Lincon Park, NJ) for 6 days, without the addition 
of interleukin 2 (IL2) . Target cells were autologous adherent peripheral blood MNC that were 
plated at the initiation of the assay. On day 5 of culture, target cells were pulsed with the 
specific antigen, PPD (1 Oµg/ml) ; an irrelevant antigen, streptokinase-streptodomase (1 : l 0 
dilution) (SK-SD, Lederle Laboratory, Wayne, NJ - 250u/ml streptokinase, 62.5u/ml 
streptodomase), or medium alone, and labelled with 6µCi/well 5 lCr for 24 h. After extensive 
washing, effectors were added to give final effector:target ratios of 10:l. 3:1 and 0.3:l. 
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Adherent target cell numbers were estimated as 10% of mononuclear cells plated. Wells 
containing target cells and medium only were used for the determination of spontaneous 51 Cr 
release. The plates were incubated at 37°C in a humidified atmosphere containing 5% CO2 for 
15 h, following which the total content of each well was transferred to a disposable counting 
tube and 100µ1 of 5% Triton X added to the remaining adherent cells for the determination of 
maximum release. After 3 h incubation at 37°C the total volume of Triton X was transferred to 
similar tubes and radioactivity counted. The percentage specific cytotoxicity for the mean of 
triplicate wells was calculated as follows : percentage specific lysis = [mean test cpm/ (mean 
test+ mean cpm after Triton X treatment of the same triplicate wells)] x 100% - percentage 
spontaneous release. The percentage spontaneous release was calculated as follows : mean cpm 
in spontaneous release wells/ (mean cpm in spontaneous release wells + mean cpm after Triton 
X treatment of the same triplicate wells) x 100%, and was always less than 20%. For the PPD-
specific cytotoxicity reported in this chapter, anomalous cytotoxicity (targets with irrelevant 
antigen or without antigen) was subtracted. 
Positive and negative selection of co4+ve and cog+ve subsets of effector MNC was 
performed with antibody coated T-25 tissue culture flasks , used according to the 
manufacturer's directions (AIS Microcellector, Applied Immune Sciences Inc, Menlo Park, 
CA). Antigen-specific cytotoxicity of the selected cell subsets was measured in a standard 15h 
51 Cr release assay. Phenotypic analysis of unseparated and selected effector MNC subsets 
was performed by flow cytometry on an Epics Profile II (Coulter Electronics, Hialeah, Florida) 
using the following monoclonal antibodies : CD3-RD1 , CD4-FITC, CD8-FITC, and NKHl-
RDl (anti-CD56) (all from Coulter Immunology, Hialeah, Fl.). The flow cytometry 
methodology is as described in detail below (section 3 of methods), except that lymphocytes 
were bitmapped visually to exclude monocytes and debris on histogram 1. 
The in vitro effects of cholorquin (Sigma Chemical Company, St Louis, Mo ), sulphasalazine 
(Salazopyrine, Keatings Pharmaceuticals, Johannesburg, South Africa ), methotrexate (Lederle 
Laboratory, Wayne, NJ) and prostaglandin E2 (PGE2, Sigma Chemical Company, St Louis, 
Mo) on proliferation and antigen-specific cytotoxic function of PBMNC from 5 nom1al 
subjects were investigated. Effects on proliferation were determined by adding the agents at the 
initiation of the culture period. The effects of chloroquin and PGE2 on both the generation, and 
effector function of cytotoxic cells, were investigated by adding the agents at the initiation of 
culture of the effector cells, or during the 15h incubation period of the 5 lcr release assay. 
3. PGE2 production by CD14+ synoviocytes 
Thawed SFMNC (2x 106/ml) were adhered to 24 well tissue culture plastic plates (Falcon 
3047, Becton Dickinson Labware) for 3 h. The percentage of viable cells expressing CD14 in 
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unseparated and non-adherent fractions was determined by dual parameter flow cytometric 
analysis performed on an Epics Profile II (Coulter) using FITC-conjugated anti CD 14 (Mo2-
FITC, Coulter Immunology, Hialeah, Fl) and propidium iodide (Sigma Chemical Company) . 
Histograms generated were (i) forward scatter (FS) vs log side scatter (LSS), (ii) log 
fluorescence 1 (LF 1) vs log fluorescence 2 (LF2), (iii) and (iv) single parameter histograms of 
LFl and LF2. Monocytes were bitmapped on histogram 1 to visually exclude lymphocytes and 
debris. Non-specific antibody binding was evaluated using the relevant mouse isotypic control, 
allowing for 2% false positives. Histogram data were generated for 104 events . Together, 
these data allowed quantitation of numbers of viable adherent CD 14+ synoviocytes, which 
were found to be in the range of 1.8 x 105 to 5.28 x 105 cells per well. 
Supematants were collected from the unstimulated adherent cells after 18h incubation in the 
presence or absence of 10-5M indomethacin in 1 ml of culture medium. For measurement of 
PGE2 concentrations, aliquots of supematants underwent standard solid phase extraction and 
derivation of PGE2 to the methyl oximate form prior to freezing 13 . Samples were stored at -
70°C for no longer than 3 days prior to assay. PGE2 concentrations were measured by 
commercial RIA ( Prostaglandin E2 (1125) assay system, code RPA 530, Amersham 
International) according to the manufacturer's directions . For comparative purposes, 
concentrations of PGE2 were corrected for numbers of viable adherent CD14+ve cells 14 . 
4. Cytokine assays 
The supematants of SFMNC (3 x 106/ml in culture medium), stimulated by PHA (5 . 75 x l o-3 
mitogenic units/ml) in 24 well tissue culture plates, were collected after 48 h. Samples were 
stored at -70°C until measured. Interferon-y (IFN-y) concentration in the supematants was 
measured by commercial RIA (IFN-y IRMA, Medgenix Diagnostics, Fleurus, Belgium) and 
interleukin 4 (IL4) concentration determined by commercial ELISA (IL-4 EASIA, Medgenix 
Diagnostics), according to the manufacturers' directions . 
5. Cytotoxic CD4+ T-cell clone 
Clone TS7.2E was obtained by standard limiting dilution cloning15 of synovial membrane 
mononuclear cells from a patient with acute gout, using PPD as the antigen, as detailed in 
chapter 7 (pg. 177). This clone was maintained in culture by weekly re-stimulation with PPD, 
irradiated (4000 rads) autologous PBMNC and recombinant interleukin 2 (rIL2 - 100 iu/ml) 
(Cetus, Emeryville, CA - kindly provided by Dr Eli Kedar, Hadassah Medical School, 
Jerusalem, Israel). Cultures were supplied with additional fresh medium and rIL2 (l OOiu/ml) 3 
- 4 days after re-stimulation. Phenotypic and functional analyses have demonstrated that 
TS7.2E is a Thl CD4+ve T-cell clone, with PPD-specific proliferative and cytotoxic responses 
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(see chapters 5 and 7) . Cytotoxic function of the clone was measured 2 days after stimulation 
with feeders and antigen, in a standard 15 h 5 lcr release assay. 
6. Statistical analysis 
Regression analysis was performed using the software program Statgraphics (STSC Inc, 
Rockville, MD). Krukskal Wallis non-parametric analysis of variance, and where appropriate 
the Mann-Whitney-U test, were employed for statistical comparison using the program Instat 
(GraphPad Software, San Diego, CA) . Unless stated otherwise, two-tailed p values are 
reported; p values Jess than 0.05 were considered significant. 
RESULTS 
1. Dissociation of SFMNC proliferative and cytotoxic responses m a sub-group of 
patients with RA 
A significant positive linear relationship was found between PPD-induced proliferation and 
PPD-specific cytotoxicity, at an effector:target ratio of 3: 1, for PBMNC from 13 healthy 
laboratory normals and 20 patients with seropositive RA (r = 0.80; p < 0.001) (Figure 2.1) . A 
similar correlation was found for SFMNC from the RA patients (r = 0.82; p < 0.001) (Figure 
2.2) . In addition, similar correlations were also found for the PBMNC (patients and normals) 
and SFMNC at two additional effector:target ratios (10: l and 0 .3: 1) (data not shown). Non-
specific cytotoxicity, against targets with no antigen and targets pulsed with an irrelevant 
antigen, streptokinase-streptodomase, was in the range of 2-15 %. These data confirm previous 
reports that have indicated a positive linear relationship between MNC antigen-induced 
proliferation in primary in vitro culture, and levels of cytolysis against antigen-pulsed 
autologous macrophages 16. However, there was some heterogeneity in the responses of 
SFMNC allowing the categorization of the patients into three distinct sub-groups of similar 
numbers, which have been termed groups A, B and C (Figure 2.2) . Group A consisted of 6 
patients who demonstrated a marked dissociation between PPD-induced proliferation and PPD-
specific cytotoxicity, with significantly lower levels of cytotoxicity than predicted by the 
amount of proliferation; group B comprised 7 patients with significant levels of proliferation 
(defined as ~cpm > 20000) and predicted levels of cytotoxicity; group C included 7 patients 
with low proliferative (defined as ~cpm < 20000) and predictably low cytotoxic responses to 
PPD. 
The impaired antigen-specific cytotoxicity of patients in group A was confined to cells from the 
synovial compartment, and not associated with an impairement of antigen-induced 
proliferation. These patients demonstrated significantly lower cytotoxic function in their 
SFMNC than their PBMNC (effector:target ratio 10:l : mean PBMNC cytotoxicity 41.4 ± 
7.7%; mean SFMNC cytotoxicity 19.5 ± 3.2%, p < 0.05; effector:target ratio 3:1 : mean 
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PBMNC cytotoxicity 28.4 ± 4.6% ; mean SFMNC cytotoxicity 10.7 ± 2.7%, p < 0.01) . 
Patients in group B had high levels of cytotoxicity in both compartments, with significantly 
higher SFMNC cytotoxicity than patients in group A (group B mean SFMNC cytotoxicity 
41.9 ± 6.2% at effector:target ratio of 10: 1, p < 0.01 compared to group A SFMNC; and 29.0 
± 4.4% at an effector:target ratio of 3:1, p < 0.01 compared to group A SFMNC). Box and 
whisker plots of PPD-specific cytotoxicity at an effector to target ratio of 3: l for patient 
groups A and Bare shown in figure 2.3. Low levels of both PBMNC and SFMNC cytotoxicity 
were found in patients in group C (at an effector:target ratio of 10: 1 : mean PBMNC 
cytotoxicity 5.0 ± 1.9% ; mean SFMNC cytotoxicity 4.5 ± 2.1 % ). Cytotoxicity data at 3 
effector:target ratios, for an individual representative patient from group A and B, are 
displayed in chapter 5, figure 8 (pg. 141). This figure also illustrates the antigen-specificity of 
the findings. 
Figure 2.1 
Correlation of cytotoxicity, at an ejfector:target ratio of 3:1, and proliferation to PPD of 
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Figure 2.2 
Correlation of cytotoxicity, at an effector:target ratio of 3: 1, and proliferation to PPD of 
SFMNC from 20 seropositive RA oatients* . 
50 
r = 0.82 
0 
p < 0 .001 
40 
U) o .. 
U) 0 
>- o · 
0 30 ..... 
>-
0 
0 - 20 0 o · Cl) 
0 • a. 
en 
• o . • cfl. 10 • • group A . . . 0 
0 group B 
• 
0 • 0 group C 
0 0.4 0.8 1.2 1 .6 2 
Day 6 Proliferation (CPM x 1 o5 ) 
•Patients cun be grouped into 3 culcgories according to their SFMNC responses. Group /1. : 6 patients whose 
SFMNC demonstrate significantly lower levels of cytotoxicity than predicted by the amount of proliferation; 
Group B: 7 patients with significant levels of proliferation (L'icpm > 20000) and predicted levels of cytotoxicity; 
Group C: 6 patients with low proliferative (L'icpm < 20000) and cytotoxic responses. Dotted lines indicate 95% 
confidence limits. 
The levels of SFMNC and PBMNC proliferation to PPD were not significantly different 
between patients in groups A and B. Patients in group C had significantly lower proliferative 
responses to PPD in both PBMNC and SFMNC than patients in groups A and B (p < 0.005 ). 
SFMNC from all patients, including those in group C with poor proliferation to PPD, had 
significant proliferative responses to the mitogen PHA (mean day 3 ~cpm: 60236 ± 8325). 
There was no significant difference between the groups in the amount of SFMNC proliferation 
to mitogen, but when compared as a whole, the SFMNC responses were significantly lower 
than PBMNC (p < 0.005) . 
65 




Box and whisker plots of PPD-specific cytolysis, at an effector:target ratio of 3: 1, of PBMNC 
and SFMNC from patients with RA with significant proliferative responses (Lkpm > 20 000)* . 
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"Impaired cytotoxic function is confined to the synovial compartment of patients in Group A and is significantly 
lower than PBMNC from the same group (p < 0.05 ) and SFMNC of group B (p < 0.0 I ). The interquartile range 
(75% - 25%) is indicated by the upper and lower borders of the "box", the median by the horizontal line within 
the "box" and the population range by the vertical "whiskers" . 
Confirmation that PPD-specific cytolysis measured in the l Sh S 1 Cr release assay is mediated 
by CD4+ T-cells was obtained using effector PBMNC positively or negatively selected for 
CD4+ or CD8+ cells . Depletion of CD4+ effector MNC resulted in almost complete 
abrogation of PPD-specific cytotoxicity (control/unseparated effectors: 22% and 12 % PPD-
specific cytolysis at effector:target ratios of I 0: l and 3: l respectively; CD4 depleted effectors : 
1.2% and 0% PPD-specific cytotoxicity at corresponding effeccor:cargec ratios), while 
depletion of CD8+ effector MNC did not significantly affect PPD-specific cytolysis (22% and 
15% at effector:target ratios of IO: I and 3: l) . Conversely, positively selected CD4+ effector 
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MNC were capable of higher PPD-specific cytotoxicity than unseparated PBMNC effectors 
(38% and 26% at effector:target ratios of 10: l and 3: 1), while CD8+ enriched MNC effectors 
did not demonstrate PPD-specific cytolysis at any of the effector:target ratios tested. Efficiency 
of effector subset selection was investigated by phenotypic analysis . CD4+ depleted effectors : 
11 % CD4+ and 42% CD8+ (unseparated effectors : 62% CD4+ and 20% CD8+); CD4+ 
enriched effectors : 88% CD4+ and l % CD8+; CD8+ depleted effectors : 71 % CD4+ and 3% 
CD8+; CD8+ enriched effector: < 1 % CD4+ and 90% CD8+. CD4+ depleted effectors also 
showed an increase in CD56+ cells (unseparated 20%, CD4+ depleted 42%) which was not 
observed in other selected effectors . 
2. SFMNC proliferative and cytotoxic responses correlate with therapy 
In order to identify whether classification of patients according to SFMNC in vitro 
proliferative and cytotoxic responses had clinical significance, analysis of patient clinic records 
was performed. An association between therapy, disease duration and SFMNC proliferative 
and cytotoxic responses was noted (Table 2.1) . Specific impairment of cytotoxicity confined to 
the synovial compartment (group A) was associated with DMARD therapy at the time of study 
in 5 of 6 patients . Of note, while three of these patients were also receiving variable doses of 
NSAIDs, three patients in this group were not on NSAID therapy at all . One patient was 
newly-diagnosed and untreated. Conversely, high levels of SFMNC cytotoxicity in a group of 7 
patients was associated with NSAID monotherapy (group B). The absence of a significant 
PPD-proliferative response in both PBMNC and SFMNC (group C) occurred in 7 patients 
with significantly longer disease duration (p < 0. 0 l) . There were no significant differences in 
the age or sex distribution between the three patient sub-groups . The stability of this 
classification of RA patients with respect to time and changes in therapy was not examined as 
recurrent synovial effusions were not observed in any of the patients during the course of this 
study; monitoring the effects of changes in therapy and increased disease duration on SFMNC 
function in RA may provide additional insight into the pathogenetic significance of our 
findings . 
3. PGE2 production by CD 14+ve synoviocytes and association with SFMNC function 
As E series prostaglandins suppress cytotoxic function ofNK cells and CD8+ T-cells9,I0,17, we 
theorised that these cyclooxygenase products may mediate similar suppressive effects on 
SFMNC CD4+ T-cell cytotoxicity. The correlation of therapy with SFMNC function may thus 
have been the result of therapeutic modulation of synovial prostaglandins. Prostaglandin E2 
production by CD 14+ synoviocytes was significantly higher in patients from group A 
(DMARD ± NSAID), whose SFMNC demonstrated a specific impairment in cytotoxicity, than 
in patients from group B (NSAID monotherapy) where intact SFMNC cytotoxic function was 
found (p < 0.05) [Figure 2.4]. 
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Table 2 .1. 
Clinical parameters of 20 seropositive RA patients classified according to S
FMNC 
* 
proliferative and cytotoxic responses to PPD . 
Duration 
TREATMENT 
PATIENT AGE SEX DMARD NSAID 
GROUPS (vrs) M:F (vrs) 
A 47.6 ± 5.5 2 : 4 5.2 ± 2.7 SSZ (2), CHQ (2), MTX (I) 
INDO (2), DS (J)t 
B 51.8±4.0 I : 6 2.5 ± 0.9 NIL NAP
 (2), INDO (4) DS (3)# 
C 61.6 ± 4.7 2 : 5 16.0 ± 1.8§ SSZ (I), CHQ (2) N
AP (I), INDO (3) DS (2)t 
*Group A: significant proliferation but impaired cytotoxicity; Group B: significan
t proliferation and predicted 
levels of cytotoxicity; Group C: impaired proliferation and cytotoxicity. 
t One patient was newly diagnosed and w1treated; 3 patients were receiving combinations of DMARDs and 
NSAIDs. (n) = number of patients. 
# Two patients were receiving combinations ofindomethacin and diclofenac sodium; § (
p < 0.01) 
t 3 patients were receiving combinations ofDMARDs and NSAIDs. 
SSZ: sulphasalazine; CHQ: chloroquin; MIX: methotrexate; NAP: naproxen; INDO: 
indomethacin; DS: 
diclofenac sodium; 
4. SFMNC cytokine production 
The majority of cytotoxic CD4+ T-cell clones belong to the Th l and Tho p
henotypes 
(predominantly IFN-y producing) and a dissociation between proliferative and
 cytotoxic 
responses at the clonal level is commonly observed in antigen-specific Th2 CD4+ c
lones (IL4 
producing) 18 . In addition, recent reports have indicated that PGE2 favours the emergence o
f 
Th2 clones19. To determine whether the observed dissociation between prolife
ration and 
cytotoxicity in group A was the result of a predominantly Th2 population in the SF
MNC, 48h 
supematants of mitogen stimulated cells from 3 patients in group A and 2 in gro
up B were 
assayed for IFN-y and IL4 levels. SFMNC from all patients tested produced moder
ate to high 
levels of IFN-y with low or undetectable levels of IL4 [Table 2.11], indicating a
 Th 1- like 
cytokine profile in both patient groups, and not the distinct Th2 profile of high levels
 of IL4 ( > 
80 pg/ml) and low or absent IFN-y production (< 5 iu/m1)
20 . Thus the impaired cytotoxic 
function in patients of group A was not due to the presence of predominantly
 Th2 non-
cytolytic T-cells, suggesting a direct suppression of cytotoxic effector function, p
ossibly by 
PGE2, or other products of cyclooxygenase metabolism of arachidonic acid . 
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Figure 2.4 
Box and whisker plot of PGE2 concentration in 18 h supernatants of CDI 4+ve synoviocytes 
from 4 RA patients with impaired SFMNC cytotoxic jimclion (group A) and 4 patients with 
high levels of SFMNC cytotoxic jimction (group BJ*. 
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*PGE2 production is expressed as pg/ 105 CD14+ synoviocytes / ml supernatant. Impaired SFMNC cytotoxicity 
was associated with significantly higher PGE2 production (p < 0.05). 
Table 2.11. 
SFMNC mitogen-ind11ced . cytokine production from 5 RA patients with significant PPD 
proliferation* 
GROUP PATIENT SFMNCPPD IFN-y IL4 
RESPONSES (iu/ml) (pg/ml) 
A I Significant proliferation; 165.6 < 0.8 
2 impaired cytotoxicity 308.5 2.32 
3 1048.0 5.77 
B I Significant proliferation 359.2 < 0.8 
2 and cytotoxicitv 66.9 5.62 
* SFMNC (3 x 106/111!) were stimulated i11 vitro for 48 h using the mitogen PI-IA. IFN-y and JL4 concentrations 
in supematants were detennined by RIA and ELISA. Patients were grouped according to Sf<MNC proliferative 
and cytotoxic responses to PPD. 
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5. PGE2 mediates dissociation of in vitro PBMNC proliferative and cytotoxic functions 
The in vitro effects of PGE2 on nom1al PBMNC proliferative and cytotoxic function were 
investigated. Significant inhibition of PPD-specific cytotoxicity, but not proliferation, was 
found with PGE2 at a final concentration of l µM (one-sided p < 0.05 ) (Table 2.III) . This 
dissociation in functions was sinlilar to that found in the SFMNC from patients with high 
CD14+ synoviocyte PGE2 production (group A) . In contrast to PGE2, specific inhibition of 
cytotoxicity with sparing of proliferation was not a feature of the DMARDs tested; inhibition 
of cytotoxicity by chloroquin was associated with a marked dose-dependent inhibition of 
proliferation, which was also observed with methotrexate and sulphasalazine (Table 2.III) . The 
finding that chloroquin inhibited proliferation more than cytotoxicity may be a result of 
chloroquin being present in the proliferation assay for considerably longer than the cytotoxicity 
assay (7 days compared to 15h). 
Table 2.111. 
The in vitro effects of prostaglandin E 2, chloroquin, methotrexate and sulphasalazine on 
PPD-induced proliferation and PPD-specific cytotoxicity of PBMNC from 5 healthy 
individuals. 
AGENT* FINAL PROLIFERA TIONt CYTOTOXICITYt 
CONCENTRATION (% Inhibition) (% Inhibition) 
PGE2 1.0 µM -3 .3 29.61 
(352 pg/ml) 
CHLOROQUIN 0.4 µg/ml 36. l 3.2 
2.0 µg/ml 58.2 6.6 
10 µg/ml 99.2 22.4 
25 ug/ml 99.3 30. l 
METHOTREXA TE 3.2 µM 99.4 NT 
16 µM 99.6 NT 
80 µM 99.9 NT 
SULPHASALAZINE 9 µg/ml 38.7 NT 
18 µg/ml 62.7 NT 
36 u!!lml 64.l NT 
* Effects on proliferation and cytotoxicity were determined by adding the agents at the initiation of the 6 day 
culture or for the duration of the cytotoxicity assay. Final concentrations of the DMARDs were in the range of 
phannacological levels in vivo21 ,22 . PPD-induced proliferation and PPD-specific cytotoxicity were detennined in 
vitro using standard tritiated thyrnidine incorporation and 51 Cr release assays. 
tvalues shown represent the mean of at least triplicate determinations (SEM < 25% for proliferation assays and 
< 10% for cytotoxicity assays). PPD-induced proliferation of PBMNC in the absence of drugs was in the range tJ. 
cpm 98 000 to 150 000 and control PPD-specific cytotoxicity between 35 - 55%. 
lone-tailed p < 0.05 
NT - not tested 
70 
Chapter 2 Prostanoid modulation of CD4+ T-ce/1 cytotoxicity in RA 
6. Effects of CD 14+ve synoviocyte supernatants on a cytotoxic CD4+ve clone 
To test the hypothesis that prostanoids produced by macrophage lineage synoviocytes have a 
suppressive effect on CD4+ T cell cytotoxic function, the effect of supematants generated from 
CD 14+ synoviocytes on the function of a cytotoxic CD4+ T-cell clone were evaluated. A 
CD4+ T-cell clone was used in preference to PBMNC in order to examine specific effects on 
CD4+ T-cell cytotoxicity in isolation, thereby excluding potential effects on cytotoxic cells of 
other lineages. CD 14+ synoviocyte supematants were generated in the presence or absence of 
10-5 M indomethacin for 18h. Supematants from 2 patients who demonstrated impaired 
SFMNC cytotoxicity and high levels of PGE2 production per CD 14+ synoviocyte (group A), 
and 2 patients who had high levels of SFMNC cytotoxicity and low PGE2 production per 
CD14+ synoviocyte (group B), were added to the 15h 5lcr release assay (final concentration 
50% v/v) of clone TS7.2E against PPD-pulsed target macrophages (Table 2.IV). Supematants 
from all 4 patients generated in the absence of indomethacin contained PGE2 (110 - 1650 
pg/ml) and suppressed the cytotoxic function of the clone. However, significant abrogation of 
this suppressive effect by indomethacin was confined to the 2 patients from group A, and 
associated with a marked reduction of PGE2 concentration in the supematants (>70% 
inhibition) . This abrogation was not due to the presence of indomethacin in the assay (see 
control, Table 2.IV), and suggests a role for products of the cyclooxygenase pathway being 
responsible for suppression of cytotoxic CD4+ effector function in these patients . Addition of 
indomethacin to the CD 14+ synoviocytes of the two patients from group B resulted in minimal 
reduction in PGE2 concentrations (< 30% inhibition), and failure to abrogate the observed 
suppressive effect on cytotoxicity, indicating that the function of cyclooxygenase had been 
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DISCUSSION 
The data presented provide evidence of antigen-specific cytotoxic function of SFMNC from 
patients with RA previously inferred by observations of cytolytic mediators in these cells5•23 , 
and highlight an effector function of CD4+ T-cells that may be relevant to the pathogenesis of 
the disease. A consequence of cytotoxic T-cell activity, even in an infectious disease, may be 
tissue damage24 . In a chronic autoimmune disease such as RA, it is possible that on-going 
cytolysis of target cells bearing self or foreign antigenic epitopes, sequestered in the synovial 
compartment, may contribute to joint destruction25 . The specific aetiological antigen in RA is 
not known and thus investigation of T-cell cytotoxic function requires the use of an alternate 
antigenic stimulus. PPD was chosen for this purpose because, although mycobacterial 
reactivity is not specific for RA26, SFMNC from many RA patients do in fact proliferate in 
response to these antigens27 . PPD-specific cytolysis is HLA class II-restricted and almost 
entirely due to the function of cytotoxic CD4+ T-cell effectors12,28,29 . Mycobacterium 
tuberculosis has been invoked in the pathogenesis of RA30 and it also has previously been 
suggested that cytolysis of mycobacterial antigen-expressing target cells in synovial membrane 
by cytotoxic T-cells may be an important pathogenetic mechanism31 . 
As T-cell proliferation is required to generate CD4+ cytotoxic effectors 16, low levels of 
antigen-specific cytotoxicity found in association with impaired antigen-induced proliferation 
(group C PBMNC and SFMNC) were as expected. Given that BCG vaccination and 
environmental exposure to mycobacteria was uniform for all patients studied, impaired 
proliferation to PPD (and two additional recall antigens - data not shown) may reflect a state of 
anergy in this group of patients32 . It is interesting to note that these patients had significantly 
longer histories of disease, suggesting that MNC proliferative and cytotoxic function may be 
relevant earlier in the pathogenesis of RA when maximum erosive damage occurs33 . Impaired 
PPD-specific cytotoxicity of MNC from patients in group A was associated with adequate 
proliferative responses to PPD and confined to cells from the synovial compartment. This 
implies a different mechanism from that responsible for the low MNC cytotoxicity of patients 
in group C, and suggests the presence of modulators of T-cell cytotoxic function at the site of 
pathology in patients in group A. 
Previous reports have indicated that DMARD suppression of lytic mediators in T-cells may be 
an important mechanism of action of these agents5,23 . The data from this study suggest that 
modulation of SFMNC cytotoxic function cannot be accounted for by the effects of DMARD 
therapy alone, but may also mediated by the effects of NSAID therapy on synovial prostanoid 
production. Evidence in support of this hypothesis includes: (i) the association of specific 
impairment of SFMNC cytotoxicity with significantly higher PGE2 production by 
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macrophage-lineage synoviocytes (group A), and intact SFMNC cytotoxic function with 
NSAID monotherapy and lower CD14+ synoviocyte PGE2 production (group B); (ii) 
abrogation of the suppressive effect of CD 14+ supernatants from patients with elevated PGE2 
production, on the CD4+ cytotoxic clone, by the generation of the supernatants in the presence 
of indomethacin; (iii) in vitro suppression of normal PBMNC antigen-specific cytotoxicity by 
PGE2, with sparing of proliferation, and (iv) inhibition of cytotoxicity with sparing of 
proliferation was not an in vitro effect of the DMARDs tested. Given the comparatively small 
size of the patient population investigated, conclusions should, however, remain guarded; these 
findings need to be confirmed in a larger study. 
High concentrations of arachidonic acid metabolites have previously been described in the 
synovial compartment of patients with RA34, and originate mainly from activated neutrophils 
and macrophage lineage synoviocytes35,36 . The in vitro concentrations of PGE2 used in these 
studies is, however, considerable higher than found in vivo, and thus represent pharmacological 
concentrations37. However, as has been suggested by others, prostaglandins are essentially 
locally acting hormones, often involving cells that are in direct contact where concentrations 
approaching pharmacological levels may be achieved38. Although PGEs have been traditionally 
viewed as having harmful effects in RA, there is increasing evidence to the contrary. In a study 
reported 25 years ago, the beneficial effects of PGE2 on adjuvant arthritis, an animal model of 
RA, were noted39 . Misoprostol, a synthetic PGE l analogue that is increasingly used to treat 
NSAID-associated gastropathy in patients with RA, does not appear to aggravate synovitis40 . 
Anti-inflammatory effects on in vivo models of acute and chronic inflammation have also been 
demonstrated8. Suppression of cytotoxic function ofNK and CD8 cells by PGE is mediated by 
increased intracellular cAMP, resulting in reduced recycling oflytic mediatorsl O_ 
In conclusion, the data suggest that heterogeneity in SFMNC antigen-specific cytotoxicity may 
be accounted for by prostanoid modulation in vivo . Release of prostanoids by activated 
macrophage-lineage cells may provide a negative feedback signal that controls the extent and 
duration of cytotoxic T-cell effector function . In an autoimmune disease like RA, NSAID 
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Chapter3 Eicosanoid regulation ofCD4+ T-cells 
INTRODUCTION 
Evidence from the patient-based study reported in chapter 2 indicates that CD4+ T cells from 
the synovial compartment of patients with RA are capable of effecting antigen-specific 
cytotoxicity and that impairment of this function in a subset of these patients may have been 
mediated by synoviocyte-derived prostanoids. As the rheumatoid synovial compartment is 
characterised by the accumulation of CD4+ T cells and the presence of significant levels of 
eicosanoids, including products of both cycloxygenase and lipoxygenase metabolism, further 
elucidation of the effects of these products on CD4+ T cell functions may have pathogenetic 
and therapeutic relevance1,2. 
As discussed in chapter 1 (pg. 25), leukotrienes (predominantly L TB4 and L TC4) and 
prostanoids (essentially E-series prostaglandins) exert reciprocal modulatory effects on a broad 
spectrum of immune functions ; in general leukotrienes have stimulatory effects and prostanoids 
are inhibitory. With particular relevance to cell mediated cytotoxicity, reciprocal modulation of 
natural killer (NK) function by leukotrienes and prostaglandins has been described3,4,5. 
Previous reports of the effects of eicosanoids on CD4+ T-cell effector functions have been 
confined to PGE2 modulation of cytokine production, noting differential effects on cytokine 
secretion by Th 1 and Th2 CD4+ clones 6, 7 . In addition, recent evidence from animal studies has 
highlighted novel pathways of cytotoxicity of CD4+ T cells that may be distinct from NK 
cytotoxic mechanisms8,9. 
The data reported in this chapter have been obtained using in vitro models of CD4+ T cell 
effector functions. The effects of eicosanoids on polyclonal and monoclonal CD4+ T cell 
populations were examined and attempts made to define the underlying mechanisms 
responsible for the observed effects . The findings extend previous observations of reciprocal 
influences of leukotrienes (B4 and C4) and PGE on immune functions to include CD4+ T-cell 
mediated cytotoxicity and, in certain instances, cytokine production. Marked inhibition of 
cytokine production was a common effect of the prostanoids on both Thl and ThO cytotoxic 
clones, indicating similar signalling pathways in these two CD4+ T-cell subsets. Modulation of 
CD4+ T-cell cytotoxicity by the eicosanoids tested was mainly due to effects on calcium-
dependent pathways of cytotoxicity. In addition, the data indicate that PGE suppression of 
cytotoxicity by CD4+ T-cell clones is a result of modulation of both effector to target binding 
and post-binding events. The implications of these observations for the treatment of RA, and 
the approach to the further definition of the mechanisms of eicosanoid modulation of CD4+ T 
cell functions are discussed. 
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MATERIALS AND METHODS 
1. Leukocyte separation and T-cell clones 
Modulation of CD4+ T-cell functions by PGE was examined in both bulk (unseparated) 
mononuclear cell populations and at the clonal level; examination of the effects of leukotrienes 
on CD4+ T cell function was limited to CD4+ T cell clones . For investigation of effects on 
peripheral blood mononuclear cells (PBMNC), venous blood was obtained from 5 healthy 
volunteers known to have significant mycobacterial antigen reactivity. PBMNC were isolated 
from samples by Ficoll-Hypaque density centrifugation (Lymphoprep - Nycomed, Oslo, 
Norway) as described in chapter 2 (pg 60) . Tissue culture medium used throughout these 
studies was RPMI 1640 (Flow Laboratories, Mclean, VA) containing l OOU/ml of penicillin, 
lOOµg/ml of streptomycin and 10% pooled AB human serum. 
CD4+ T-cell clones were obtained from the site of pathology of three patients with 
inflammatory synovitis, and PBMNC from one healthy laboratory worker. A panel of 11 
clones were used in the studies reported in this chapter. Details of the clones are provided in 
chapters 7 and 5. Briefly, seven of the clones were obtained by limiting dilution cloning ofIL2-
dependent T cell lines from synovial explants of patients with inflammatory synovitis (TS7.2E, 
TS7.5E and TS8 .5A (gout), VS1.3D and VS2.5A (inflammatory OA) and AP2.3E and 
AP2.3C (RA)), and 4 clones from the circulation of a healthy individual (PL 2.2B, PL3 .2D, 
PL18 .1B and PL19.5D). Apart from the VS clones (SK-SD reactive) and clones PL18 .1B and 
PL19.5D (tetanus toxoid reactive) all clones demonstrated PPD-specific reactivity. Limiting 
dilution cloning was performed using either a mitogenic stimulus (AP and VS clones - PHA) or 
antigenic stimulus (TS and PL clones - generated with PPD with the exception of PLl 8. lB and 
PL19.5D [tetanus toxoid]) . Clones were maintained by weekly stimulation with antigen or 
mitogen, irradiated (4000 rads) autologous PBMNC feeders and recombinant interleukin 2 
(rlL2 - 100 iu/ml) (Cetus, Emeryville, CA - kindly provided by Dr Eli Kedar, Hadassah 
Medical School, Jerusalem, Israel), and fed with additional fresh medium and rIL2 (l 00 iu/ml) 
every 3 - 4 days . 
2. Reagents 
Prostaglandin E2 (PGE2), forskolin (FSK, a cyclic AMP agonist) and indomethacin 
(cycloxygenase inhibitor) were purchased from Sigma Chemical Company (St Louis, 
Missouri) . Misoprostol, a synthetic PGEl analogue, was kindly donated by Dr R Marks, GD 
Searle and Co, Skokie, 11. Agents were solubilised in dimethyl sulphoxide (DMSO) (BDH 
Chemicals, Poole, England), and diluted in culture medium so that final concentrations of 
DMSO were always less than 0.1 %; as a vehicle control DMSO 0.1 % was added to all 
relevant control cultures and assays. Stock solutions were stored at -100c in light-protected 
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containers. Leukotriene B4 (LTB4) and leukotriene C4 (LTC4) were purchased from Sigma, 
stored at -2ooc and diluted in tissue culture medium immediately prior to use in the assays . 
Ethylene glycol bis - (P-amino ethyl ether) N,N,N',N' - tetraacetic acid (EGTA, Sigma) was 
solubilised in RPMI, and pH adjusted to 7.4. 
3. Cytotoxicity assays 
Antigen-specific cytotoxicity of PBMNC and CD4+ T-cell clones was measured in a 15 h 
5 lchrornium (5 lcr) release assay as described in chapter 2 (pg. 60) . Cytotoxic function of 
PBMNC was measured after 6 days of antigen exposure and of the clones 2 days after re-
stimulation with feeders and antigen. Adherent autologous MNC were used as target cells 
following an optimal interval of 4-7 days culture at 37°C in l 00µ1 complete medium in 96-well 
U-bottomed tissue-culture plates (Flow Laboratories) . Target cells were pulsed with PPD (10µ 
g/rnl), SK-SD (1 : l O dilution), tetanus toxoid (Lederele Laboratories, American Cyanamid Co, 
Pearl River, NY) ( l : l O dilution), or medium alone, and labelled with 6µCi/well 51 Cr for 24h. 
Effectors were added to give final effector:target ratios of 10:1. 3:1 and 0.3:1. The percentage 
specific cytotoxicity for the mean of triplicate wells was calculated as detailed in chapter 2 (pg. 
61) . The percentage spontaneous release was always less than 20%. Lectin-dependent 
cytotoxicity of the T-cell clones was measured by the addition of PHA (Wellcome, final 
concentration of 5.75 x 10-3 mitogenic units/ml) to the 15h assay, using 5 lcr-labelled 
autologous mononuclear cells without antigen as targets 10 . The effects of the eicosanoids on 
cytotoxicity were investigated by adding the agents at the initiation of the 15h incubation 
period of both the antigen-specific and lectin-dependent 5 lcr release assays . Effects of PGE2 
on the generation of cytotoxic effectors in PPD-stimulated PBMNC were determined by adding 
the agent at the initiation of the 6 day effector culture period. 
To determine the extracellular calcium ([Ca2+1exd dependency of antigen-specific cytotoxicity 
mediated by the CD4+ T cell clones, T cell clones (5 x 105/ml in complete medium) were 
incubated on anti-CD3 (OKT3, Jannsens Pharmaceuticals, Johannesburg, South Africa ) 
coated 96 well flat-bottomed plates (Flow Laboratories) for 3h at 37°C in a humidified 
atmosphere containing 5% CO2. Plates were centrifuged at 200g for 5 minutes prior to 
incubation. Anti-CD3 (5µg/rnl) was adhered to the tissue culture plates by overnight incubation 
at room temperature in PBS; the antibody coated plates were washed 3 times prior to use. 
Following stimulation by plastic adherent anti-CD3, T cell clones were resuspended and 
washed and used in 15h 5lcr release assays in the presence or absence of MgEGTA (3mM 
MgCl2 and 6mM EGTA), as previously described11 . This concentration of EGTA was 
calculated to be sufficient to chelate all free ca2+ present in complete medium. Viability of 
effector cells cultured in the presence of MgEGTA for 15h was determined by trypan blue 
exclusion. The effects of MgEGT A on spontaneous release of 51 Cr by target cells were 
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investigated by culturing 51 Cr-labelled target cells in the presence or absence of MgEGT A for 
15h (without the addition of antigen or effector cells), and measuring spontaneous and 
maximum 5 lcr release as in the cytotoxicity assay. 
4. Phenotypic analysis 
Dual parameter flow cytometric analysis of clones and PPD-stimulated PBMNC was 
performed on an Epics Profile II (Coulter Electronics, Hialeah, Florida) . Monoclonal 
antibodies used were CD3-RD1 , CD4-FITC, CD8-FITC, NKHl-RDl (anti-CD56), IL2-Rl-
FITC, 12-FITC (anti-HLA-DR), B4-FITC (anti-CD19) and Tll-RDl(anti-CD2) (Coulter 
Immunology, Hialeah, Florida) . Histograms generated were (i) forward scatter (FS) vs log side 
scatter (LSS), (ii) log fluorescence 1 (LFl) vs log fluorescence 2 (LF2), (iii) and (iv) single 
parameter histograms of LF 1 and LF2. Lymphocytes were bitmapped on histogram 1 to 
visually exclude monocytes and debris . Non-specific antibody binding was evaluated using the 
relevant mouse isotypic control, allowing for 2% false positives. Histogram data were 
generated for 104 events . With this technique it is possible to determine (i) percentage of cells 
positive for a particular surface phenotypic marker, and (ii) the fluorescence intensity of the 
phenotypic marker. The latter parameter is measured as the mean channel number of 
fluorescence, and is an indicator of the density of expression of the cell surface marker. The 
units of expression of mean channel number are arbitrary, and comparable only for an 
individual antibody. 
5. Cytokine assays 
CD4+ T-cell clones (2 x 106/ml in culture medium) were re-stimulated using either feeders 
and antigen, feeders and rnitogen, or plastic-adherent anti-CD3 (OKT3) and rIL2, in the 
presence or absence of varying concentrations of PGE2, rnisoprostol, L TB4 and L TC4 for 
48h. Supernatants were collected and stored at -70°C until assayed. Interferon-y (IFN-y) 
concentration in the supernatants was measured by commercial RIA (IFN-y IRMA, Medgenix 
Diagnostics, Fleurus, Belgium) and interleukin 4 (IL4) concentration determined by 
commercial ELISA (IL-4 EASIA, Medgenix Diagnostics), according to the manufacturers' 
directions. 
6. Data analysis 
All cytotoxicity assays of the T cell clones were performed in triplicate on at least 2 separate 
occasions. The paired students t test was employed for statistical comparison using the 
program Instat (GraphPad Software, San Diego, CA). Unless stated otherwise, two-tailed p 
values are reported; p values less than 0.05 were considered significant. 
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RESULTS 
1. PGE2 inhibits antigen-specific and non-specific cytotoxicity of PPD-stimulated 
PBMNC. 
PGE2 (lo-6M) caused significant inhibition of PBMNC cytotoxicity. Both the generation of 
cytotoxic effectors as well as the cytotoxic function of these effectors were inhibited (Figure 
3.1). Inhibition of both antigen-specific (against PPD-pulsed targets) and non-specific 
cytotoxicity (targets without antigen or with irrelevant antigen, SK-SD) was found and was 
maximal when PGE2 was added at the initiation of the effector culture (Figure 3.1). 
Figure 3.1 
The in vitro inhibitory effects of PGE2 on antigen-specific and non-specific cytotoxic 












• PGE2 in assay (15h) 
0 PGE2 preincubation 
with effectors (6 d) 
3 0.3 
EFFECTOR:TARGET RATIO 
PBMNC from 5 healthy individuals were primed in vitro for 6 days with PPD (triangles). PGE2 (10-6M) was 
added either at the initiation of the effector culture period (open circles) or for the duration of the 15h 5 lcr 
release assay only (diamonds). Solid lines indicate antigen-specific cytotox.icity and dotted lines show non-
specific cytotox.icity. Mean± standard error are shown. * p < 0.05; ** p < 0.005 
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2. Modulation of effector PBMNC phenotypic expression by PGE2 
Phenotypic analysis of effector PBMNC indicated differential modulation of cytotoxic cell 
populations by PGE2 (Table 3.1). A significant reduction in the percentage of CD56+ MNC 
(NK/LAK) (p < 0.05) and a trend to lower percentages of CD8+ lymphocytes was found in 
MNC stimulated with PPD in the presence of PGE2, and contrasts with the significant increase 
in the percentage of CD4+ lymphocytes in these effectors (p < 0.005) . As PPD-specific 
cytotoxicity measured in the 51 Cr release assay is mediated almost entirely by CD4+ T-
cells12, 13, the finding of increased percentages of CD4+ T-cells in effectors generated in the 
presence of l o-6M PGE2 suggests a functional rather than quantitative inhibitory mechanism 
on cytotoxicity. This contrasts with the parallel reduction in the percentage of CD56+ cells and 
the impairment in anomalous cytotoxicity of the PBMNC effector cells stimulated in the 
presence of PGE2. Although PGE2 resulted in a relative increase in the percentage of CD4+ T-
cells in response to PPD, these cells were less activated, with a reduced percentage of CD4+ 
cells expressing HLA-DR when compared with control effectors(Table 3.1). In addition, 
reduction in cell surface expression of CD4 was indicated by a significant decrease in CD4 
mean channel number or brightness of fluorescence (Table 3.I) (Figure 3.2). Marked reduction 
ofHLA-DR expression on CD4- cells was also observed as an effect of PGE2 (Fig 3.2). 
TABLE 3.1 
Phenotypic analysis of PPD-stimulated peripheral blood mononuclear effector cells cultured 
in the presence or absence of 10-6M PGE2for 6 daysf 
PERCENTAGE POSITIVES MEAN CHANNEL NUMBER 
CONTROL PGE2 CONTROL PGE2 
CD3 73 .7 ± 3.6 79.8 ± 4.5 6.17 ± 0.37 5.63 ± 0.69 
CD4 53 .2 ± 2.6 65.7 ± 1.7** 4.79 ± 0.40 3.42 ± 0.39** 
CD8 21.7 ± 3.0 18 .9 ± 3.7 5.11±0.42 6.27 ± 1.82 
CD56 20.87 ± 3.3 7.9 ± 1.3* 14.76 ± 3.95 5.84 ± 1.03 
%CD4 IL2R# 16.5 ± 6.3 11.9 ± 2.6 2.22 ± 0.33 2.64 ± 0.33 
%CD4DRt 32.0 ± 6.7 20.87 ± 4.4* 5.07 ±0.91 4.01 ± 0.58 
IL2R 19.7 ± 6.5 9.2± 1.8 2.14±0.33 2.37 ± 0.47 
DR 35.3 ± 5.4 21.2 ± 2.0* 5.77 ±0.45 4.14 ± 0.38 
t Peripheral blood mononuclear cells were obtained from 3 healthy PPD-reactive volunteers. Dual parameter 
flow cytometric analysis of PPD-stimulated effector cells cultured in the presence or absence of PGE2 ( 1 o-6M) 
was performed as described in materials and methods. 
# Percentage ofCD4+ cells positive for JL2 receptor expression 
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3. PGE2, misoprostol and forskolin inhibit cytotoxicity of CD4+ T-cell clones. 
The mechanism of prostaglandin suppression of CD4+ T-cell cytotoxicity was further 
investigated by detennining the effects of PGE2, misoprostol and forskolin on the cytotoxic 
effector function of a panel of seven CD4+ T-cell clones. PGE2, misoprostol and forskolin, 
alone or in combination, suppressed cytotoxicity when added to the 5 I Cr release assay of these 
clones (Table 3.II) . Representative cytotoxicity data at multiple effector:target ratios for clone 
TS 7.2E is shown in figure 3.3 . In addition, significant inhibition of cytotoxicity was found 
with PGE2 and misoprostol at final concentrations of 10-7M and 10-SM; forskolin was only 
weakly inhibitory at concentrations less than 10-SM (Table 3.Jl) . PGE2 suppression of 
cytotoxicity was not titratablc (unlike misoprostol}, displaying a dose response with peak 
inhibition at 10-6M. 
FIGURE 3.2 
Dual parameter flow cytometric analysis of PBMNC cultured for 6 days with PPD in the 
absence (a) or presence (b) of PGE2. 
(a) (b) 
35.6% I 17.9% 
43.6% 15.2% 
I ___ .... -.... __ 
I"- --- ••• 
I 
__ .. r-·· I ) 
R-_.::--_ ._l ( () _,-!/ 
,,\ ___ --\ [..... ------·-... ·· 
·, ) J / - ·------·---
' .1·· ~~ ,' 
·"_r-- _.- --·· ..... _..,.-_,.,.. 
• -- _ _,...-.~ II 
;=--=- -------•- - ----- ~-- - ~ l-
·120.2% .---···r_.- -1 \ J - / '-i"' ,-., . ( . • 
I ',J • •. ___ ti..:,· .. ~. \ ) ) I • J"• l \.,. ./ 
I '='. •.. L ~ ...., ~ ..r·· 1 
I -.i ··1-· ~. 
~,.:.7.-~· (._' -+-__ ll.. (~.:. ~--26.3% 
• .. 
DR 
* Analysis was perfonned as described in materials and methods. Although PGE2 resulted in increased 
percentages of CD4+ cells, the mean channel number of CD4 on these cell s was lower than controls (see Table 
3.1). PGE2 caused reduced expression of 1-Il..A-DR on CD4+ and CD4- cells. Figures shown represent the 
percentage of cells in each quadrant. 
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TABLE 3.11 
Percentage inhibition of cytotoxic effector junction of CD4+ T cell clones by PGE 2 and 
other cAMP agonists* 
CLONE PGE2 PGE2 PGE2 MISO MISO MISO FSK FSK PGE2+ 
10-5M 10-6M 10-7M 10-5M 10-6M 10-7M 10-5M 10-6M FSKt . 
TS7.2E 26.9 55.9 25.4 58 .8 57.8 42.8 38 .6 8.3 59.8 
TS7.5E 29.2 44.2 30.l 49.l 45 .6 29.8 nd nd nd 
TS8 .5A nd 32 .6 nd 48 .5 22.3 18.4 20.5 6.3 nd 
PL2.2B 16.4 48.2 22.3 52.3 18 .9 12.2 17.9 nd 63 .8 
PL3 .2D 10.6 51.9 35.6 48 .8 nd nd 22 .3 7.7 57 .9 
VS2 .5A nd 89.3 nd nd nd nd nd nd nd 
VS1.3D# nd 23 .9 nd nd nd nd nd nd nd 
*Data shown as percentage inhibition of antigen-specific cytotoxicity (unless indicated otherwise), at an effector 
to target ratio of 10:1, by the presence of the agent for U1e duration of the 15h Sier release assay. Cytotoxicity 
assays were perfonned in triplicate on a least two occasions. Control (maximum) cytotoxicity: TS7.2E - 44%, 
TS7.5E - 25%, TS8.5A - 48%, PL2.2B - 36%, PL3 .2D - 30%, VS2 .5A - 28%, VS 1.3D - 29%; with the exception 
of U1e lectin dependent assay of clone VS 1.3D, non-specific cytolysis of targets without antigen, or targets with 
irrelevant antigen was less than 2%. 
t PGE2 I o-6M and forskolin I o-5M 
# Lectin dependent cytotoxicity 
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The inhibitory effects of cyclic AMP 
agonists on the PPD-specific cytotoxic 
effector function of a CD4+ T cell clone, 
TS7.2E. 
The agents were added for U1e duration of the I Sh 
51 Cr release assay. Data represent the mean of 
triplicate detenninations perfonned under the same 
experimental conditions. Similar results were 
found with this clone on a further two occasions 
and with 6 0U1er CD4+ T cell clones. 
FSK - forskolin; MISO - misoprostol; PGE2 + FSK 
- PGE2 10-6M and forskolin 10-SM. 
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4. Modulation of CD4+ T cell mediated lectin dependent cytotoxicity by the presence 
of cAMP agonists in the assay. 
CD4+ T-cell mediated cytolysis may be mediated by granule exocytosis and fas/fas ligand 
interactions (see Chl pg 20) . Both mechanisms of cytotoxicity involve effector-to-target 
binding that initiates a series of events leading to target cell death. We undertook to define 
whether PGE2 and forskolin exert their suppressive effects on CD4+ T-cell cytotoxicity at 
effector-to-target binding or post-binding events. Effects on binding were investigated in a 
lectin-dependent cytotoxicity assay in which PHA was used as a non-specific adhesive agent, 
thereby overcoming any inhibition of effector-to-target binding14 . Both PGE2 (lo-6M) and 
forskolin (1 o-5M) inhibited lectin-dependent cytotoxicity of clone TS7 .2E if present during the 
assay, although the levels of inhibition were lower than that observed on antigen-specific 
cytotoxicity: PGE2 mean inhibition of antigen specific cytotoxicity : 56 .6 ± 4.4% and mean 
inhibition of lectin dependent cytotoxicity : 29.7 ± 2.7%; forskolin mean inhibition of antigen 
specific cytotoxicity : 24.3 ± 3.6% and mean inhibition of lectin dependent cytotoxicity : 13.5 ± 
2.1 %; (n=3, 10: l effector:target ratio) . Representative lectin dependent cytotoxicity data of 
clone TS7.2E at multiple effector to target ratios is shown in Figure 3.4. The reason for the 
plateau in cytolysis between 3: 1 and 10: 1 effector to target ratios is not clear; this may reflect 
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FIGURE 3.4 The inhibitory effects of cyclic 
AMP agonists on the lectin dependent cytotoxic 
effector function of a CD4+ T cell clone, 
TS7.2E. 
The agents were added for the duration of the 15h 5 lcr 
release assay in the presence of PHA (5 .75 x 10-3 
mitogenic units/ml). Similar results were found with this 
clone on a further two occasions. 
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5. Pre-incubation of CD4+ T cell clones with PGE2 inhibits antigen-specific but not 
lectin dependent cytotoxicity. 
To investigate the effects of PGE2 on the generation of cytolytic potential, CD4+ T-cell clones 
were pre-incubated in the presence of 10-6 M PGE2 for periods of between 48h and 3 weeks . 
For the longer pre-incubation periods (> l week), T cell clones were cultured on plastic 
adherent anti-CD3 in complete medium supplemented with rIL2 (50 iu/rnl) and PGE2 or 0 .1 % 
DMSO in RPMI (control), fed every 3-4 days with fresh medium containing PGE2 or control 
solution, and passaged weekly. Cytotoxicity assays were performed after extensive washing of 
effector cells, without the addition of PGE2 to the assay. Inhibition of antigen-specific but not 
lectin-dependent cytotoxicity was a consistent finding . Representative data obtained with clone 
PL3 .2D following a 3 week pre-incubation in the presence of PGE2 are shown in Figure 3.5; 
similar results were observed with this clone on two additional occasions (pre-incubation 
periods of 48h and 1 week) and with clones PL2.2B and TS7.2E following a 48h pre-
incubation with PGE2. These findings thus indicate that pre-incubation with PGE2 had no . 
direct effect on the generation of cytolytic potential in the CD4+ T cell clones, as demonstrated 
in the lectin dependent assays . The suppression of antigen-specific cytotoxicity under the same 
experimental conditions was an interesting observation, suggesting sustained modulation of 
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FIGURE 3.5 
Pre-incubation with PGE2 (1 o-6M) inhibits antigen-
specific, but not lectin-dependent cytotoxic function of a 
CD4+ T-cell clone. 
Clone PL3.2D was passaged for 3 weeks using plastic-adherent anti-
CD3 and recombinant lL2 (50 iu/ml), in the presence or absence of 
PGE2. Effectors were washed extensively before measuring 
cytotoxicity in a standard 15h 5 lcr release assay, without the 
addition of PGE2 to the assay. 
Control (PPD) - control effectors (antigen-specific); Control (PHA) 
- control effectors (Jectin-dependent); PGE2 (PHA) - PGE2 pre-
incubated effectors (lectin dependent); PGE2 (PPD) - PGE2 pre-
incubated effectors (antigen-specific). 
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6. Effects of PGE2 on phenotypic expression of CD4+ T cell clones 
Phenotypic analysis of CD4+ T-cell clones stimulated with feeders and antigen in the presence 
of 10-6M PGE2 for 48 h indicated no significant modulation of CD4, CD28 or CD29 when 
compared to controls . Pooled data obtained with clones TS7.2E, TS7.5E and PL 2.2B are 
shown in Table 3.III. Thus the observed functional inhibition of cytotoxicity cannot be 
attributed to effects on these antigens . Interestingly, differential modulation of activation 
markers on CD4+ clones by PGE2 was observed, with significant reduction in HLA-DR 
expression (p < 0.05) and a trend to increased IL-2 receptor expression (p = 0.06, ns) (Table 
3.III) . 
TABLE 3.111 
Phenotypic analysis of 3 antigen-specific CD4+ T-cell clones cultured in the presence or 
absence of 10-6M PGE2for 48 hf 
PERCENTAGE POSITIVES MEAN CHANNEL NUMBER 
CONTROL PGE2 CONTROL PGE2 
CD4 91.5±1.0 91.0 ± 1.4 19.28 ± 6.41 21.95 ± 7.18 
IL2R 15.4 ± 1.6 25.3 ± 5.4 10.57 ± 2.70 11 .32 ± 3.32 
DR 53.5 ± 13.3 48.2 ± 16.5 34.59 ± 6.69 25.61 ± 9.62* 
CD29 45 .0 ± 4.7 39.6 ± 6.2 2.78 ± 0.70 3.68 ± 0.20 
CD28 36.2 ±3.0 37.8 ± 4.6 2.13±0.31 1.68 ± 0.07 
t Clones were re-primed using irradiated autologous feeders and antigen at optimal concentrations. Indomethacin 
( I0-5 M) was used to inhibit de novo prostaglandin synthesis. Dual parameter flow cytometric analysis was 
performed as described in materials and methods. *p < 0.05 
7. PGE2 and misoprostol inhibit cytokine production by Thl and ThO cytotoxic CD4+ 
T-cell clones. 
The effects of PGE2 and misoprostol on cytokine production by a panel of six cytotoxic CD4+ 
T-cell clones were investigated. Cytokines were measured in supernatants of cells stimulated 
for 48 h, in the presence or absence of PGE2 or rnisoprostol, with either autologous feeders 
and antigen, autologous feeders and mitogen or immobilised anti-CD3 and rIL2, without 
feeders . Indomethacin (lo-5M) was used to inhibit de novo prostaglandin production by 
feeders . IFN-y and IL4 were quantified using commercial kits (Medgenix) . Marked inhibition 
(60-95%) ofIFN-y production by 3 Thl clones and IFN-y and IL4 production by 3 ThO clones 
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was caused by both PGE2 and misoprostol, irrespective of the mode of stimulus. 
Representative data from 3 clones is shown in Figure 3.6. PGE2 and misoprostol inhibition of 
IL4 production by ThO clones occurred even in the presence of high concentrations of 
recombinant IL2 (100 iu/ml) used in combination with solid phase anti-CD3 to stimulate 
cytokine production (Fig 3.6c) . 
FIGURE 3.6 
Prostanoid inhibition of cytokine production by cytotoxic CD4+ T cell clones* 
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*PGE2 and misoprostol inhibit IFN-y production by a Thi CD4+ clone stimulated with feeders and antigen (a), 
and IFN-y and II.A production by ThO cytotoxic CD4+ clones stimulated with feeders and mitogen (b) or with 
plastic adhered anti-CD3 and rIL2 ( !OOiu/ml) (c). Supematants were harvested after 48 hand assayed for IFN-y 
and II.A using commercial kits. Similar results were found for an additional ThO clone and 2 Thi clones. 
8. Leukotriene B4 and C4 augment cytotoxic effector function of CD4+ T cell clones 
The effects of L TB4 and L TC4 on CD4+ T cell mediated antigen-specific cytotoxicity were 
investigated by adding the agents to the 15h 5 lcr release assay of a panel of 3 CD4+ T cell 
clones (PL2.2B, PL18.1B and TS7.2E). Indomethacin (lo-5M) was used to inhibit de nova 
prostaglandin synthesis, known to be stimulated by leukotrienes 15 . In addition, the effects of 
PGE2 ( l o-6M) on cytotoxicity were assayed under the same experimental conditions. Pooled 
cytotoxicity data, at an effector to target ratio of l O: 1, for the 3 clones on at least 2 separate 
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occasions is shown in figure 3.7. Both LTB4 {lo-lOM and 10-12M) and LTC4 {lo-lOM only) 
resulted in moderate but significant increases in antigen specific cytotoxicity (p < 0.05) . Under 
the same experin1ental conditions, PGE2 caused significant suppression of cytotoxic effector 
function (p < 0.01) . Increase in cytotoxicity was in the range 12.3 ± 3.5% (LTB4 10-IOM) to 
17.3 ± 4.8% (LTC4 10-lOM). Pooled data from experiments performed under the san1e 
conditions indicated that PGE2 resulted in mean inhibition of cytotoxicity of 31.9 ± 8.2%. 
Figure 3.7 
Modulation of cytotoxic effector function of a panel of 3 CD4+ T cell clones by leukotrienes 



















nleukotrienes and PGE2 were added for the duration of the I Sh 5 lcr release assay. Data shown represent the 
mean ± standard error of antigen specific cytotoxicity ( effector:target ratio l 0: I) of a panel of 3 CD4+ T cell 
clones assayed on a total of7 occasions.• p < 0.05; ••p < 0.01 
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9. Modulation of CD4+ T cell cytokine production by leukotrienes. 
The effects of L TB4 and L TC4 on cytokine production by a panel of three cytotoxic CD4+ T-
cell clones were investigated. Cytokines were measured in supematants of cells stimulated for 
48 h by PHA and autologous feeders, in the presence or absence of the agents . Indomethacin 
(lo-5M) was used to inhibit de nova prostaglandin production by feeders. Some diversity in 
the effects of LTB4 and LTC4 on cytokine production was noted (Table 3.IV). High levels of 
IFN y production by a Thl clone were essentially unaffected by the presence of exogenous 
L TB4 and LTC4. However, low levels of IFN y production by a ThO and an additional Th 1 
clone were increased in the presence of L TC4 (both clones) and L TB4 (Th 1 clone only). IL4 
production was not influenced by the leukotrienes; levels of IL4 remained undetected in the 
supematants of Th 1 clones stimulated in the presence of L TB4 and L TC4, and high levels of 
production ofIL4 by the ThO clone was unaltered in the presence of the leukotrienes . 
Table 3.IV 
Effects of leukotrienes B4 and C4 on cytokine production by CD4+ T cell clones* 
TS 7.2E PL 18.lB# PL 19.5D# 
IFNy IL4 IFNy IL4 IFN y IL4 
(iu/ml) (og/ml) (iu/ml) (og/ml) (iu/ml) (pg/ml) 
CONTROL 195 < 16 34 > 1358 15 < 16 
LTB4 10-8M 187 (-4.1) < 16 33 (-2.9) > 1358 25 (66.7) < 16 
LTB4 10-lOM 197 (1.0) < 16 33 (-2.9) > 1358 23 (53.3) < 16 
LTB4 10-12M 198 (l.5) < 16 36 (5 .9) > 1358 25 (66.6) < 16 
LTC4 10-8M 178 (-8.7) < 16 44 (29.4) > 1358 24 (60) < 16 
LTC4 10-lOM 179 (-8.2) < 16 38 (11.8) > 1358 27 (80) < 16 
LTC4 10-12M 190 (-2.6) < 16 34 (0) > 1358 31 (106) < 16 
* T cell clones were stimulated in vitro with PHA and autologous irradiated PBMNC as feeder cells. 
Leukotrienes were added at the initiation of the culture period. Supernatants were harvested after 48 hand 
assayed for IFN-y and IIA using commercial kits . Values in parentheses are percentage change in cytokine 
concentration. 
#clones PL18. IB and PLI 9.SD were obtained by limiting dilution cloning ofnornrnl PBMNC and have tetanus 
toxoid-specific proliferative responses. 
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10. Extracellular calcium ([Ca2+1ext) dependency of antigen-specific cytotoxicity 
mediated by CD4+ T cell clones 
Antigen-specific cytotoxicity of a panel of 5 clones used in the above experiments was 
measured under [Ca2+1ext free conditions following pre-activation by plastic adherent anti-
CD3 stimulation for 3h. Parallel assays performed in standard culture conditions, after a 
similar pre-activation procedure, served as controls . In the presence of MgEGTA (3mM 
MgCl2 and 6 mM EGT A) cytotoxic effector function of all clones tested was markedly 
inhibited; control cytotoxicity: 33.4 ± 2.2%, [Ca2+1ext free cytotoxicity: 2.19 ± 0.83% at an 
effector to target ratio of 10:l (p < 0.001) (Figure 3.8a) . Both effector cell viability and levels 
of spontaneous 51 Cr release by target cells were unaffected by the presence of the chelating 
agent at the concentrations used in the cytotoxicity assays . Effector cell viability after 15h 
culture in the presence of MgEGTA was greater than 95% (determined by trypan blue 
exclusion for each of the 5 clones); spontaneous:maximum 5 lcr release of target cells 
incubated in the presence ofMgEGTA for 15h was always less than 20% (determined for each 
cytotoxicity assay), and was similar to controls . 
Clone TS7.2E was pre-activated as described above and cytotoxicity assays performed in the 
presence of variable concentrations of MgEGT A. A dose-dependent inhibition of cytotoxic 
effector function was observed, with almost complete suppression of cytotoxicity at a final 
EGTA concentration of 6mM (Figure 3.8b) . 
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Figure 3.8 
Extracellular calcium-dependency of antigen specific cytotoxicity mediated by CD4+ T cell 
clones 
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(a) Pooled cytotoxicity data (effector:target ratio 10:1) of 5 clones following preactivation on plastic adherent 
anti-CD3, under standard conditions (control) or [Ca2+lext free conditions (6mM EGTA). Data points represent 
the mean of triplicate determinations for each clone and error bars indicate mean ± standard error for the pooled 
data. 
(b) Dose dependent inhibition of cytotoxic effector function of clone TS7.2E by MgEGTA. Antigen-specific 
cytotoxicity at an effector to target ratio of 10: I is shown. Data points represent the mean of triplicate 
determinations; variation was less than I 0% for each triplicate. 
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DISCUSSION 
In the studies reported in this chapter the role of eicosanoids in the in vitro regulation of CD4+ 
T cell effector functions has been examined and the mechanisms of their actions addressed. 
Within the limitations of the in vitro studies, the findings provide evidence suggestive that 
leukotrienes (B4 and C4) and prostaglandins have opposite modulatory effects on CD4+ T-cell 
effector functions . As current paradigms of the irnmunopathogenesis of RA support a central 
role for synovial CD4+ T cells in the initiation and perpetuation of the disease, the potential 
regulatory effects of eicosanoids suggested in the current study may be of importance at the 
site of pathology in RA 16, 17. 
A relative increase in the in vitro expansion of CD4+ PBMNC in response to soluble antigen 
was observed in the presence of PGE2. However, these cells were found to have impaired 
cytotoxic function. As antigen-specific cytotoxicity of the T cell clones demonstrated in the 
current study was mainly calcium dependent, inhibition of the granule exocytosis pathway of 
cytotoxicity by cAMP agonists is suggested, in common with previous studies of CD8+ T cells 
and NK cells 17,5 . PGE2 inhibition of antigen-specific cytotoxicity mediated by the T cell clones 
displayed an unusual titration effect, with maximal inhibition observed at a final concentration 
of l o-6 M (table 3 .II). Recently a similar bi-phasic inhibitory phenomenon of T cell mediated 
cytotoxicity has been described with the cAMP analog 8-chlorophenylthio-cAMP, and may be 
related to activation status of effector cells 18. It is possible that a similar mechanism may 
account for the findings of the current study, given that PGE2 is a potent stimulator of 
intracellular cAMP. The difference in the titration of the inhibitory effects on cytotoxicity of 
PGE2 and rnisoprostol may be due to the relative potency of these agents, with the rnisoprostal 
titration curve to the left of that for PGE219. 
The inhibitory mechanisms of cAMP agonists on CD4+ T cell mediated cytotoxicity were 
further investigated using a lectin dependent cytotoxicity assay. Suppression of antigen-specific 
but not lectin-dependent cytotoxicity by pre-incubation of T cell clones with PGE2 is indicative 
of inhibitory effects on effector to target cell binding14. In addition, inhibitory effects of PGE2 
and other cAMP agonists on post-binding events are implied by the suppression of lectin 
dependent cytotoxicity when the agents were present in the assay; similar effects on post-
binding events have previously been demonstrated in a cytotoxic CD8 T cell clone and 
attributed to inhibition of intracellular cytolytic granule delivery mechanisms17. The 
maintenance of lectin dependent cytotoxicity despite long-term culture of a CD4+ T cell clone 
in the presence of high concentrations of PGE2 suggests that PGE2 does not modulate the 
generation of cytolytic machinery, and thus inhibits T cell cytotoxicity at a level distinct from 
cyclosporin and corticosteroids20,21 _ 
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Inhibition of effector to target binding by PGE2 could not be attributed to effects on the cell 
surface antigens studied. In particular, modulation of CD28, a structure thought to be relevant 
to the activation and function of cytotoxic T-cells, was not an effect of PGE2 or 
misoprostol22,23. While PGE2 inhibition of class II MHC expression is well-established, and 
confirmed in the present study, this does not account for impairment of effector to target 
binding, as (i) antigen-specific cytotoxicity of T cell clones pre-incubated in the presence of 
PGE2, but without PGE2 in the assay, was inhibited - thus inhibition of target cell HLA-DR 
expression cannot be invoked in this setting, and (ii) as demonstrated in the next chapter, HLA-
HLA-DR expression of cytotoxic CD4+ T cell clones does not necessarily correlate with 
cytotoxic function 24 . It is possible that inhibition of binding is due to effects of cAMP agonists 
on other surface antigens or, as has been described in a cytotoxic CD8+ T-cell clone, may be 
due to modulation of dynamic cytoskeletal function 17. 
The role of leukotrienes in T cell function is somewhat controversial, as discussed previously 
(Chi pg. 29) . It has been demonstrated that T cells are capable of converting macrophage-
derived LT A4 to L TB4 by the action of L TA4 hydrolase and that L TB4 stimulates T cell 
proliferation25 ,26 . The current study provides a novel demonstration that LTB4 and LTC4 have 
moderate but significant stimulatory effects on CD4+ T cell cytotoxicity. However, the effects 
of L TB4 were not titratable, which may question the reliability of the finding . As indicated 
above, these effects were mainly on the calcium dependent cytotoxic function of the CD4+ T 
cell clones and thus may be the result of similar mechanisms as have been described for 
leukotriene augmentation of NK function3. 
The mechanisms of T cell cytotoxicity have been discussed previously (Chi pg. 20) . Based on 
animal studies it has been suggested that a [Ca2+Jext independent pathway, mediated by 
fas/fas-ligand binding, is the major mechanism of CD4+ T cell mediated cytotoxicityl 1 _ 
However, recent evidence indicates that cytotoxic CD4+ and CD8+ T cells mediate both fas-
and perforin ([Ca2+Jext dependent) pathways of cytotoxicity, and that considerable variation 
with respect to the relative importance of either pathway exists within each subset27 . In the 
present study, antigen-specific cytotoxicity mediated by a panel of 5 human CD4+ T cell 
clones of diverse origin was demonstrated to be almost entirely [Ca2+1ext dependent. It is 
possible that this finding may reflect a difference between murine and human CD4+ T cell 
cytotoxicity mechanisms, or as previously reported, may be a function of the target cells used 
in the assays11 . In addition, although [Ca2+Jext independent cytotoxicity may be mediated by 
fas/fas ligand binding, up regulation of fas ligand on effector T cells and apoptosis (the result of 
fas binding) of target cells may be [Ca2+Jext dependent, and consequently inhibited under 
[Ca2+Jext free conditions28,29 . Furthermore, fratricidal killing by human CD4+ T cell clones, a 
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function demonstrated to involve apoptosis, was reported to be almost completely inhibited in 
the presence of lmM MgEGTA30. 
Cytotoxic T cell-induced apoptosis of target cells may be mediated by fas/fas ligand binding or 
the constituents of cytotoxic granules, particularly granzyme B; regulation of fas-mediated 
apoptosis within the target cell may be controlled by the bcl-2 gene product31 ,32,33 ,34,35 . To 
date, reports of the effects of eicosanoids on apoptosis have been limited to PGE modulation of 
apoptosis induced by mechanisms other than fas binding, with conflicting results. Although 
PGE2-augmented apoptosis of thymocytes and other cells has been demonstrated, a recent 
report has indicated no effect on human mononuclear cells36,37. In addition, increased cAMP 
promotes a cell survival response and retards apoptosis38 . 
It is now well established that human CD4+ T-cell clones can be divided into three populations 
according to their pattern of cytokine production (see chapter 1, pg. 19) . Differential 
modulation of Thl and Th2 cytokine production by PGE has been demonstrated, with 
inhibition of Thl production ofIFN-y, but either stimulation or no effect on Th2 production of 
IL46,7. In addition, misoprostol has been shown to have similar effects7. Inhibition may be the 
result of suppression of cytokine mRNA expression 7. PGE2 modulation of cytokine production 
by ThO clones appears to reflect heterogeneity of this cell population, with both Th l and Th2-
like responses39. The findings reported in this chapter that PGE2 and misoprostol cause 
marked inhibition of both IFN-y production by Thi clones, and IFN-y and IL4 production by 
ThO cytotoxic T-cell clones, supports the recent suggestion that modulation of cytokine 
production by cAMP agonists is a property of the cell type and not the cytokine40. This data 
thus indicates that signalling pathways in the cytotoxic ThO clones studied resemble those of 
Thl CD4+ clones . 
Although PGE2 caused marked suppression of IFN-y production by cytotoxic CD4+ T-cell 
clones, long term passaging of a clone in the presence of high concentrations of PGE2 did not 
affect the cytolytic potential of this clone, as demonstrated in a lectin dependent cytotoxicity 
assay. This differential modulation by PGE2 of lectin-dependent cytotoxicity and IFN-y 
production provides interesting insight into the association of CD4+ T-cell cytotoxicity and 
IFN-y production. Several lines of evidence have indicated a relationship between IFN-y 
production and cytotoxic function of CD4+ T-cells : cytotoxicity is almost exclusively confined 
to CD4+ T-cell clones that produce IFN-y (Thl and ThO subsets); levels of cytotoxicity 
correlate with the amount of IFN-y production, and IFN-y drives Thl differentiation and 
increases cytolytic activity of T-cell lines10,41 . The findings reported here indicate that the 
maintenance of cytolytic potential of CD4+ T-cell clones occurs independently of IFN-y 
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production and supports a previous suggestion that IFN-y is not responsible for CD4+ T-cell 
mediated cytotoxicityIO_ 
LTB4 augmentation of IFN-y and IL2 secretion by polyclonal CD4+ T cell populations has 
previously been reported42 . However, the effect of leukotrienes on cytokine production by 
CD4+ T cell clones has not previously been described. In the present study, LTB4 and L TC4 
augmentation of IFN-y production by CD4+ T cell clones was found, but restricted to clones 
with low control levels ofIFN-y production. In addition, the effects of the leukotrienes showed 
unusual titration patterns which may question the reliability of the data. The lack of effect of 
the leukotrienes on the high IFN-y production by a Thl clone may indicate that maximal levels 
of secretion had been achieved. The finding that LTC4 but not LTB4 stimulated IFN-y 
production in a ThO clone is of interest and warrants further investigation. Differential 
modulation of IFN-y and IL4, as previously reported for PGE2, was not found to be an effect 
of leukotrienes in this study as no direct modulation of IL4 production was demonstrated. 
Nevertheless, the data provide additional suggestive evidence of the immunostimulatory 
properties of LTB4 and LTC4, especially given the role of IFN-y in cellular immune 
functions 1° . 
Having provided functional evidence suggestive of the role of eicosanoids in the modulation of 
CD4+ T cell effector functions , the studies reported in this chapter raise several issues about 
the mechanism of action of these agents that require further investigation. In particular, the 
effects of eicosanoids on fas- and perforin-dependent pathways of T cell cytotoxicity may be 
further defined by investigation of their effects on fas expression of target cells, and fas ligand 
and intracellular granzyme and perforin expression of effector T cells using cytofluorimetric 
techniques . Given the recent awareness of the role of apoptosis in animal models of 
autoimmunity and the potential role in immune regulation, investigation of the effects of 
eicosanoids on apoptotic pathways of cell death (both fas-dependent and independent) may 
have relevance to RA 43 ,44,45,30 . 
There is increasing understanding of the role of cytotoxic CD4+ T-cells in a broad spectrum of 
clinical conditions in addition to RA, including the immune response to infectious diseases, 
tumours, and transplant rejection46,47,20 . The in vitro studies reported here indicate a potential 
target for novel therapeutic modulation of CD4+ T-cell effector functions in these settings; 
specific inhibition of 5 lipoxygenase metabolism or antagonism of L TB4 and L TC4 at chronic 
inflammatory sites (including the rheumatoid synovial compartment) may reduce the 
stimulatory effects of leukotrienes on CD4+ T cell helper and cytotoxic functions . In addition, 
the inhibition of CD4+ T cell functions by the PGEl analogue, misoprostol , may contribute to 
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its beneficial effects in vivo on graft survival, and indicates the therapeutic potential of this 
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INTRODUCTION 
A series of cellular events occur following the interaction of a CD4+ T cell with its specific 
antigenic epitope in association with the MHC molecule of an antigen-presenting cell. This 
stimulus transmitted by the T cell receptor/CD3 complex activates intracellular signalling 
pathways that promote transcription of cytokine and other genes leading to upregulation of a 
variety of cell surface receptors, cytokine secretion with autocrine and paracrine effects and 
progression into the cell cycle with associated blastogenesis and cellular proliferation1,2,3,4 . In 
the case of a cytotoxic CD4+ T cell (Thl and ThO subsets), these events may be accompanied 
by killing of the antigen-presenting cell5. Given the possibility that cytotoxic effector function 
of CD4+ T cells in the rheumatoid joint may be involved in the pathogenesis of the disease (see 
Ch2 pg. 58), defining the cellular regulation of CD4+ T cell mediated cytotoxicity and its 
relationship with other cell functions may be of importance. 
In a polyclonal T cell population, a positive linear relationship between levels of in vitro 
antigen-induced proliferation and antigen-specific cytotoxicity has previously been 
demonstrated and was confirmed in the studies of peripheral blood and synovial fluid 
mononuclear cells from patients with RA reported in chapter 2 6 . It has also previously been 
shown that the kinetics of proliferation following an antigenic stimulus closely parallel the 
kinetics of antigen-specific cytotoxicity in polyclonal T cells from tuberculous effusion7. 
However, it is possible that the relationship between in vitro proliferation and cytotoxicity of 
CD4+ T cells observed in polyclonal populations noted above is due to clonal expansion of 
specific effector cells, and do not reflect the interaction of these functions at a single cell or 
monoclonal level. 
Separation of in vitro proliferation and cytokine production from cytotoxicity in murine CD4+ 
T cell clones has been demonstrated with the use of peptide substitution involving critical T cell 
receptor binding residues8. These findings thus suggest different pathways of control of effector 
functions in CD4+ T cells and are supported by the description of similar dissociations in 
cellular functions of anergic murine CD4+ T cell clones that retain cytotoxicity in the absence 
of proliferation or IL2 secretion9 . Separation of murine CD4+ T cell proliferation from 
cytotoxicity has also been demonstrated as an in vitro effect of cyclosporin and in cells 
activated through CD2 and using different monoclonal antibodies as ligands1o. Further 
evidence indicating independent regulation of T cell proliferation and cytotoxicity includes the 
finding that senescent human CD8 T cell cultures retain cytolytic function in the absence of 
proliferative responses 11 . 
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In this chapter the in vitro relationship between human CD4+ T cell functions at the clonal 
level have been addressed by investigating the kinetics of activation marker expression, 
proliferation, cell cycle progression, cytokine production and cytotoxicity following a single 
initiating stimulus . A panel of human Thl and ThO clones, including clones generated from 
rheumatoid synovium, were studied. The findings demonstrate dissociation in CD4+ T cell 
functions in that post-activated clones retained cytolytic potential, irrespective of levels of 
proliferation, cytokine secretion or activation marker expression. Physiological, 
pathophysiological and therapeutic relevance of these findings are discussed. 
MATERIALS AND METHODS 
1. T cell clones. 
A total of 6 CD4+ T-cell clones were included in these investigations . A brief description of the 
clones is included in Table 4.1; detailed descriptions of cloning techniques and functional 
properties of the clones are included in chapters 7 and 5 (pgs . 177 and 126). Tissue culture 
medium used throughout these studies was RPMI l 640 (Flow Laboratories, Mclean, VA) 
containing 1 OOU/ml of penicillin, l OOµg/ml of streptomycin and I 0% pooled AB human serum. 
T cell clones were maintained by weekly passaging with irradiated autologous PBMNC feeder 
cells, antigen or rnitogen at optimal concentrations, and rIL2 ( l 00 iu/ml), and fed with 
additional fresh medium and rIL2 (IOO iu/ml) every 2 to 3 days . Experiments were timed such 
that the cells had not received additional rIL2 for 3 days and feeders and antigen/mitogen for 7 
days at the commencement of study. 
For investigation of kinetics of responses, T cell clones (106/well) were re-stimulated with 
irradiated autologous PBMNC (5 x 105/well), antigen and rIL2 (IOO iu/ml) in 24 well tissue 
culture plates (Costar) in a final volume of 1ml of culture medium. A series of experiments 
was also performed without supplemental rIL2 . Cells and their supernatants were harvested 
after 24h (day 1), 48h (day 2), 96h (day 4) and 168h (day 7), and analysed as described below. 
During this culture period the cells were resuspended regularly to disrupt clumping, but were 
not provided with additional medium or rIL2 . Cell viability was determined by trypan blue 
exclusion. 
2. Cytotoxicity assays . 
Antigen-specific and lectin-dependent cytotoxic functions were determined at each time point in 
a 15h 5 lcr release assay as described previously (chapter 3 pg. 82). Autologous MNC target 
cells were plated between 4 and 6 days prior to use at each time point to ensure uniformity in 
target cell maturity. 
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3. Proliferation. 
Proliferative responses of CD4+ T-cell clones were assayed in triplicate in rnicroculture as 
previously described12 . Cloned T cells (5 x 104 per well) were stimulated with PPD (Central 
Veterinary Laboratory, Weybridge, Surrey, England) at a final concentration of 3µg/ml, and 
irradiated autologous PBMNC (4000 rads) as feeder cells (104/well) in a final volume of 200 
µl in the presence or absence of rIL2 (lOOiu/mJ) . 3H thyrnidine incorporation was measured 
over 15h at the termination of the incubation period for each time point. 
4. Cytokines. 
Cell supematants were collected and stored at -70°C until assayed. Interferon-y (IFN-y) 
concentration in the supematants was measured by commercial RIA (IFN-y IRMA, Medgenix 
Diagnostics, Fleurus, Belgium) and interleukin 4 (IL4) concentration determined by 
commercial ELISA (IL-4 EASIA, Medgenix Diagnostics), according to the manufacturers' 
directions . 
5. Monoclonal antibodies . 
Monoclonal antibodies used were T4-RD l (CD4), 12-FITC (HLA-DR), IL-2Rl-FITC (IL2 
receptor, CD25) and 4B4-FITC (memory, CD29), all from Coulter Immunology (Hialeah Fl. 
USA), and CD28-FITC (lmmunotech, Westbrook, Maine) . Corresponding isotypic controls 
were used in all cases to set cursors to allow 2 % false positives . Antibodies were used at the 
concentrations suggested by the manufacturer. 
6. Flow cytometry. 
An Epics Profile II flow cytometer was used (Coulter Electronics) to perform 
immunophenotyping and cell cycle analysis . Histograms were analysed using Cytologies 
Software (Coulter) . Histograms were gated on the lymphocyte population by forward scatter 
(FS) versus log side scatter (LSS), and data generated for 104 events . 
Changes in cell morphology following stimulation were investigated by analysis of the dual 
parameter histograms of forward scatter (FS) vs log side scatter (LSS), where FS is a measure 
of cell size and LSS reflects cell granularity13 . Gates were set to include the whole cell 
population and exclude debris . Single parameter histograms were projected from the gated area 
of the dual parameter histogram and analysed using Cytologies Software. 
7. Cell cycle analysis . 
T-cell clones were permeabilised, fixed and stained with propidium iodide using DNA Prep Kit 
(Coulter) . Gating was performed as described for immunophenotyping and in addition doublets 
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were excluded from the analysis by gating on the histogram, fluorescence 3 peak (FL3P) vs 
fluorescence 3 (FL3). Single parameter histograms of FL3, showing GO/G l, Sand G2/M, were 
analysed using Cytologic software (Coulter) to calculate proliferative index (Pl == S + G2/M). 
The method of broadened rectangles was used to analyse DNA histograms 14 . Cells in GO/Gl 
phase of the cell cycle have the normal diploid amount of DNA (DNA index (DI) == 1). 
Tetraploid amounts of DNA are found in cells in the G2/M phase (DI == 2). Intermediate 
amounts of DNA are present in cells in the S phase of the cell cycle (2 >DI> 1). 
8. Intracellular IFN-y and PCNA. 
Detection of intracellular antigens was performed using a modified technique of Jung et al1 5 . 
Antibodies used were anti-interferon-y (Genzyme, Cambridge, MA), anti-PCNA (Coulter) and 
GAM-FITC (Cappel, Organon Teknika, Turnhout, Belgium). Cells were washed twice with 
RPMI 1640 to remove protein . The cell pellet was resuspended in 100µ1 RPMI. Cells were 
fixed and permeabilised by adding methanol (stored at -20°C) dropwise while vortexing. 
Dehydration was allowed to continue on ice for 30 minutes . Cells were washed twice with 1 % 
AB serum in RPMI and resuspended in 100 % AB serum at a cell concentration of 4 x 106 I 
ml. Antibodies were added to V-bottom rnicrotitre wells (4µg of each antibody I well) . A 
negative control of 4µg mouse IgG was included. A 50µ1 aliquot of cells was added to each 
well and incubated on ice for 60 minutes . Cells were washed 3 times with 1 % AB serum in 
RPMI at 4°C and resuspended in 50µ1 100 % AB serum. GAM-FITC was added to a final 
volume of 100µ1 at a 1: 100 dilution. This was incubated on ice for 60 minutes and then washed 
3 times as above. The cells were resuspended with a pipette between washes and finally 
resuspended in 50µ1 1 % AB serum in RPMI and 100µ1 1 % paraformaldehyde in PBS . Flow 
cytometry was performed on an Epics II flowcytometer (Coulter) . Cells were gated on forward 
scatter (FS) and log side scatter (LSS) . FITC labelling was measured as integrated 
fluorescence on a log scale and a linear scale as well as peak fluoresence. 
9. Statistics. 
Statistical analysis were performed using the program lnstat (GraphPad Software, San Diego, 
CA). Repeated measures analysis of variance (nonparametric) was used to analyse data 
obtained from kinetics experiments; p values less than 0.05 were considered significant. 
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RESULTS 
1. Kinetics of cytotoxicity 
The cytotoxic function of a panel of 6 Th l and ThO clones was assayed at four time points ( day 
1, day 2, day 4 and day 7) following stimulation with irradiated autologous PBMNC, antigen 
and rIL2 . No significant changes in cytotoxicity were noted over the seven day test period 
{Table 4.I). Comparable kinetics of cytotoxicity were observed in antigen specific and lectin-
dependent assays, with moderate levels of cytotoxicity observed at each time point in all 6 
clones . Similar results were obtained using clone PL2.2b on a further two occasions {Table 
4.I) . The mean and standard error of antigen-specific cytotoxicity at each time point is shown 
in figure 4.1. Lower (but not significant) cytotoxicity on day l following stimulation may have 
been the result of residual contamination of effector cells by irradiated feeder cells . 
Table 4.1 
Kinetics of antigen-specific and lectin-dependent cytotoxicity of a panel of 6 CD4+ T cell 
clones* 
KINETICS OF CYTOTOXICITY (% Cytolysis) 
D 1# D2 D4 D7 
CLONE DESCRIPTION Agen PHA Agen PHA Agen PHA Agen PHA 
PL2.2B Source: normal PBMNC; 31.9 29.2 34.4 49.1 27.6 37.6 36.9 29.7 
(Exp. l) cloned with PPD; ThO 
PL2.2B as above 32.6 24.2 39.2 20.3 48.4 38.7 45.2 53.5 
(Exp. 2) 
PL2.2B as above 31.3 22.3 44.4 30.5 46.9 43 .7 48.0 nd 
(Exp. 3) 
PL2.2B mean of 3 experiments 31.9 25.2 39.3 33.3 41.0 40.0 43.4 41.6 
(mean± se) ±0.3 ± 1.7 ±2.4 ±6.9 ±5.5 ±1.5 ±2.7 -
PL 7.2E Source: normal PBMNC; l l.5 34.2 23.2 53.9 21.6 40.5 20.9 27.4 
cloned with PPD; Thl 
PL 18. lB Source: nonnal PBMNC; nd 35.9 nd 55.8 nd 38.0 nd 34.8 
cloned with TT; ThO 
AP 2.3C Source: RA synov1um; nd 21.3 nd nd nd 28.1 nd 36.3 
cloned with PHA; ThO 
AP 2.5E Source: RA synovium; nd 23.5 nd nd nd 28.6 nd 31.3 
cloned with PHA; Th? 
AP 3.7F Source: RA synovium; nd 25.l nd nd nd 23 .1 nd 27.5 
cloned with PHA; Thi 
Mean ±se POOLED DATA 26.8 27.0 35.3 41.9 36. 1 34.8 37.8 34.4 
±4.4 ±1.8 ±3.9 ±6.3 +5.9 + 2.4 +5.3 +3.2 
• Cytotoxicity was measured in a l 5h 51 Cr release assay at four time points following a single activating 
stimulus of the clones ( effector to target ratio I 0: l) 
# Days following stimulus. 
Agen - antigen; TT - tetanus toxoid; nd - not done; se - standard error 
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Kinetics of antigen-specific cytotoxicity and activation marker expression of a panel of 4 
CD4+ T cell clones 
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Assays were perfonned at four time points following a single antigenic stimulus. Data shown represents mean ± 
standard error for 4 clones. 
• p <0.05; ** p <0.01 
2. Surface immunophenotyping and cell cycle analysis 
Flowcytometric analysis of a panel of four CD4+ clones following stimulation was performed 
at the same time points as for the cytotoxicity assays . The percentage of cells expressing TL2-R 
and HLA-DR peaked 2 days after stimulation and then declined to significantly lower levels on 
day 4 (IL2-R) (p < 0.01) and day 7 (HLA-DR) {p < 0.05) . The mean and standard errors for 
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Modulation in the cell surface density of activation markers and other surface antigens was 
indicated by changes in mean channel number or brightness of fluorescence 16 . Representative 
one parameter histograms from clone PL2.2b are shown in figure 2. Peak surface density of 
HLA-DR (fig 4.2a) and IL2-R (fig 4.2b) occurred on day 1 following stimulation and declined 
at subsequent time points; the bimodal HLA-DR expression observed on day l may have been 
the result of contaminating feeder cells (DR dim), or dual populations of activated (DR bright) 
and pre-activated (DRdim) clones. A modest increase in mean channel number of CD28 
expression (fig 4.2c) was found on days 4 and 7 following stimulation, while CD29 cell density 
remained essentially unchanged (fig 4.2d). Interestingly, cell surface density of CD4 was 
modulated following stimulation (fig 4.2e) . Peak CD4 brightness was observed on day I and 
declined to a nadir on day 4, with a return to near peak levels on day 7. 
Cell cycle analysis was performed concurrently with surface immunophenotyping in clones 
PL2.2b, PL7.2e and PL18 . lb . As was found for activation marker expression, the peak 
proliferative index (percentage of cells in G2M and S phase) was observed on day 2 following 
stimulation, and declined at subsequent time points (Table 4.11) . Representative DNA 
histograms from clone PLl 8 .1 b are shown in figure 4 .3. 
Table 4.11 
Changes in proliferative index following stimulation of 3 CD4+ T cell clones* 
CLONE Day 1 Day2 Day4 Day7 
PL2.2B 11.5 21.6 16.0 15 .9 
PL7.2E 6.3 15.4 15 .8 6.1 
PL18.1B 5.9 35.4 3.8 3.0 
• Proliferative index (percentage of cells in G2M and S phase of U1e cell cycle) was calculated as described in 
materials and meU10ds. 
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*Immunophenotyping was perfonned by flow cytometry at 4 time points following stimulation of the clone with 
irradiated autologous PBMNC, antigen and recombinant IL2. Similar results were obtained with 3 additional clones . 
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Figure 4.3 
Cell cycle analysis of clone 
PL18.1B at 4 time points 
following stimulation. 
Stages of the cell cycle are indicated in 
parentheses in the upper panels 
PI - proliferative index. FL3 - red 
fluorescence. 
As an additional indicator of cell cycle activity, the kinetics of intracellular express10n of 
proliferating cell nuclear antigen (PCNA) or cyclin17, 18 were investigated in 3 clones . Maximal 
percentage of cells with detectable intracellular PCNA was found on day 2 following 
stimulation in each clone, and declined to pre-stimulated levels by day 4. Representative single 
parameter histograms for clone 18. lB are shown in figure 4.4 
Figure 4.4 
Modulation of intracellular PCNA expression of clone PLJ 8.1 B following stimulation* 
LOG FLUORESCENCE 
- control 
~--- 18 h 
D-D 42 h 
*Intracellular detection of PCNA was perfom1ed by flow cytometry at each time point, following 
permeabilization and fixation of cells as described in materials and methods. 
Control - isotypic antibody control 
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3. Cell size and granularity 
Significant changes in cell size but not granularity were observed after stimulation of clones 
PL2.2b, PL7.2e, PL18 . lb and AP2 .5e. The mean channel number of forward scatter, a 
reflection of cell size, was significantly greater on day 2 than day 7 after stimulation (p < 0.0 l) 
(Table 4.III) . Representative single parameter histograms for clone AP2.5e are shown in figure 
4.5a (cell size) and 4.5b (granularity) . Similar results were obtained if log side scatter 
histograms were converted to a linear scale. 
Table 4.111 
Changes in cell size and granularity of a panel of 4 CD4+ T cell clones following a single 
antigenic stimulus# 
DAYl DAY2 DAY4 DAY7 
Cell size (FS) 33 .5 ± 0.32 35.4 ± 1.0* 29.6 ± l.8 25.4 ± l.l * 
(MCN ±se) 
Granularity (LSS) 32.5 ± 0.56 33 .1±0.15 32.8 ± 0.72 3 l.9 ± 0.6 
(MCN ± se) 
#changes in cell morphology of clones PL2.2b, PL 7.2e, PL! 8. lb and AP2.5e were detennined by flow cytometry 
as described in materials and methods. 
FS - forward scatter, LSS - log side scatter; MCN - mean channel number; se - standard error. 
•p < 0.01 
4. Cytokine production 
Concentrations of IFN-y and IL4 in cell supernatants were assayed as a function of time 
following stimulation of clones PL2.2b, PL7.2e and PL18 .lb. Peak concentrations ofIFN-y in 
the supernatants of the Th l clones and IL4 in the supernatant of the ThO clone were found 
24h after stimulation (Table 4.IV) . In general , IFN-y concentrations remained near peak levels 
at subsequent time points, whereas IL4 levels in the supernatants of the ThO clone declined 
rapidly. It is interesting to note that while the IL4 levels in the supernatant of this ThO clone 
declined rapidly between day l and day 2, IFN-y concentrations remained constant. 
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Figure 4.5a 
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*Changes is cell morphology following activation were detennined by flow cytometry, as described in materials 
and methods. Data is displayed as a single parameter projection from the dual parameter histogram of forward 
scatter (FS) vs log side scatter (LSS). 
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*Changes is cell morphology fo llowing activation were detennined by flow cytometry, as described in materials 
and methods. Data is displayed as a single parameter projection from the dual parameter histogram of forward 
scatter (FS) vs log side scatter (LSS). 
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As the concentration of cytokine in the cell supernatant reflects an equilibrium between 
secretion and utilization or breakdown, it is possible that the rapid decline in IL4 levels in the 
supematants of the ThO clone reflects autocrine utilization. The maintenance of near peak 
levels ofIFN-y concentrations in the supematants of the Thl clones may indicate a steady state 
between production and utilization, or the lack of uptake or breakdown of the cytokine once 
secretion had ceased. To distinguish between these latter two possibilities, the kinetics of 
intracellular expression of IFN-y were investigated. As shown in table 4.V, the peak 
percentage of cells with detectable intracellular expression of IFN-y occurred at 18h after 
stimulation and was considerably lower at the subsequent time point (42h) . These findings thus 
indicate that IFN-y secretion diminishes after an initial peak and the maintenance of high 
concentrations of this cytokine in the cell supematants described above may be the result of low 
levels of utilization or breakdown. 
Table 4.IV 
Concentrations of IFN-yand IL4 in cell supernatants of 3 CD4+ T cell clones following 
antigenic stimulation* 
4 h# 8 h D 1 D2 D4 
IFN-y IL4 IFN-y IL4 IFN-y IL4 IFN-y IL4 IFN-y IL4 
(iu/ml) (pg/ml) (iu/ml) (m!lml) (iu/ml) (pg/ml) (iu/ml) (m!lml) (iu/ml) (nQ/ml) 
PL7.2E 38 < 16 214 < 16 588 < 16 576 < 16 574 < 16 
(exp 1) 
PL7.2E 58 nd 179 nd 177 nd 151 nd 143 nd 
(exp 2) 
PL18.1B < 0.5 < 16 2.0 191 27 625 32 107 18 < 16 
(exp 1) 
PL18.1B 2 nd 5 nd 32 nd 43 nd 29 nd 
(exp 2) 
PL2.2B nd nd nd nd 587 < 16 576 < 16 535 < 16 
(exp 1) 
PL2.2B nd nd nd nd 167 nd 165 nd 165 nd 
(exp 2) 
*T cell clones were stimulated with irradiated autologous PBMNC, antigen and r!L2 and supematants harvested 
after the time intervals indicated. Cytokine concentrations in supematants were measured using commercial kits. 
#Incubation period; nd - not done 
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Table 4.V 
Percentage of T cell clones with detectable intracellular IFN-y following antigenic 
stimulation*. 
CLONE 8h# 18h 42h 
PL18.lB 2.3 6.0 1.3 
PL2.2B nd 18.9 2.3 
PL7.2E 2.0 3.6 2.7 
*Detection of intracellular IFN-y was perfonned by flow cytometry following penneabilisation and fixation of 
the clones, as described in materials and methods. The peak percentage of cells positive for intracellular IFN-y 
are comparable witl1 those previously reported using this technique14. 
#Incubation interval after stimulation; nd - not done 
5. The effects of exogenous IL2 on kinetics of activation, proliferation and cytotoxicity. 
To determine whether exogenous IL2 added at the time of initial stimulation modulated the 
kinetics of the functions studied, clone PL2.2b was stimulated with irradiated autologous 
PBMNC and PPD, in the presence or absence of recombinant IL2 (100 iu/rnl) . Cytotoxic 
function, surface immunophenotyping and proliferation were then assayed at the same time 
points as described above. The kinetics and levels of cytotoxicity at each of three effector to 
target ratios were unaltered by the absence of IL2 at the time of initial stimulation (Fig 4.6) . 
However, the presence of IL2 at the time of initial stimulation caused markedly elevated 
proliferative responses and expression of IL2-R. It is interesting to note that peak proliferation, 
as determined by 3H thymidine incorporation, consistently occurred earlier when cells were 
stimulated in the absence of exogenous IL2 (day 1), although the magnitude of the proliferative 
response was considerably lower than for cells stimulated in the presence of IL2 (Fig 4.7) . 
Comparable kinetics of IL2-R expression were found irrespective of the presence or absence of 
exogenous IL2; however, exogenous IL2 stimulated greater levels of IL2-R expression (Fig 
4.8). Peak HLA-DR expression was unaffected by exogenous IL2 (81 ,9% day 2 without 
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Figure 4.6 
The effects of recombinant IL2 on 
the kinetics of antigen-specific 
cytotoxicity of clone PL2. 2b 
Clone PL2.2b was restimulated using 
autologous irradiated PBMNC and 
antigen, in the presence or absence of 
rIL2 (lOO iu/ml). Antigen-specific 
cytotoxicity was measured at each time 
point in a standard I Sh SI Cr release 
assay. Data points represent the mean of 
triplicate determinations. 
Figure 4.7 
















DAYS AFTER STIMULATION 
• Clone PL2.2b was restinrnlated using autologous irradiated PBMNC and PPD, in the presence or absence of 
rIL2 (lOO iu/rnl). Proliferation was measured by 3H thymidine incorporation for !Sh at the termination of the 
incubation period. Data shown represent the mean of triplicate detenninations. 
No stim - unstimulated (background) proliferation 
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Figure 4.8 
The effects of exogenous recombinant IL2 on the kinetics of antigen-induced IL2 receptor 
expression of clone PL2.2b, (a) cells stimulated without recombinant IL2 and (b) cells 























Immw10phenotyping of effectors used in fig 6 was performed by flow cytometry. Data is displayed as contour 
plots of dual parameter histograms ofCD4 (vertical axis) vs Il.,2-receptor (horizontal axis). Figures indicate the 
percentage of CD4+ cells positive for Il.,2 receptor (upper right quadrant). 
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DISCUSSION 
The retention of cytolytic function by post-activated CD4+ T cell clones observed in the current 
study has not previously been described and provides novel evidence suggesting a marked 
difference of kinetics of effector functions in these cells . Thus cytolysis of target cells by 
cytotoxic CD4+ T cell clones may occur, irrespective of the size, state of activation, 
proliferation, stage in the cell cycle or cytokine production of the effector cells. These findings 
may have implications for the pathogenesis of RA; while the rheumatoid synovial CD4+ T cell 
infiltrate is almost entirely memory cells that display evidence of a state of activation, it has 
been reported that these cells are generally small, not actively proliferating and not secreting 
cytokinesl9,20,21 ,22,23,24_ Based on the in vitro observations reported in this chapter, it is 
possible that the rheumatoid synovial CD4+ T cell infiltrate may retain cytolytic potential in 
vivo, despite their morphological appearance and paucity of cytokine production. 
The mechanisms of CD4+ T cell mediated cytotoxicity have been discussed previously (Chi 
and Ch3) . Delivery of the "lethal hit" is an active process in CD4+ T cells, requires protein 
synthesis and can be suppressed by metabolic inhibitors and cyclosporin25,10. It is probable that 
interaction of the effector cells with specific antigen-bearing target cells in the course of the 15h 
incubation of the cytotoxicity assay may have stimulated intracellular pathways within the 
cytotoxic T cell and in effect constitute a re-prime of the clone; calcium fluxes within CD4+ T 
cells have previously been demonstrated within similar incubation periods following 
stimulation26. In addition, fas ligand expression occurs rapidly following T cell receptor 
engagement (chl pg 20), although it is difficult to comment on the possible contribution of the 
fas dependent pathway of cytotoxicity in the current study based on the data in the preceeding 
chapter. It is also possible that modulation of the other parameters measured in this study may 
have occurred during the 15h incubation of the cytotoxicity assay, although these changes are 
likely to have been minor as the assay was performed in the absence of exogenous rIL2 . This 
is supported by evidence from the current study that demonstrates minimal upregulation of IL2 
receptor expression of a clone 24h after restimulation by antigen alone (Fig 4.7) . IFN-y 
secretion, as demonstrated in this study, may also occur within 15h of stimulation of a clone, 
although the absence of IL2 in the cytotoxicity assay would affect levels of production. 
Irrespective of potential events occurring during the cytotoxicity assay, the data reported in 
this chapter demonstrate that considerable differences in activation status, size, cell cycle 
position, proliferation and cytokine production of CD4+ T cell clones at the commencement of 
the cytotoxicity assays do not affect the final levels of cytolysis attained. This was shown both 
in the studies of the kinetics of cytotoxicity and in the comparative study of the effects of rIL2 
at the time of antigenic stimulation on the parameters investigated. 
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The CD4 molecule is a 55kDa cell surface glycoprotein that may be important in the formation 
of a high affinity complex that stabilizes the T cell receptor/MHC-peptide interaction27,28 . In 
addition a role for CD4 in signal transduction has been suggested, with effects on p56lck 
recently demonstrated29 . Down regulation of cell surface expression of CD4 following T cell 
activation has previously been demonstrated and has been suggested to be the result of 
phosphorylation of the molecule16. The current study confirms the previous reported finding 
that CD4 expression is reduced following T cell activation, but extends the observation to show 
recovery to preactivation levels with time after stimulation. It has been suggested that down-
regulation of CD4 expression following T cell activation may serve as a negative feedback 
inhibitor of cellular proliferation and activation, based on the experimental evidence of the role 
of CD4 in these functions 16,27 . In the data reported in this chapter it is interesting to note that 
reduction in CD4 expression following activation was not associated with modulation of 
antigen-specific cytotoxic function . Lowest CD4 expression was observed at day 4 following 
stimulation, the time point at which reduction in proliferation and activation marker expression 
commenced, while cytotoxicity remained constant. Thus this finding may suggest differential 
requirements for the CD4 molecule in proliferation and antigen-specific cytotoxicity. Cell 
surface expression of CD28 slightly increased with time after activation, paralleling antigen-
specific cytotoxicity. This observation is compatible with the proposed role of CD28 as an 
important co-stimulatory factor of T cell mediated cytotoxicity3o_ 
The potential physiological role for the retention of cytolytic potential by post-activated CD4+ 
T cells may include the regulation of the extent and duration of an immune response and the 
prevention of autoimmunity. Thus it has been postulated that fratricidal killing (T cell killing of 
other T cells) may limit clonal expansion at an inflammatory site and that rapid cytolysis of 
professional antigen-presenting cells expressing self tissue-specific antigen, before the 
development of a helper response, may suppress the induction of potentially autoreactive naive 
T cells31,9 . The maintenance of cytolytic potential by postactivated CD4+ T cells may 
contribute to the depletion of CD4+ cells in IIlV infection, which may be mediated by cytotoxic 
CD4+ T cells32 . The relevance of the findings of the current study to the pathogenesis of RA 
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INTRODUCTION 
The pursuit of an infective aetiological agent of RA has yielded numerous candidate micro-
organisms, including Mycobacterium tuberculosis 1,2,3 . Several lines of evidence have been 
cited in support of a causative association between Mycobacterium tuberculosis infection and 
RA, as discussed previously (Chl pg. 11). In particular, the demonstration of in vitro 
proliferation of MNC and T-cell clones from rheumatoid joints in response to mycobacterial 
antigens has been claimed to have aetiological significance4,5,6 . Furthermore, a previous report 
has suggested that mycobacterial antigen-specific cytolytic T-cells present in synovial joints 
may be relevant to the immunopathogenesis of the disease7. Cross-reactivity between 
mycobacterial HSP65 and host antigens has been proposed as a possible aetiopathogenetic 
mechanism of RA, based on experimental animal models8. 
Recent evidence has, however, indicated the non-specific nature of the mononuclear cell 
infiltrate at chronic inflammatory sites; such infiltrates incorporate a diverse array of memory 
T-lymphocytes recruited to the site by non-specific mechanisms9. Standard in vitro 
proliferation assays of cells obtained from these sites may thus reflect responses to a range of 
antigens for which the individual retains immunological memory. Thus it has been suggested 
that quantitative (precursor frequency) and qualitative (kinetics of proliferation) differences in 
MNC antigenic responses may be more specific indicators of aetiological significance10,11 . 
While limiting dilution analysis of mycobacterial antigen-reactive T-cells in RA has been 
reported, there have been no previous reports of the kinetics of in vitro MNC proliferation to 
mycobacterial antigens 12 . 
In the data reported here, we have studied mycobacterial antigen-reactivity of MNC from the 
circulation and site of pathology, and CD4+ T-cell clones generated from the site of pathology, 
of RA patients and controls (non-rheumatoid inflammatory synovitis and PBMNC from 
healthy laboratory workers) drawn from a population where tuberculosis has been endemic for 
several decades (estimated prevelance of 700 / 100 000 population13). Using these cells, we 
have investigated (i) the kinetics and specificity of PPD-induced proliferation of circulating and 
synovial MNC, (ii) the frequency of positive MNC proliferative responses to a recombinant 
HSP65 of Mycobacterium bovis among patients and controls, and (iii) the magnitude and 
specificity of PPD-specific cytotoxicity. The findings indicate that synovial CD4+ T-cell PPD-
specific proliferative and cytotoxic responses are non-specific phenomena, readily 
demonstrable in patients with inflammatory synovitis of diverse aetiologies . Potential 
mechanisms for the observed differences in the kinetics of proliferation to PPD between 
PBMNC and SFMNC are discussed. A lower frequency of MNC reactivity to HSP65 among 
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PPD-responsive RA patients compared to healthy PPD-responsive controls was found, and 
may have pathogenetic significance. 
MATERIALS AND METHODS 
1. Patients and controls 
PBMNC and SFMNC obtained from a total of 20 patients with seropositive RA and 6 control 
patients with synovial effusions due to causes other than RA are included in these studies. 
Additional clinical details of the RA patients are provided in chapter 2 (pg. 68) . The control 
arthritis group comprised 3 patients with osteoarthritis, 2 patients with acute gout and one 
patient with psoriatic arthropathy, who were undergoing routine diagnostic or therapeutic 
arthrocentesis (TABLE 5 .I). Diagnoses of these patients were made by characteristic clinical 
and radiographic findings and the demonstration of birefringent crystals in the SF or SM of the 
two patients with gout. Furthermore, all patients included in the control arthritis group were 
seronegative for rheumatoid factor. PBMNC from 9 apparently healthy PPD-reactive 
individuals were used as normal controls (mean age: 35 ± 4.5; 4 males and 5 females) . 
Synovial membrane from a knee joint was obtained from 3 patients at the time of diagnostic 
arthroscopy (one 37 yr old male with acute gout) or arthroplasty (one 52 yr old female with 
seropositive RA and one 37 yr old male with post-traumatic inflammatory OA). 
Table 5.1 
Control Arthritis Patients (non RA) 
PATIENT AGE SEX DIAGNOSIS DURATION TREATMENT 
(yrs) (yrs) 
I 63 F OA 8 Analgaesics 
2 62 M GOUT 7 NSAIDS 
3 55 M PSORIASIS 5.5 NSAIDS 
4 37 M GOUT 2 NSAIDS 
5 84 F OA 15 Analgaesics + NSAIDS 
6 54 F OA 10 Analgaesics + NSAIDS 
129 
Chapter 5 Mycobacteria/ antigen reactivity 
2. Proliferation and cytotoxicity assays 
Tissue culture medium used throughout these studies was RPMI supplemented with 10% 
pooled AB serum. Proliferation of PBMNC and SFMNC in response to mitogen (PHA) and 
antigens (PPD, SK-SD and recombinant HSP65 of M bovis) was assayed in microculture by 
3H thymidine incorporation, as detailed in chapter 2 (pg. 60 ). Recombinant HSP65 of M bovis 
was a kind gift of Dr JDA van Embden14 and was used at final concentration of 5µg/ml. 
Proliferative responses of CD4+ T-cell clones and T-cell lines obtained from synovial explants 
were determined as described in chapter 7. Cytotoxic functions of PBMNC, SFMNC and 
CD4+ T-cell clones were measured in 15h 5lcr release assays, as described in chapter 3 (pg 
82) . 
3. Synovial membrane explants 
Fragments of synovial membrane (2 - 3 mm3) were cultured in 1ml complete medium . 
supplemented with recombinant IL2 (Cetus, 100 iu/ml) in 24 well plates (Griner) and passaged 
weekly, as described in chapter 6 (pg. 155). T-cells growing out of first or second passage 
explants were cloned or used in functional assays . 
4. T-cell clones 
T-cells growing out of first passage synovial membrane explants were cloned in limiting 
dilution using either a non-specific mitogenic stimulus (PHA) or antigens (PPD, SK-SD and 
recombinant 65kDa heat shock protein of Mycobacterium bovis (HSP65)), as described in 
detail in chapter 7 (pg. 177). 
5. Statistical analysis 
Statistical analysis was perfom1ed using the computer software progran1 Instat (GraphPad 
Software, San Diego, CA). Analysis of variance (nonparan1etric), and where appropriate 
students t test were employed for comparison of proliferation data. Fisher's exact test was used 
for comparison of frequency data; p values less than 0.05 were considered significant. 
RESULTS 
1. PBMNC and SFMNC proliferation to bacterial antigens in arthritis 
In vitro proliferative responses of PBMNC and SFMNC to mycobacterial antigens (PPD) and, 
as controls, streptococcal antigens contained within SK-SD, were measured on day 7 following 
stimulation in a total of 20 seropositive RA patients and 6 patients with non-rheumatoid 
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synovial effusions. Moderate to high levels of PPD induced proliferation were found in 
PBMNC and SFMNC from 13 out of20 RA patients, and in the PBMNC of 4 and SFMNC of 
3 out of 6 control patients (FIGURE 5.1) Low or absent proliferative responses (defined as !).. 
cpm < 20 000) to PPD were associated with significantly longer disease duration in 6 RA 
patients (see Ch2 pg. 68) . While there was a trend to higher PPD-proliferation in PBMNC 
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FIGURE 5.1 
In vitro PPD-induced proliferation of peripheral blood and synovial fluid mononuclear cells 
from 20 seropositive RA patients and 6 patients with non-rheumatoid synovial effusions. 
Proliferative responses to SK-SD were generally lower than PPD responses in MNC from both 
compartments in both patient groups (FIGURE 5.2) . Among the RA patients, PPD 
proliferation was significantly higher than SK-SD proliferation in both PBMNC and SFMNC 
(PBMNC PPD proliferation mean !)..cpm = 77820 ± 15965, PBMNC SK-SD proliferation 
mean !)..cpm = 28408 ± 9812: p < 0.05 ; SFMNC PPD proliferation mean !)..cpm = 50091 ± 
13038, SFMNC SK-SD proliferation mean !)..cpm = 6532 ± 3752: p < 0.001) ; in the control 
patient group this observation was restricted to SFMNC (PPD proliferation mean !)..cpm = 
91981 ± 39918, SK-SD proliferation mean !)..cpm = 33161 ± 15270: p < 0.01) . In addition, 
SK-SD induced proliferation was significantly lower in SFMNC compared to PBMNC in both 
RA and non-rheumatoid control patients (RA p < 0.005 ; non-RA p < 0.01) (FIGURE 5.2) . 
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FIGURE 5.2 
In vitro SK-SD - induced proliferation of peripheral blood and synovial fluid mononuclear cells 
from 20 seropositive RA patients and 6 patients with non-rheumatoid synovial effusions. 
* p < 0.01; ** p < 0.005 
2. Kinetics of PBMNC and SFMNC in vitro proliferative responses 
The kinetics of PBMNC and SFMNC proliferative responses to PPD and SK-SD were 
investigated by standard tritiated thymidine incorporation measured over the last 18h of a 4 or 
7 day incubation period, in a total of 13 seropositive RA patients and 3 patients with 
inflammatory synovitis due to other causes. Seven RA patients and 3 OA patients with low or 
absent proliferation in response to PPD were excluded from this analysis . MNC from the RA 
patients exhibited peak proliferative responses to both antigens on day 7 following stimulation 
(Figs. 5.3 and 5.4). However, a difference in the kinetics of PPD responses of PBMNC and 
SFMNC was observed (Fig. 5.3) . RA PBMNC displayed similar kinetics of proliferation to 
PPD as was found in normal PBMNC (FIGURE 5.5) with a significantly greater response on 
day 7 than day 4 (p < 0.001 RA PBMNC; p < 0.001 normal PBMNC). By comparison, RA 
SFMNC proliferation to PPD acheived near maximal levels by day 4, which was significantly 
higher than PBMNC proliferation at the same time point (p < 0.05). While suggesting a more 
rapid response to the antigenic stimulus, this finding is distinct from accelerated kinetics of 
proliferation which has been defined as day 4 proliferation significantly greater than day 7 11 . 
The rapid proliferation of SFMNC was antigen-specific, and not a feature of SK-SD 
responses, which remained unifom1Jy low (FIG. 5.4) . Interestingly, proliferation of 
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unstimulated RA SFMNC was also significantly higher than PBMNC on day 4 (mean ~cpm 
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FIGURE 5.3 
Kinetics of PPD-proliferation of PBMNC and SFMNC from 13 patients with seropositive RA. 
PBMNC responses are indicated by the solid line, and SFMNC by the dotted line. 
* p < 0.05 
Although it has previously been reported that increased in vi tro proliferation of lymphocytes in 
patients receiving methotrexate may be due to the high folate concentrations of culture 
mediun115, this is an unlikely explanation of our findings as (i) only 2 patients were receiving 
methotrexate at the time of this study and (ii) observations of rapid PPD-induced responses and 
higher spontaneous MNC proliferation were restricted to cells from the synovial compartment, 
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7 
Kinetics of SK-SD proliferation of PBMNC and SFMNC from 13 patients with seropositive 
RA. 
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FIGURE 5.5 
Kinetics of PPD and SK-SD proliferation of PBMNC from 9 healthy normal PPD-reactive 
controls. 
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Kinetics of PPD-induced proliferation of SFMNC from patients with non rheumatoid 
inflammatory synovitis were similar to those found in RA SFMNC (Figs 5.6 and 5.7) . In 
addition, higher day 4 proliferation to PPD, but not SK-SD, was also found in these patients' 
SFMNC compared to their PBMNC (p < 0.05) (Fig 5.6). Although the numbers of patients 
included in the control arthritis group are small and thus conclusions remain guarded, the 
findings indicate that rapid proliferative responses to PPD are not limited to SFMNC from 
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Kinetics of SK-SD proliferation of PBMNC and SFMNC from 3 patients with non rheumatoid 
inflammatory synovitis 
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3. Proliferative responses to HSP65 of Mycobacterium bovis 
In vitro proliferation of PBMNC and SFMNC to a recombinant HSP65 protein of M bovis 
were investigated. Of the 13 RA patients who demonstrated moderate to high levels of PPD-
reactivity in their PBMNC and SFMNC, significant HSP65 proliferation (defined in this 
setting as ~cpm > 2000 and SI > 3.0) was confined to the SFMNC of 2 patients and the 
PBMNC of one of these patients (Table 5 .II) . By comparison, PBMNC from 6 out of 9 healthy 
PPD-reactive controls demonstrated significant HSP65 reactivity, indicating a lower incidence 
of HSP65 reactivity among PPD-responsive RA patients than healthy controls (p < 0.005 
Fisher's exact test) . Of the three PPD-reactive patients in the control (non-RA) arthritis group, 
significant HSP65 proliferation was found in MNC from the site of pathology in both patients 
with gout.but was not found in synovial MNC from the patient with psoriatic arthritis . 
4. Restricted localisation of HSP65-reactive T-cells to acutely inflamed synovium in a 
patient with gout 
Multiple sight-directed synovial biopsy samples were obtained from a single knee joint of a 
patient with acute gout, and classified according to macroscopic and microscopic appearance 
(Fig. 5 .7). Tissue explants of acutely inflamed and macroscopically normal synovium were 
cultured separately in 24 well plates in standard tissue culture medium supplemented with 
recombinant IL2 (100 iu/rnl). MNC from acutely inflamed synovium (biopsy 2) demonstrated 
comparatively high levels of HSP65 reactivity and a relative lack of SK-SD response 
compared to MNC from tissue that was macroscopically normal but had evidence of chronic 
inflammation on histology (biopsy l} (TABLE 5.III) . MNC from both sites had similar levels 
of PPD-reactivity, although this was lower than found in PBMNC and SFMNC from the same 
patient. PBMNC from this patient did not demonstrate significant HSP65 reactivity . 
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TABLE 5.11 
Proliferation in response to HSP65 of Mycobacterium bovis of mononuclear cells from 
PPD-reactive patients and controls* 
Peripheral bloodMNC Synovial fluidMNC 
Patient / Control Diagnosis !),.cpm SI !),.cpm SI 
l RA 3728 1.1 431.6 2.1 
2 RA 619.3 1.3 0 0.6 
3 RA 223 .5 1.5 1979 2.2 
4 RA 1651 1.0 1635 1.6 
5 RA 32199 15 2698 2.8 
6 RA 0 0.9 2706 1.8 
7 RA 787 1.2 2501 11.9 
8 RA 2180 1.3 0 0.4 
9 RA 0 0.5 191 1.3 
10 RA 455 1.0 0 0.8 
11 RA 0 0.8 819.7 1.5 
12 RA 552 1.5 1928 1.9 
13 RA 1560 1.7 0 0.7 
14 Gout 11307 12.7 9772 13.1 
15 Gout# 763 1.3 15483 11.7 
16 Psoriasis 0 0.9 836 1.3 
1 Normal control 12785 14.9 - -
2 Normal control 5687 5.2 - -
3 Normal control 978 1.2 - -
4 Normal control 40587 21.2 - -
5 Normal control 13745 11.7 - -
6 Normal control 744 0.8 - -
7 Normal control 478 0.9 - -
8 Normal control 21744 15.6 - -
9 Normal control 4479 2.9 - -
* All patients and controls had significant in vitro MNC proliferative responses to PPD (L'l cpm > 20 000). 
Proliferation in response to a recombinant 65k.Da heat shock protein of mycobacteriwn bovis was assayed by 
tritiated thymidine incorporation after a 7 days incubation. Data shown represent the mean of triplicate 
detenninations. 
# Mononuclear cells from synovial membrane, not synovial fluid . 
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FIGURE 5.7 
Histological appearance of gout synovium * 
(a) Biopsy 1: Chronic synovitis 
(b) Biopsy 2: Fibrinous exudate suggestive of acute inflammation 
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FIGURE 5.7 (cont.) 
(c) Multinucleate giant cells containing urate crystals 
* Biopsy fragments were prepared using standard histological techniques . Samples in 
photomicrographs were stained with haematoxylin and eosin. 
(a) histological appearance of macroscopically normal biopsy fragment (200x 
magnification). Predominant mononuclear cell infiltrate and mild non-specific chronic 
synovitis . 
(b) histological appearance of macroscopically inflamed synovial biopsy (200x 
magnification). Evidence of acute inflammation includes fibrinous exudate, necrosis and 
the presence of polymorphonuclear neutrophils . 
( c) diagnosis of gout was confirmed by the presence of birefringent urate crystals within 
mutlinucleate giant cells (400x magnification) (section from biopsy 2) . 
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TABLE 5.111 
Antigen-induced proliferation of MNC from multiple sites in a patient with gout# 
SITE DESCRIPTION PHA PPD SK-SD HSP65 rIL2 
Biopsy 1 synovium: chronic 126059 9656 19294 2097 68845 
inflammation (39.1) (8.4) (I 5. 9) (2.6) (54) 
Biopsy 2 synovium: acute 33450 13007 3514 15483 38395 
inflammation (7.9) (10) (3.4) (11.7) (28) 
Blood PBMNC - 176881 19479 763 -
(69) (8 .5) (1.3) 
Synovial SFMNC - 183410 - - -
Fluid (I l. 7) 
# Values shown are mean Llcpm (Stimulation Index) for triplicate determinations 
5. PPD-specific cytotoxicity 
The ability of in vitro PPD-stimulated PBMNC and SFMNC to cytolyse autologous 
macrophages in the presence or absence of PPD was investigated in a 15 h 51 Cr release assay. 
Moderate to high levels of PPD-specific cytotoxicity were found in PBMNC of all RA patients 
with significant PPD-induced proliferation and in the SFMNC of a subset of 7 of these patients 
receiving NSAID monotherapy at the time of study (see Ch 2) . Representative data from a RA 
patient with similar levels of PBMNC and SFMNC cytotoxicity and a patient with 
compartmentalized impairment of SFMNC cytotoxicity are shown in figures 5.8 (i) and 5.8 (ii) 
respectively. As was observed for PPD proliferation, PPD-specific cytotoxicity was also found 
in PBMNC and SFMNC from a patient with acute gout (Fig. 5.8 (iii)) and psoriatic arthritis 
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FIGURE 5.8 
PPD - specific cytotoxicity of 
PBMNC and SFMNC from 
patients with arthritis: (i) RA 
receiving NSA/0 monotherapy, 
(ii) RA receiving DMARD, (iii) 
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6. Antigen reactivity of CD4+ T-cell clones generated from the synovial membrane of 
patients with RA, OA and gout. 
Mycobacterial antigen reactivity in RA was further investigated by examining proliferative and 
cytotoxic responses of a panel of CD4+ T-cell clones generated from the synovial membrane of 
a patient with seropositive RA. CD4+ T-cell clones from the synovial membrane of patients 
with OA and gout were used as controls . Details of the cloning techniques are provided in 
chapter 7. Briefly, clones from the patients with OA and RA were generated from synovial 
explant-derived T-cell lines by limiting dilution using a rnitogenic stimulus (essentially non-
selective), whereas clones from the patient with gout were generated in the presence of the 
antigens PPD, HSP65 and SK-SD(selective technique) . Data obtained with the CD4+ T-cell 
clones from the patient with RA are shown in table 5.IV. In contrast to the high proliferative 
response to rnitogen and recombinant IL2, antigenic responses were generally low in these 
clones . Significant PPD responses (defined as ~cpm > 2000 and SI > 3.0) were observed in 9 
out of 27 clones tested. There were no significant proliferative responses to SK-SD or 
recombinant HSP65 of M bovis . 
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TABLE 5.IV 
Proliferation of a panel of CD4+ T-ce/1 clones from rheumatoid synovium in response to 
microbial antigens, mitogen and recombinant interleukin-2. Values shown are fj cpm 
(Stimulation Index). 
CLONE PPD SK-SD HSP65 PHA IL2 
AP1.8C 2690 (12.3) 608 (3.5) 95 (l.4) 76855 (324) 32434 (137) 
AP7.2B 1004 (5.7) 243 (2 .1) 0 ( l.O) 141211 (665) 26226 (124) 
AP4.3E 1557 (6 .8) 371 (2.4) 34.7(1.1) 128765 (477) 22510 (84.3) 
AP8.2A 2683 (11.2) 919 (4.5) 0 ( l.O) 160654 (611) 45139 (172.6) 
AP6.7E 818 (3 .0) 219 (2 .1 ) 0 (0 .9) 136290 (676) 28557 (142) 
AP2.6F 247 (1.8) 159 (l.5) 0 (0 .9) 133877 (414) 31814 (99.2) 
AP7.4C 1468 (5 .8) 14 (1.0) 34 (1.1) 139076 ( 458) 31410 (104) 
AP3.10C 1014 (5.4) 32 (1.1) 58 ( 1.2) 104610 (450) 36999 (160) 
AP7.9A 1778(8.9) 710 (4. 1) 155 (l.7) 141072 (628) 56185 (250) 
AP2.1D 2012 (7.6) 222 ( 1.7) 50 (1.2) 127688 (420) 28965 (96.2) 
AP2.5E 2346 (8.8) 132 (1.4) 127 (l.4) 140583 (471) 53856 (181.1) 
AP3.5B 1124 (4.6) 99(1.3) 25(1.1) 118112 (378) 52270 (168.1) 
AP8.3C 2818 (8.4) 114(1 .3) 0 (0.7) 105646 (278) 62291 (164) 
AP3 .3A 1324 (4.2) 134 (1.3) 0 (0.9) 129859 (318) 65894 (162) 
AP6.6E 1074 (6 .5) 1081 (6.4) 20 (1.1) 164678 (837) 41532 (211) 
AP8.10B 1240 (6.8) 275 (2 .3) 40 ( 1.2) 133614(631 ) 50312 (238) 
AP6.3D 3413 (17.4) 1002 (5.8) 12 (1.1) 129269 (622) 50541 (240) 
AP2.5A 999 (5 .2) 116(1.5) 18 (1.1) 148088 (628) 31769 (135.1) 
AP2.9A 1668 (6 .9) 207 (1.7) 0 (0.8) 111996 (394) 32521 (132.8) 
AP2.4F 1493 (8 .7) 136 (1.7) 11 (I.I) 139379 (723) 35729 (186) 
AP6.8E 1105 (5 .7) 551 (3 .3) 93.5 (1.4) 86543 (367) 22226 (95) 
AP2.3C 2045 (9.3) 946 (5 .0) 25 (1.1) 1429 19 (607) 50949 (217) 
AP3.8F 1162 (9.8) 296 (3.2) 2 ( l.O) 151138 (1145) 40037 (304) 
AP3.10F 198 (2.5) 52 (l.4) 14 (l.l) 19506 (157) 4556 (37) 
AP3.7F 2169 (12.1) 153 (1.6) 0 (0.9) 134044 (685) 38768 (199.8) 
AP4.7E 983 (6.3) 196 (2. 1) 24 ( 1.1) 144397 (785) 49079 (267.7) 
AP3.7C 2565 (14.9) 613 (4.3) 27 (1.1) 126924 (687) 43382 (235 .5) 
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Proliferative responses of a panel of 7 CD4+ T-cell clones from the synovium of a patient with 
post-traumatic osteoarthritis of the knee are shown in table 5.V. Five of these clones had 
significant responses to SK-SD, while no responses to PPD or HSP65 were observed. It is 
notable that this patient had no clinical or laboratory evidence of streptococcal arthritis or 
local streptococcal infection during the course of his arthritis . Using an alternative cloning 
strategy (synovial MNC cloned in limiting dilution in the presence of antigen rather than non-
specific mitogenic stimulus), 2 CD4+ T-cell clones with PPD-specific reactivity and l clone 
with SK-SD-specific proliferation were generated from the synovial membrane of a patient 
with gout (Table 5.VI) . In addition, two clones from gout synovium proliferated to both PPD 
and SK-SD, suggesting a degree of cross-reactivity between these antigens or that the 
population of cells was not monoclonal. One of these clones (TS8 .5A) mediated PPD and not 
SK-SD specific cytolysis (see Table 5.Vll), as did an additional clone with a degree of SK-SD 
induced proliferation (TS7.5E). The finding of PPD-specific cytotoxicity provides a more 
reliable indicator of the antigenic specificity of the clones. Two clones generated in the 
presence of recombinant HSP65 did not have significant proliferative responses to this antigen 
on subsequent testing. 
TABLE 5.V 
Proliferation of a panel of CD4+ T-ce/1 clones from osteoarthritic synovium in response to 
microbial antigens, mitogen and recombinant interleukin-2. Values shown are ,1cpm 
(Stimulation Index). 
CLONE PPD SK-SD HSP65 PHA IL2 
VS1.2C 582.4 3614 164 191760 62415 
(2.5) (10.3) (1.4) (491) (160.8) 
VS1.3D 656.3 5641 0 70739 97229 
(2 .3) (12.6) (0.9) (146) (200.4) 
VS1.5C 259 1141 561 106448 39524 
(2.0) (5.6) (3.3) (433) (161.7) 
VS1.6A 605 6422 329 180601 95826 
( 1.9) (11.1) ( 1.5) (284) (151.2) 
VS2.5A 1285 11544 0 165250 114152 
(2.5) (31.6) (0.9) (438) (303 .5) 
VS2.9D 235.7 4548 62.3 179631 97590 
( 1.8) (17.2) ( 1.2) (641) (348.7) 
VS2.4D 191.3 273.6 69.3 105899 22143 
(1.5) ( 1.8) (1 .2) (303) (64.3) 
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TABLE 5.VI 
Proliferation of a panel of CD4+ T-ce/1 clones from gout synovium in response to microbial 
antigens, mitogen and recombinant interleukin-2. Values shown are L'icpm (Stimulation 
Index). 
CLONE CLONING PPD SK-SD HSP65 PHA IL2 
ANTIGEN 
TS1.6F SK-SD 11623 6708 0 184854 57049 
(4.7) (3.1) (0.7) (60) (19.1) 
TS7.1C PPD 5949 8009 1018 56627 46610 
(2.7) (3.2) ( 1.3) ( 17.1) ( 14.3) 
TS7.2E PPD 27620 2835 226 99451 95904 
(19.3) (2.5) (I.I) (66.9) (64.5) 
TS7.5E PPD 51277 16831 770 175605 145757 
(5.5) (2.5) (I.I) (16.3) (13 .7) 
TS 8.5A PPD 14583 22709 815 51534 64616 
(4.7) (6.7) ( 1.2) (13 .9) (17.2) 
TS14.3C HSP65 942 2579 0 115764 85931 
(I.I) ( 1.2) (0.6) (9.8) (7.6) 
TS14.5D HSP65 0 0 0 71228 35498 
(0 .8) (0.9) (0.5) (4.1) (2 .5) 
Antigen-specific and lectin-dependent cytotoxic functions of a selection of the CD4+ T-cell 
clones described above were measured in 15h 5 lcr release assays . All clones tested had 
moderate levels of cytolytic potential, as demonstrated in the lectin-dependent assay (Table 
5.VII). In addition, antigen-specific cytotoxicity was observed in the clones from OA and gout 
synovium. Interestingly, although the three PPD-reactive clones from the RA synovium that 
were tested had moderate lytic potential, as demonstrated in the lectin-dependent cytotoxicity 
assay, none of these clones demonstrated PPD-specific cytotoxicity. This finding indicates that 
these clones are very unlikely to be PPD-specific. 
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TABLE 5.VII 
Cytotoxic function of synovial CD4+ T-ce/1 clones from patients with arthtitis. 
CLONE DESCRIPTION LECTIN-DEPENDENT ANTIGEN-SPECIFIC 
CYTOLYSIS(%)# CYTOLYSIS (%)#t 
AP2.3C Cloned from RA 36.3 0 (PPD) 
AP2.5E synoviwn with 31.3 0 (PPD) 
AP3.7F PHA 27.5 0 (PPD) 
VS1.3D Cloned from OA 38.8 29.8(SK-SD) 
VS2.5A svnoviwn with PHA 18.1 9.3(SK-SD) 
TS7.2E Cloned from gout 35.1 33 .9(PPD) 
TS7.5E synovium with 34.4 20.2(PPD) 
TS8.5A PPD 38.2 29. l (PPD) 
#Effector:target ratio 10: l 
tLevels of cytotoxicity against non antigen-pulsed targets and targets pulsed with antigen other than 
indicated were less than 2%. 
DISCUSSION 
Several different strategies have been adopted to identify the putative infectious agent(s) 
thought to be responsible for the initiation, and perhaps perpetuation, of the chronic 
inflanunatory and immune response in RA3. These approaches could be divided into two broad 
categories: (i) the identification of microrganisms or their components in tissue/fluid samples of 
patients with RA16,17,18, and (ii) the elucidation of potentially relevant inununological 
responses, humoral and cellular, to antigens of candidate pathogens18,J9,io_ Based on 
observations in reactive arthritis, where specific causative organisms and inunune responses to 
these organisms have been identified, it has been suggested that proliferative responses of 
synovial lymphocytes to microbial antigens may indicate the microbiological causes of RA21 _ 
The data reported in this chapter support earlier published observations that proliferation to 
mycobacterial antigens is frequently observed in RA synovial MNC and T-cell clones4,5,6,20 
but, in common with additional evidence, demonstrates that this phenomenon is neither 
restricted to cells from the synovial compartment, nor confined to SFMNC from patients with 
RA9, 12 . These observations thus indicate that mycobacterial antigen-reactivity in RA is a non-
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specific occurrence and do not support an aetiological role for M tb infection in RA, and were 
confirmed by data obtained in studies of the kinetics of PPD-induced MNC proliferation. 
Recently it has been reported that MNC from tuberculous effusions respond with accelerated 
kinetics of proliferation when stimulated in vitro with PPD 11 . This phenomenon was specific to 
the disease-relevant antigen, restricted to MNC from the site of pathology, and closely 
resembles a secondary/ in vitro re-prime immune response with peak proliferation occurring 
on day 4 rather than day 7 following stimulation. In the current study, PPD-induced (but not 
SK-SD induced) proliferative responses of SFMNC were indeed more rapid than PBMNC, as 
indicated by greater day 4 proliferation, but this observation was not confined to RA SFMNC, 
and does not constitute accelerated kinetics of proliferation as previously defined in the 
tuberculosis modeJI 1. Nevertheless, rapid kinetics of proliferation to PPD in SFMNC is an 
interesting finding that may indicate specific properties of the stimulus and the mononuclear 
cell population localised to an inflammatory site. The precise mechanism responsible for the 
more rapid PPD-induced proliferative response of synovial MNC compared to circulating 
MNC is unclear; it is unlikely to be due to an increased precursor frequency of PPD-reactive 
MNC in the synovial compartment as (i) previous reports have been unable to demonstrate an 
enrichment of mycobacterial antigen-reactive T-cells in the synovial compartment in patients 
with RA 12,22 and (ii) kinetics of proliferation appear to be unrelated to the precursor frequency 
of responding cells in the tuberculosis model [PT Lukey et al, unpublished observations]. 
While it is theoretically possible that the rapid proliferative response of SFMNC may be due to 
a superantigenic effect of PPD, especially given the reports of specific accumulation of VP T-
cell families in RA synovial compartments23 , this mechanism does not explain the finding in 
non-RA inflammatory synovitis and is not supported by any other evidence of superantigenic 
properties of PPD. An alternative potential mechanism may involve the superior antigen 
processing capabilities of synovial antigen presenting cells, as has previously been 
demonstrated in RA24, although this does not account for the restriction of the phenomenon to 
PPD responses . 
Nine out of 27 clones generated from rheumatoid synovmm displayed low levels of 
proliferation to PPD (table 5.IV) . While it is possible that this finding represents antigen-
specific responses, the low levels of PPD-induced proliferation may be due to the phenomenon 
of "back stimulation". This phenomenon occurs where a major recall antigen such as PPD 
induces IL2 production by the irradiated antigen-presenting cells, in tum stimulating low levels 
of proliferation of the clone, and may also account for low levels of proliferation observed in 
other clones. Proliferative responses of the clones using T cell depleted irradiated autologous 
PBMNC would assist in distinguishing between "back stimulation" and true antigenic 
responses, but was not perfom1ed in the current study. 
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Mycobacterial HSP65 is a member of the HSP60 family of heat shock proteins which function 
as molecular chaperones and are highly conserved throughout evolution, with approximately 
48% shared homology between mycobacterial HSP65 and its mammalian homologue, 
HSP60 25 . Heat shock proteins are considered to be immunodominant constituents of many 
microorganisms, possibly due to their increased production by the microbe following host 
invasion and the suggestion that the immune system is pre-set for their recognition26. 
Upregulation of mammalian tissue expression of HSP60 as a result of a variety of stressful 
stimuli is a physiological response, and has been demonstrated in synovium of patients with 
RA and juvenile chronic arthritis27,28. Initial evidence from mycobacterial-induced adjuvant 
arthritis indicated that T-cell responses to amino acids 180-188 of mycobacterial HSP65 were 
central to the disease process29. However, attempts to induce AA by vaccination of susceptible 
animals with HSP65 (rather than killed mycobacteria) proved unsuccessful and instead 
conferred protection against the subsequent induction of several forms of experimental 
arthritis, and other experimental autoimmune diseases30,31 ,32. Recently it has been shown that 
the protective effect of HSP65 preimmunisation is not due to the induction of tolerance, either 
to the parent protein or the arthritogenic epitope (amino acids 180-188), but may be the result 
of regulatory T-cells activated by alternative protective epitopes of HSP65 not present in 
sufficient quantity in killed organism preparations33 . As HSP65 preimmunisation is effective in 
protecting against the development of chemical as well as bacterial-induced forms of 
experimental arthritis, it has been suggested that the common protective mechanism involves a 
T-cell population that is cross-reactive between mycobacterial HSP65 and host HSP60, and 
that regulates subsequent immune responses33 . 
Reports of T-cell proliferative responses to HSP65 in humans with inflammatory arthritis have 
been somewhat varied and controversial and may have, in part, been due to proliferative 
responses to E coli contaminants contained in preparations of the recombinant protein34_ 
Increased synovial lymphocyte proliferative responses to HSP65 have been demonstrated in 
HLA B27 +ve patients with pauciarticular juvenile chronic arthritis and in patients with 
reactive arthritis34,35 . In common with observations in patients with RA 36,37, T-cell responses 
to HSP65 in JCA appear to be directed against mycobacterial and not human epitopes34. In 
patients with RA, evidence of significant lymphocyte proliferative responses to HSP65 has 
perhaps been the most controversial ; while some studies have found increased proliferative 
responses in early disease4,38, our data indicate that significant proliferation to HSP65 occurs 
less frequently in RA patients with early disease than in healthy normals, despite vigorous 
lymphocyte proliferation in response to other mycobacterial antigens . Our findings are 
supported by similar observations in patients with RA from an area with comparatively low 
tuberculosis prevalence [JSH Gaston - personal communication], and the evidence from 
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limiting dilution analysis that the rheumatoid synovial compartment does not contain a specific 
enrichment ofHSP65-specific T-cells22 . 
Interpretation of our findings in the light of current theories emanating from animal models 
would suggest that the observed relative lack of MNC proliferation to HSP65 , in patients with 
RA, may be indicative of a failed regulatory T-cell response in these individuals that may have 
contributed to the persistent synovial immuno-inflammatory process . In this context, our 
observation of significant HSP65 proliferation restricted to T-cells from an acutely inflamed 
area of synovium in a patient with gout is of interest. The localisation of this HSP65 T-cell 
proliferative response to an area of acute inflammation does not discriminate between a 
potentially pathogenic or immunoregulatory role for these cells, but may indicate their specific 
involvement in the local acute immune response. 
Cytotoxic CD4+ T-cells may be important in the immune response to infections, particularly 
against facultative intracellular pathogens39, and host responses to tumours and transplanted 
organs40,41 . These cells mediate their cytotoxic function, following specific binding of their T-
cell receptor and antigenic epitope in association with class II MHC, by fas-dependent or 
granule-mediated mechanisms resulting in target cell apoptosis and/or cytolysis, as discussed 
previously (Chl , pg. 20) . While target cell disruption in the immune response to an 
intracellular infection has the potential beneficial effect of exposing the pathogen to alternate 
defence mechanisms42, it is likely that this process may be pro-inflammatory and contribute to 
joint destruction in RA. An isolated previous report of cytolytic function of T-cells from RA 
synovial fluid and synovial membrane indicated high levels of antigen-specific cytotoxicity in 
all mycobacterial antigen-specific T-cell lines and clones studied
7. However, although it was 
suggested that T-cell mediated cytolysis of mycobacterial antigen-expressing target cells in the 
synovium may be relevant to the pathogenesis of RA, this phenomenon was not investigated in 
control patients with non-rheumatoid inflammatory arthritis . The data in this chapter indicate 
that mycobacterial antigen-specific cytotoxicity can also be demonstrated in MNC from the 
circulation and synovial fluid of patients with gout and psoriatic arthritis. These data, together 
with the finding of PPD and SK-SD - specific cytotoxicity among CD4+ T-cell clones 
generated from the synovium of patients with gout and OA, further emphasize the non-specific 
nature of the T-cell infiltrate in inflammatory synovitis . Although the demonstration of T-cell 
mediated microbial antigen-specific cytotoxicity thus has limited aetiological significance in 
RA, cytotoxic CD4+ T-cells directed against the as yet unidentified "rheumatoid antigen" may 
have relevance to the immunopathogenesis of the disease. In addition, the apparently quiescent, 
non-specific cytotoxic CD4+ T-cell infiltrate also has immunopathogenic potential as discussed 
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INTRODUCTION 
As the rheumatoid synovmm is characterised by an accumulation of T cells that display 
evidence of a state of activation, identification of the T cell stimulus is of considerable 
importance in the understanding of the disease and for the development of specific 
immunomodulatory agents 1,2,3,4,5,6, 7. Based on current understanding of T cell activation, it is 
possible that T cell stimuli in RA synovium may include specific MHC-restricted T cell 
epitopes (foreign or self), or non-specific factors8,9,10,11 , 12, 13 . To date, the approach to the 
identification of the synovial T cell stimulus in RA has focussed on the investigation of 
proliferative responses to microbial or selected purified or synthetic self antigens or specific 
cellsl4,9,I5,11 _ However, as discussed in chapter 5, identification of synovial lymphocyte 
proliferation to microbes or their products in RA may have limited aetiological significance. In 
addition, synovial T cell proliferation to selected self antigens has yielded controversial 
results 15,16 . 
An alternate strategy used in the examination of T cell stimuli in organ-specific autoimmune 
disease has been the investigation of T cell responses to a wide range of target organ-derived 
constituents17,I8, I9_ T cell proliferation identified with this method may be in response to self 
constituents or locally-sequestered microbial antigens present in the target organ. Using this 
approach, it has previously been reported that a high molecular weight component of synovial 
fluid (not restricted to rheumatoid synovial fluid) exerted a costimulatory effect on the IL2-
induced proliferation of rheumatoid synovial T cell lines and clones20 . A recent report has 
demonstrated T-cell reactivity to synovial fluid and plasma antigens in the > 1 OOkDa and 40 -
60kDa range in patients with RA21 . However, as the pathogenetic processes in RA would 
appear to be centred largely in the synovial membrane, identification of T cell stimuli in this 
tissue may also have relevance, and has not previously been reported. 
The studies reported in this chapter have been based on the hypothesis that the rheumatoid 
synovium may be the source of both the pathogenetic T cell population and the on-going 
stimulus of these cells . With the use of synovial explant culture techniques, the phenotypic and 
functional characteristics of T cells growing out of synovial membrane under conditions that 
may select for in vivo activated T cells were investigated. Samples of synovium obtained from 
patients with RA and a control arthritis group were included in these investigations . The in 
vitro proliferative response of synovial explant-derived T cell lines to a broad range of 
constituents of autologous synovial membrane were examined using a T cell immunoblot assay. 
Prolonged outgrowth of T cells from rheumatoid synovial explants was observed, with a 
clustering of synovial T cell proliferative responses to a high molecular weight constituent of 
autologous synovium in patients with RA but not other arthritides . Additional investigations 
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indicated that the stimulatory fraction of synovium includes components of the extracellular 
matrix proteins, collagen and fibronectin. The approach to further characterisation of the 
synovial T cell stimulus and the potential role of extracellular matrix proteins in T cell 
activation within the rheumatoid joint are discussed. 
METHODS 
1. Patients and controls. 
Samples of synovial membrane and venous blood from a total of 12 patients with arthritis 
undergoing arthroplasty are included in studies reported in this chapter. Clinical details of the 
patients are shown in Table 6.1. In all cases, diagnoses were made according to the revised 
ARA criteria and typical clinical, radiographic and laboratory findings22 . In addition, venous 
blood from 3 healthy laboratory workers (l male and 2 female, mean age 42 ± 8.8 years) was 
used as a source of normal PBMNC. 
TABLE 6.1 
Patient information 
PATIENT DIAGNOSIS AGE SEX DISEASE 
DURATION (YRS) 
1 RA 32 F 2.5 
2 RA 64 F 6 
3 RA 63 F 8 
4 RA 72 F 15 
5 RA 64 F 8 
6 RA 52 F 7 
7 JRA 27 F 13 
8 SLE 43 F 2 
9 OA 71 M 12 
10 OA 68 F 14 
11 OA 64 F 8 
12 OA 58 M 7 
2. Synovial membrane culture and antigen-reactivity of T cell lines 
Fragments of freshly-harvested synovial membrane (2 - 3 mm3) were cultured in 1ml complete 
medium (RPMI 1640 containing lOOU/ml of penicillin, lOOµg/rnl of streptomycin and 10% 
pooled AB human serum) supplemented with recombinant IL2 (100 iu/rnl , Cetus) in 24 well 
plates (Greiner) . Growing cultures were fed with fresh medium supplemented with recombinant 
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IL2 every 3 - 4 days . Tissue explants were passaged weekly to new culture plates and 
mononuclear cells harvested by vigorous re-suspension, washed in PBS and either used in 
experiments or cryopreserved for later investigations . 
Autologous and heterologous PBMNC were obtained by ficoll-hypaque density centrifugation 
of huffy layer cells, as described previously23 . Fallowing the final wash cells were resuspended 
at 106/rnl in complete medium. Proliferative responses of T cell lines to soluble antigens and 
mitogen were performed in triplicate at least 3 days after last feeding with rIL2 . Details of the 
methods are as described for the T cell clones in chapter 7. Briefly, T cell lines (5 x 104/well) 
were stinmlated by antigen or mitogen at optimal concentration in the presence of 2.5 x 104 
irradiated autologous PBMNC, but in the absence of rIL2 . Incorporation of 3H thymidine was 
measured over the last 8h of the 48h incubation. Wells with feeders and T cell line but no 
antigen/mitogen served as background controls . 
3. Separation of synovial and collagen constituent proteins by polyacrylamide gel 
electrophoresis 
Fragments of synovial membrane ( l cm3) from each patient were immersed in liquid nitrogen 
and ground into a fine powder using a pestle and mortar24 . Tissue particles were solubilised 
using the following buffer: 20mM Tris-HCL (pH 8.4), 7M urea, 5% 2-mercaptoethanol (2-
ME) containing 1 % sodium dodecyl sulphate (SDS) and then diluted l :2 with sample buffer 
(125mM Tris-HCL (pH 6.8), 4% SDS, 20% glycerol, 10% 2-ME and 0.01 % bromophenol 
blue) and boiled for 3 minutes . Aliquots of samples prepared in this manner (40 - 50µ1) were 
electrophoresed using standard Laemmli SDS-polyacrylamide gel electrophoresis (SDS-P AGE) 
teclmiques with a 3% stacking gel and 10-12,5% running gel in a vertical slab electrophoresis 
unit (SE 600, Hoeffer Scientific Instruments, San Francisco, CA)25 . High and low molecular 
weight standards (Biorad) were boiled in sample buffer and added to relevant vacant lanes. 
Separation was performed at 4°C under constant current conditions for approximately 4 h in 
tank buffer consisting of 0.025M Tris-HCL (pH 8.3), 0.192 M glycine and 0.1 % SDS . On 
completion of the electrophoresis, gels were stained with coomassie blue (0.025% coomassie 
blue R-250, 40% methanol, 7% acetic acid) for at least 8 h with constant shaking, and then de-
stained with 50% methanol and l 0% acetic acid solution. Gels were not stained when transfer 
of separated proteins to nitrocellulose was to be perfonned. Human type I and bovine type II 
collagen were purchased from Sigma and prepared for electrophoresis as described for the 
synovial membrane san1ples; 40-50µ1 of the lmg/ml collagen preparation were loaded per lane. 
4. Transfer of separated proteins to nitrocellulose. 
Electrophoretic transfer of separated synovial and collagen constituents to nitrocellulose 
membrane (0 .2µm and 0.45µm, Hoeffer) was performed using a transphor electrophoresis unit 
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(TE 52, Hoeffer Scientific Instruments) with the same tank buffer as described above. Transfer 
was conducted over 18h at 4°C, using a current of 0.5mA. Successful transfer of separated 
proteins and location of lanes was determined by temporary staining of the nitrocellulose with 
amido black (0.01 % in 0.5% acetic acid solution) followed by washing in distilled water17. 
Residual dye and SDS were removed from the nitrocellulose by washing in PBS for 2 h with 
repeated changes of washing solution. Nitrocellulose with bound proteins was then either stored 
in cling film at 40c, or used in assays as described below. 
5. Preparation of nitrocellulose membranes for use in proliferation assays. 
Nitrocellulose was cut into individual lanes, as demarcated by prior staining with amido black, 
and each lane fractionated into 2mm horizontal bands, as previously described26 . As each lane 
was approximately 12cm in length, this procedure yielded 60 fractions of nitrocellulose with 
bound protein of known molecular weight. Individual nitrocellulose fragments were dissolved 
and sterilized in 250 µl of DMSO in glass tubes (1hr at room temperature) . Recovery of the 
protein was obtained by precipitating the mixture with the slow addition of an equal volume of 
carbonate/bicarbonate buffer (0 .05M, pH 9.6) during continuous vigorous vortexing. This 
method results in the production of small protein-bound nitrocellulose particles . DMSO was 
removed from the nitrocellulose particles by washing three times in PBS . Following the final 
wash, RPMI 1640 (0 .5ml) was added to each sample, which were then stored at -20°C until 
use in the proliferation assays . A particle suspension of nitrocellulose prepared as above but 
without bound protein was used as a background control in all proliferation assays . 
For detection of proliferative responses to nitrocellulose-bound proteins, 20 µl of 5 pooled 
samples .(recently thawed and vortexed) were added to triplicate wells containing 105 
mononuclear cells in a final volume of 200 µl of complete medium in 96 well flat bottomed 
rnicrotitre plates (Greiner). Where the proliferative responses of T cell lines were investigated, 
5 x 104 irradiated (3000 rads) autologous PBMNC were added as a source of phagocytic 
antigen-presenting cells . Cultures were incubated at 370c in a humidified atmosphere 
containing 5% CO2 for 4 days (T-cell lines) and 7 days (PBMNC). Tritiated thyrnidine 
(Amersham International, Buckinghamshire, England; specific activity 5 Ci/mmol) was added 
(2 µCi/well) for the final 18 h of incubation. Means of triplicates were calculated and results 
expressed as a stimulation index (SI), where SI = mean counts per minute in stimulated 
wells/mean counts per minute in background (unstimulated) wells. 
6. Standardisation of T cell immunoblot technique 
The above techniques have been used extensively m the study of T cell protein 
responses 17,27,28 . Prior to use in these investigations of synovial T cell responses to synovial 
proteins, the T-cell immunoblot method was standardised using recombinant HSP65 protein of 
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Mycobacterium bovis as antigen (kind gift of Dr J.D.A van Embden29) , and PBMNC and a T 
cell line from HSP65-reactive normal individuals. The HSP65-reactive T cell line was 
generated from the PBMNC of a normal PPD-reactive individual by stimulating freshly 
isolated PBMNC (106/ml) in vitro with recombinant HSP65 (5µg/ml). After 7 days 
recombinant IL2 (rIL2) was added ( l 00 iu/ml), and the cells fed with fresh medium and rlL2 
every 3 - 4 days and passaged weekly with additional antigen, rIL2 and autologous irradiated 
PBMNC (5 x 104/ml) as feeder cells. Antigen-reactivity of the T-cell line was tested at least 3 
days after the last addition of rIL2 and 7 days after passaging with fresh feeders and antigen. 
Recombinant HSP65 (lmg/ml) was subject to electrophoretic separation as described above 
and transferred to nitrocellulose. Fractions of nitrocellulose were prepared as described and 
used in proliferation assays of PBMNC from HSP65-reactive donors and the HSP65-reactive 
T cell line. 
7. Detection of collagen and fibronectin in rheumatoid synovium by western blotting 
Monoclonal antibodies used included a mouse monoclonal antibody specific for human type III 
collagen (Sigma), a mouse monoclonal antibody specific for human fibronectin (CJ2) and a 
rabbit polyclonal antibody to human fibronectin (the latter two antibodies both kind gifts of 
C.A. de Jager30). Following electrophoretic transfer of separated synovial proteins to 
nitrocellulose, individual lanes of membrane were incubated for l h at room temperature in a 
blocking solution of 2 % casein in tris buffered saline (TBS - pH 7.4 ), with continuous rocking. 
Antibodies were then added in fresh blocking solution ( 1 :500 dilution for monoclonal antibodies 
and l: 1000 dilution for the polyclonal antibody) and incubated for l h at room temperature 
with continuous rocking. Lanes of nitrocellulose were then washed three times in TBS with 
0.05% tween-20, and immersed in peroxidase conjugated goat anti-mouse (or goat anti-rabbit 
where appropriate) immunoglobulin solution (Organon Technika, Cappel, West Chester, PA) 
(l :500 dilution in blocking solution) for l h at room temperature. Following a further three 
washes in TBS and 0.05% tween-20, detection of bound immunoglobulin was performed by the 
addition of substrate for 15 minutes, and then rinsing in distilled water24 . Detection substrate 
was constituted as follows : 24mg 4 chloronapthol (Merck) dissolved in 8 ml methanol , and 
diltued with 40ml TBS; hydrogen peroxide ( 1 Oµl of 30%) was added immediately prior to use. 
8. Immunophenotyping of synovial mononuclear cell lines 
Phenotypic analysis of cell lines harvested from synovial explants was performed by dual 
parameter flow cytometry, using an Epics Profile II (Coulter Electronics) . Monoclonal 
antibodies used were CD3-RD1 , CD4-FITC, CD8-FITC, all from Coulter Immunology. 
Mononuclear cells were analysed at 106/ml in complete medium, using 100µ1 per assay. 
Histograms generated were (i) forward scatter (FS) vs Jog side scatter (LSS), (ii) log 
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fluorescence 1 {LF 1 - green fluorescence) vs log fluorescence 2 (LF2 - red fluorescence, (iii) 
and (iv) single parameter histograms of LFl and LF2. 
RESULTS 
1. Standardisation of the T-cell immunoblot technique using a recombinant protein 
The T-cell immunoblot technique was standardised using a recombinant HSP65 protein and 
PBMNC from HSP65 reactive individuals . In order to establish the technique for use in assays 
of T-cell lines, a T-cell line was generated in the presence of HSP65 from the PBMNC of a 
normal individual. This T-cell line demonstrated proliferative responses to PPD and 
recombinant HSP65 , but not SK-SD, when assayed by tritiated thymidine incorporation over 
the last 8 h of a 48 h culture in the presence of the antigens and irradiated autologous feeders 
(Table 6.Ila) . HSP65 was subject to electrophoretic separation and transferred to 
nitrocellulose. Specific proliferation to nitrocellulose-bound protein in the molecular weight 
range of 60-75kDa was found with PBMNC from the HSP65 reactive individuals and 
confirmed with assays of the HSP65-specific T cell line {Table 6.Ilb) . Levels of proliferation 
were 60-70% of that observed with the soluble recombinant protein at optimal concentration. 
No significant proliferative response to other nitrocellulose fractions (higher or lower molecular 
weight range) prepared from the HSP65 sample were found . 
Table 6.lla. 
Reactivity of a T cell line generated in the presence of recombinant HSP65 *. 
STIMULUS ~cpm SI 
PHA 12612 5.8 
PPD 17298 7.6 
SK-SD 0 0.4 
HSP65 12687 5.8 
*Data shown are means of triplicate detenninations. Similar results were obtained on an additional occasion. 
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Table 6.llb. 
Standardisation of T cell immunoblot technique: Proliferation of PBMNC and a HSP65-
reactive T cell line to nitrocellulose-bound recombinant HSP65 of appropriate molecular 
weight range. 
Fractions* Mol wt range (kDa) PBMNC 1# PBMNC 2 T Cell linet 
1 - 5 175 -217 1.0 1.0 I. I 
6 - 10 142-175 2.1 1.8 1.0 
11 - 15 114-142 l.3 I. 7 l.3 
16 - 20 93 - 114 I.I 2.1 I.I 
21 - 25 75 - 93 0.9 1.6 1.7 
26 -30 60- 75 9.7 17.9 3.6 
31 -35 49- 60 2.1 I. 9 0.8 
36 -40 39 - 49 I. 9 0.8 1.2 
41 -45 32 - 39 2.0 0.7 1.4 
46 - 50 26 - 32 0.7 2.0 I.I 
51 - 55 21 - 27 1.0 1.2 0.8 
56 - 60 17 - 21 1.4 I. I 1.4 
* Pooled 2mm horizontal bands of nitrocellulose membrane 
# Cells from normal healthy PPD and HSP-reactive individuals; data shown are mean stimulation indices 
obtained from triplicate detenninations. 6 cpm for positive results (SI> 2.5) were in the range 6 130 - 25 670. 
t Additional details of this T-cell line are provided in Table 2a 
2. Sustained out-growth of T cells from rheumatoid synovial explants. 
Fragments of synovium from a total of 12 patients with arthritis were cultured in complete 
medium supplemented with recombinant IL2 (100 iu/ml), and passaged weekly. Out-growth of 
mononuclear cells was observed, typically clustered around dendritiform cells (Figure 6. la and 
lb) . A wide interpatient variation in the number of mononuclear cells from the synovial 
explants with each passage was found (2 - 20 x 106 cells per passage); maximum yields were 
obtained with rheumatoid synovium. Flow cytometric analysis was performed with cells 
harvested from explant cultures . In all cases, irrespective of the type of arthritis, the cells were 
predominantly CD3+ (> 84%) and CD4+ (table 2), but variation in the percentage of CD4+ 
and CD8+ cells were observed with long-term passaging of rheumatoid synovium (Fig 2) . 
Synovial explants could be passaged for up to 13 weeks with sustained out-growth of T cells in 
3 patients with RA; out-growth of T cells from OA synovial membrane ceased by 3 weeks in 
culture. In addition, explants of synovium from a further 5 patients with OA did not yield 
sufficient T-cells for investigation; these patients were excluded from this study. 
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FIGURE 6.1 
Rheumatoid synovial exp/ant culture 
(a) T cells and dendritifonn cells growing out of a fragment of rheumatoid synovial membrane 
after 3 days in culture ( 1 OOx magnification) 
(b) High power view with typical appearance of T cells clustered around dendritifonn cells 
following 7 days of in vitro culture of rheumatoid synovial explant. Tissue fragment is not 
included in field of photomicrograph. (200x magnification) 
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TABLE 6.111 
Phenotypic analysis of mononuclear cells obtained from early passage synovial exp/ants*. 
PATIENT DIAGNOSIS CD3 (%) CD4 (%) CD8 (%) CD4:CD8 ratio 
I RA 96.3 69.2 21.7 3.2 
2 RA 84.1 72.6 10.8 6.7 
3 RA 97.3 88.7 7.7 11.5 
4 RA 98.1 96.2 1.6 60. 1 
5 RA 92 .7 88.6 2.9 30.6 
6 RA 88.7 78.4 6.9 11.4 
9 OA 91.8 65.0 25 .9 2.5 
10 OA 98.9 91.3 1.0 91.3 
11 OA 91.5 57.9 26 .9 2.2 
*Phenotypic analysis was not perfonned on synovial explant-derived cells from individual patients with JRA, 
SLE and OA included i.n this study. 
3. Proliferative responses of synovial membrane T cell lines 
Functional analysis of early passage synovial membrane T cell lines described above included 
investigation of proliferative responses to mitogen (PHA), soluble antigens (PPD, SK-SD and 
recombinant HSP65), and autologous synovial proteins separated by gradient SDS-P AGE. 
Significant response to soluble antigens was found in T cell lines from an individual patient 
with RA, JRA and OA (Table 6.IV) . In these cell lines, similar responses to PPD and SK-SD 
were found, while no significant proliferation to HSP65 was observed. 
Proliferative responses of synovial T cell lines to autologous synovium was investigated using 
the T cell immunoblot technique26 . Separation of synovial constituents was performed by l 0-
12.5 % gradient SOS-PAGE (Figure 6.3) . Significant proliferation (in this system defined as 
stimulation index > 2.5 and ~cpm > 2000) in response to nitrocellulose particles containing a 
high molecular weight component of synovium ( 114-142 kDa) was confined to synovial T cell 
lines of 5 out of the 6 patients with RA (Figure 6.4) . Three prominent protein bands were 
present in this molecular weight range (rf: 0.209, 0.218 and 0.242 respectively) (see Fig 6.3). 
In addition, responses to synovial constituents of lower molecular weight were noted in a single 
patient with RA (75-93 kDa, 49-60 kDa and 39-49 kDa) . No significant proliferation of 
synovial T cell lines from patients with OA, SLE or JRA in response to autologous synovium 
was found . 
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FIGURE 6.2 
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*Synovial explants were passaged weekly as described in materials and methods and cells harvested at the end of 
each passage and cryopreserved. Phenotypic analysis was performed by flow cytometry 
TABLE 6.IV 
Proliferation of synovial membrane T cell lines and autologous PBMNC in response to 
mitogen and soluble antigens*. 
P HA PPD SK- SD HSP 65 IL 2 
Patient Diagnosis PBL# SMLt PBL SML PBL SML PBL 
l RA 212 13.5 7.9 1.3 5.3 0.4 0.7 
2 RA ntt nt 1.1 6.0 0.9 4.2 0.6 
3 RA 45.5 11.2 3.5 0.9 1.1 0.6 1.0 
4 RA 12.5 9.6 nt 0.7 nt 0.6 nt 
5 RA nt nt 3.6 0.9 1.1 0.7 2.0 
7 JRA nt nt 26 7.3 160 4.5 3.1 
9 OA nt 15.3 nt 0.43 nt 0.2 nt 
11 OA nt nt 38.0 5.0 32.0 19.5 2.7 
*Values indicated are stimulation indices obtained from experiments performed in triplicate 
# autologous peripheral blood mononuclear cells 
t synovial membrane T cell line 
j not tested 
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SML PBL SML 
0.8 51.3 263 
2.5 nt nt 
0.7 nt nt 
0.9 nt 21.5 
0.8 nt 22.1 
1.2 nt nt 
0.3 nt 50.3 
l.5 30.0 41.7 
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FIGURE 6.3 







L1 L2 L3 L4 
Separation was performed using a I 0-12.5% gradient gel, under reducing conditions - as 
described in materials and methods . 
Lane I : molecular weight standards 
Lane 2: rheumatoid synovial membrane 
Lane 3: rheumatoid synovial membrane 
Lane 4 : rheumatoid synovial fluid 
Three prominent bands contained within the stimulatory fraction of synovium arc indicated by 
the arrow. 
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FIGURE 6.4 
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*Proliferative responses of synovial explant-derived T cell lines to components of autologous synvoium were 
measured using a T cell immunoblot technique, us descrihed under material and methods. Data shown arc mean 
stimulation indices of triplicate detem1inations. OA - osteoarthritis (n = 4); RA - rheumatoid arthritis (n = 6); 
JRA - juvenile rheumatoid arthritis (n = I); SLE - systemic lupus erythematosus (n = I ). 
The proliferative response to the high molecular weight component of synovium was restricted 
to cells from the synovial compartment of patients with RA, and was not found with PBMNC 
from the same patients or 3 normal donors (Fig 6.5) . Similarly, PBMNC from patients with 
other arthritides did not proliferate in response to the synovial constituents . A single RA patient 
displayed a significant PBMNC proliferative response to a low molecular weight synovial 
component (26-32 kDa) . In addition, there was no detectable response of a synovial T cell line 
from a patient with osteoarthritis to the stimulatory fraction of synovium from 2 patients with 
RA (SI< 1.2; L\cpm < 1100 for each fraction tested) . 
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FIGURE 5 
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*Peripheral blood mononuclear cell (PBMNC) proliferation in response to autologous synovial constituents was 
detennined as for synovial T cell lines indicated in Fig._ 4. NORM - 4 healthy nonnal individuals tested against 
rheumatoid synovial membrane. 
4. The stimulatory fraction of synovium includes extracellular matrix proteins 
Fibronectin and collagen (types I, II and III) are extracellular matrix proteins present m 
significant quantities in the synovial compartment30,31 . Both proteins are large complex 
molecules (fibronectin 440 kDa, collagens approx 300 kDa) that may be degraded within the 
joint by the action of a variety of enzymes or dissociated by reducing SDS-PAGE32. Type I and 
type II collagen were separated by SDS-P AGE under reducing conditions and in parallel with 
samples of RA and OA synovium. Collagen (both type I and II) separated into three bands (rf: 
0.1, 0.218 and 0.233); two of these bands corresponded with protein bands present in OA and 
RA synovium under the same experimental conditions (rf O. l and 0.218), one of which was 
found in the stimulatory fraction of synovium (rf0 .218) (Figure 6.6a). 
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FIGURE 6.6 
(a) Separation of RA and OA synovial membrane and collagen by SDS-PAGE 
(b) Detection of collagen andfibronectin in rheumatoid synovium by western blolting. 
(a) (b) 







L1 L2 LJ L4 LS L1 L2 LJ 
(a) Lane 1: molecular weight standards; Lane 2: OA synovimn; Lane 3: RA S)11ovium; 
Lane 4: RA synovium; Lane 5: Type I human collagen 
Arrows in lane 5 indicate: (i) faint band approximately 300k.Da (rf 0.1) [collagen!; (ii ) 2 prominent bands (rf 
0.218 and 0.233) [collagen]; the prominent band of collagen with an rr of0 .218 corresponds with a band present 
in the stimulatory fraction of synovium (lane 4 ). 
(b) Western blotting of synovium was pcrfonned using the tissue sho\\11 in (a) Jane 4 
Lane 1: Mouse monoclonal antibody (anti- human type ill collagen); non-r..:ducing conditions; 
Lane 2: Mouse monoclonal antibody (CJ2 - anti-human fibroncctin); non-reducing condi tions; 
Lane 3: Rabbit polyclonal antibody (anti-human tibronectin); non-reducing condit ions. 
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The presence of collagen in synovial membrane was confirmed by western blotting using a 
mouse monoclonal antibody specific for human type III collagen (Figure 6.6b, lane 1). 
According to the manufacturer's specifications, this antibody may cross-react with type I or 
type II collagen, but this was not confirmed in the current study. Under non-reducing 
conditions, two bands in the high molecular weight range (300kDa) were detected in a san1ple 
of rheumatoid synovium, and correspond to the high molecular weight band obtained when type 
I collagen was subject to SDS-PAGE under reducing conditions (Figure 6.6a, lane 5). When 
electrophoresis of rheumatoid synovium was performed under reducing conditions, western 
blotting with the mouse anti-human collagen type III antibody did not detect the presence of 
collagen. Using monoclonal and polyclonal antibodies to fibronectin, degradation products of 
fibronectin were also detected in rheumatoid synovium (Fig 6.6b, lanes 2 and 3), under the 
same experimental conditions as for the detection of collagen. Two bands detected by the anti-
fibronectin monoclonal antibody and one detected by the polyclonal antibody were in the same 
molecular weight range as the stimulatory synovial fragment {114-142 kDa) (Fig 6.6b, lanes 2 
and 3). 
5. Cross-reactivity between the synovial stimulatory fraction and nitrocellulose-bound 
type I human collagen of similar molecular weight. 
Human type I and bovine type II collagen were separated by gradient SDS-PAGE and 
transferred to nitrocellulose as described above. Lanes of nitrocellulose were fractionated into 
2mm bands and dissolved and precipitated as for the preparation of synovial membrane. 
Fractions were pooled (5 per test) and their effects on the proliferation of a T cell line from 
rheumatoid synovium examined as detailed above. Pooled fractions of nitrocellulose-bound 
type I collagen corresponding to the molecular weight range of the stinmlatory synovial fraction 
caused a low but definite proliferative response of the T cell line but not autologous PBMNC 
{L'l cpm 6520)(Figure 7) . There were no proliferative responses to fractions of bovine type II 
collagen prepared in a similar manner. This finding was confirmed on repeat testing with the 
same T cell line, but was not observed using T cell lines from an additional two RA patients 
who demonstrated proliferative responses to autologous synovium, and in two OA patients. 
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FIGURE 6.7 
Cross-reactivity between nitrocellulose-bound synovial stimulatory fraction and 
nitrocellulose-bound type I collagen of similar molecular weight range# 
. ffil PBMNC 
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# Human type I and bovine type Il collagens were subject to electrophoretic separation and transferred to 
nitrocellulose, as described for the synovium. Proliferative response of a T cell line from rhemnatoid synovium to 
fractions of collagen and autologous synovium were assayed. Data shown are mean stimulation indices of 
triplicate determinations. SYN #3 - third pooled synovial fraction 114-142 kDa; Type (n) #(n) - collagen type(n) 
pooled nitrocellulose fraction (n). Fraction #1 - 175-217kDa, fraction #2 - 142-175kDa, fraction #3 - I 14-
142kDa. 
* Stimulation index> 2.5 
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DISCUSSION 
It has previously been suggested that the synovial compartment in RA represents a special 
environment that either induces or maintains a degree of T cell activation20 . In the current 
study, the sustained outgrowth of T cells from rheumatoid synovial explants, cultured in the 
presence of exogenous recombinant IL2 but without the addition of other T cell stimuli, 
provides additional evidence that the rheumatoid synovial membrane may contain a co-
stimulatory factor for T cell proliferation. 
With the use of the T cell immunoblot technique, a compartmentalised T cell proliferative 
response to a component of autologous synovium in the molecular weight range l 14-142kDa 
was found in 5 out of 6 patients with RA but not in patients with other arthritides . The 
comparatively low levels of proliferation in response to this synovial constituent may be a 
result of the technique used, suboptimal concentration of the stimulatory fraction in the 
nitrocellulose preparation, or the due to the nature of the stimulatory constituent27. 
Nevertheless, the observation of a proliferative response to a component of autologous 
synovium in the absence of costimulatory factors may provide insight into the source of the T 
cell stimulus in rheumatoid synovial membrane. The limitation of the proliferative response to 
autologous T cells from the site of pathology in RA indicates a degree of specificity of the 
finding. Thus the observed proliferation may have been an antigen-specific response with 
compartmentalisation of the specific antigen-reactive T cells to the site of pathology, as has 
been demonstrated in a T cell dependent disease of known aetiology34. Furthermore, the 
restriction of the finding to rheumatoid synovium may imply that the antigenic stimulus or the 
specific antigen-reactive T cells are not present in the synovium of patients with other 
arthritides; the observation that a T cell line from osteoarthritic synovium did not proliferate to 
the stimulatory fraction of rheumatoid synovium supports the latter hypothesis . 
It is, however, also possible that the proliferation of rheumatoid synovial T cell lines in 
response to a fraction of autologous synovium may be due to the interaction of a certain subset 
of CD4 T cells enriched in the rheumatoid joint and a non-specific stimulus. In particular, 
up regulated cell suface expression of integrins in synovial lymphocytes of patients with arthritis 
has previously been described, and may increase non MHC-restricted proliferative responses to 
ex1racellular matrix proteins35,36 . Evidence in support of this hypothesis in the current study 
includes the demonstration that the stimulatory fraction of synovium incorporates components 
of collagen and fibronectin . Both these extracellular matrix proteins contain RGD peptide 
sequences that bind integrins on the CD4 T cell surface, independent of MHC interactions, and 
augment several T cell functions including proliferation, cytokine production, release of 
proteases by cytotoxic T cells, IL2 receptor expression and cell rnigratio1137,38,36,39,40,4J ,42 . A 
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120 kDa fragment of fibronectin that may be cleaved from the parent molecule by the action of 
several proteases previously identified in the rheumatoid joint, contains the cell attachment site 
for neutrophils and is a chemoattractant for T cells expressing the a5p l integrin that are 
enriched within the rheumatoid synovial compartment43,4 l ,35. 
The potential role of collagen as the T cell stimulus in rheumatoid joints is somewhat 
controversial, as discussed earlier (Chl pg. 16). In the current study, low levels of proliferation 
of a rheumatoid synvoial T cell line in response to human type I but not bovine type II collagen 
in the same molecular weight range as the stimulatory fraction of synovium was observed. With 
the use of the T cell immunoblot technique, it is unlikely that this proliferative response was 
due to contaminants. The lack of proliferation to bovine type II collagen may be due to species-
specific differences, although the collagens are generally conserved proteins32 . Alternatively the 
finding may reflect differences in tissue expression of collagen subtypes; type I collagen being 
predominantly a product of synovium and type II collagen essentially chondrocyte-derived32 . 
The lack of proliferation to nitrocellulose-bound collagen ( either type I or II) of the additional 2 
rheumatoid synovial T cells lines tested indicates that collagen reactivity in this model is not 
universal in RA and that the observed proliferation to a constituent of synovium of similar 
molecular weight range cannot generally be attributed to a collagen-induced response. 
Synovial T cell reactivity to foreign antigens in RA has been discussed earlier (Ch5 pg. 126). 
Significant proliferative responses of the synovial explant-derived T cell lines to PPD and SK-
SD were limited to 3 patients with arthritis of diverse aetiology in the current study and 
emphasize the non-specific nature of these responses . In addition there was no evidence of 
compartmentalisation of the responses and none of the patients demonstrated significant 
reactivity to recombinant HSP65 of Mycobacterium bovis . The finding of proliferation to recall 
antigens in the T cell lines from three patients does, however, indicate that cell lines generated 
using the synovial explant culture technique are capable of antigen-specific responses and are 
not anergic44 . 
As indicated in the preceeding discussion, further characterisation of the T cell stimulus 
contained within the stimulatory fraction of synovium is required. The experimental approach 
to this further characterisation may include the isolation of a soluble product of narrower 
molecular weight range from rheumatoid synovium and the use of synovial T cell clones to 
improve specificity. Use of a soluble form of synovial stimulatory factor will overcome several 
of the limitations of the nitrocellulose-bound product, including the need for a phagocytic feeder 
cell population and the inherent difficulties associated with particle suspensions in lymphocyte 
proliferation assays27 . Determining the mode of T cell stimulus will require MHC blockade or 
substitution experiments to investigate whether the effect is class II restricted, and RGD 
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peptide inhibition assays to demonstrate integrin-mediated effects28,45 . Precise characterisation 
of the stimulatory protein may be performed by sequence analysis techniques46. This study thus 
provides the rationale for the further investigation of synovial constituents and their effects on 
T cell function in RA, with implications for the understanding of the pathogenesis of the disease 
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Chapter 7 T-cell cloning 
INTRODUCTION 
A T cell clone is defined as a population of T cells arising from a single precursor cell .1 
Techniques for the in vitro generation of human T cell clones have been established for more 
than ten years. In addition to having potential clinical application, human T cell cloning permits 
the investigation of monoclonal human T cell populations in vitro2, 3. Such in vitro studies of 
cloned human T cells have several advantages over studies of 'bulk' mononuclear cell 
populations or polyclonal T cell lines, including (i) the precise definition of antigen reactivity, 
specific epitope mapping and HLA restriction, (ii) the determination of cytokine profiles, (iii) 
modulation of specific cell functions with minimal confounding variables introduced by other 
cell populations, (iv) investigation of phenotypic expression in response to antigenic stimuli, ( v) 
specific delineation of intracellular signalling pathways and cellular regulation, and (vi) 
defining mechanisms of effector functions, including cytotoxicity4,5,6,7,8. As a T cell clone 
constitutes a uniform population of cells, these studies can be performed repeatedly, permitting 
greater reproducibility of results . 
A variety of methods have been used to generate T cell clones, including growth of colonies 
from cells plated in soft agar, micro-manipulation or limiting dilution techniques9, 10 . The latter 
method is probably most widely applied at present and permits the estimation of clonality by 
application of Poisson statistics1. When required, precise definition of clonality of a T cell 
population may be achieved by analysis of T cell receptor VP gene expression II . All cloning 
techniques have limitations and will , to an extent, bias the selection of cells obtained. Cloning 
strategies using the limiting dilution method may involve stimulation with an antigen to obtain 
specific antigen-reactive clones, or the use of a non-specific stimulus to obtain a panel of 
individual clones that reflects, as closely as possible, the constituents of the original 'bulk' 
population. In the present studies, limiting dilution cloning was undertaken using both selective 
and non-specific stimuli . Cloning of cells from the synovium of patients with inflammatory 
synovitis and the circulation of a normal control was performed. As detailed in previous 
chapters, investigation using these clones included phenotypic and functional analyses, 
examination of the effects of eicosanoids and other agents, and a study of the kinetics of 
activation marker expression and effector functions following antigenic stimulation. 
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GENERATION OFT CELL CLONES 
1. Patients and controls 
Limiting dilution cloning was performed using T cell lines generated from synovial explants of 
3 patients with inflammatory synovitis of diverse aetiologies, and from the peripheral blood of a 
normal healthy control. Details of the patients and control have been provided previously, and 
are included below in table 7.I for completeness. 
Table 7.1 
Patients and control used as sources of CD4 + T cells for cloning. 
PATIENT DIAGNOSIS AGE SEX CELL SOURCE 
AP RA (sero positive) 52 F Synovium: arthroplasty 
left knee 
vs Post traumatic 37 M Synovium: arthroplasty 
inflammatory OA right knee 
TS Gout 37 M Synovium: arthroscopic 
biopsy right knee 
PL Nom1al control 38 F Venous blood 
2. Generation of T cell lines 
Synovial explant-derived T cell lines were obtained as described in chapter 6. Briefly, 
fragments of recently-obtained tissue (2-3mm3) were cultured in complete tissue culture 
medium supplemented with rIL2 (lOOiu/ml)(Cetus), in 24 well tissue culture plates (Greiner). 
Early passage mononuclear cells growing out of the explants were harvested by vigorous 
resuspension and used either for cloning immediately (patients VS and AP) or to generate 
antigen-specific T cell lines which were subsequently cloned (patient TS - gouty synovitis) . 
These procedures are summarised in table 7.11. Mononuclear cells were harvested from 
synovial explants of patient TS after 48h growth in the presence of rIL2 ( l OOiu/ml), and 
stimulated in 24 well plates (2 .5 x 105 cells per well) with irradiated (4000rads) autologous 
PBMNC (1.25 x 105 per well) and one of the following antigens : PPD (Central Veterinary 
Laboratory - final concentration 3µg/ml) , streptokinase-streptodomase (SK-SD, Lederle - 1:40 
dilution), or recombinant HSP65 of Mycobacterium bovis (provided by Dr JDA van Embden -
final concentration 5µg/ml) . Cultures were fed with fresh medium containing rIL2 (lOOiu/mJ) 
after 3-4 days and cells harvested at day 5 for limiting dilution cloning. 
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PBMNC were separated from huffy layer cells of a venous blood sample from the normal 
control by density centrifugation. Antigen-stimulated T cell lines were generated prior to 
cloning by culturing PBMNC (5 x l 06 cells at l 06/ml in complete medium) with either PPD 
(Central Veterinary Laboratory - final concentration 3µg/ml) or tetanus toxoid (Lederle 
Laborotories, American Cyanamid Co, Pearl River, NJ ; 1 :40 dilution) in 25cm2 tissue culture 
flasks (Becton Dickinson Labware, Lincon Park, NJ) for 7 days . Cells were then fed with fresh 
medium and rIL2 (final concentration 1 OOiu/ml) and cloned in limiting dilution after 4 days . 
Table 7.11 
Summary of cloning strategies 
Patient Cell Source IL2-dependent Antigen-stimulated Stimulus used in 
T-cell lines T-cell lines limiting dilution cloning 
AP synovial yes no PHA 
explant 
vs synovial yes no PHA 
explant 
TS synovial yes PPD, SK-SD, PPD, SK-SD, 
explant HSP65 HSP65 
PL venous no PPD, Tettox PPD, Tettox 
blood 
PHA - phytohaemagglutinin; PPD - purified protein derivative of Myocbacterium tuberculosis; SK-SD -
streptokinase-streptodomase; HSP65 - recombinant 65kDa heat shock protein of Mycobacterium bovis; Tettox -
tetanus toxoid. 
3. Limiting dilution cloning 
Limiting dilution cloning of T cell lines detailed above was performed as previously 
described12 . Cells to be cloned were washed in PBS and resuspended at 106;rn1 in fresh culture 
medium containing RPM! 1640 supplemented with l 0% autologous serum, 2-mercapto-ethanol 
(BDH Chemicals, Poole, England; final concentration 5 x 10-5M), non-essential amino acids 
(Highveld Biologicals, Johannesburg, South Africa; final concentration I OmM), 1-glutamine 
(Highveld Biologicals; final concentration 2mM), sodium pyruvate (Highveld Biologicals; final 
concentration lmM) and antibiotics (lOOU/ml of penicillin, lOOµg/rnl of streptomycin) (cloning 
medium) . Cells were re-counted at this concentration and serially diluted as required . Cloning 
was performed in Terasaki plates and responder cells seeded in the range 100, 50, 10, l , 0.5 
and 0.3 cells per well. Feeder cells used were autologous irradiated (4000 rads) PBMNC 
(104/Terasaki well) . Cells were stimulated with rIL2 and either rnitogen (PHA) or antigens 
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(PPD, SK-SD, HSP65 or tetanus toxoid) at optimal concentrations, as indicated above, in a 
final volume of 20µ1. Plates were incubated at 37°C in a humidified 5% CO2 atmosphere; given 
the small volumes of the Terasaki wells, care was taken to ensure accurate temperature and 
humidity control to avoid evaporation. A single row of feeder cells without responders was 
used to provide a negative control for screening of cell growth. Cell growth was determined by 
visual inspection using an inverted microscope after 7-10 days . Wells were scored as positive 
if greater than one third of the well surface was occupied by cells . 
Cloning efficiency has been defined as the proportion of seeded cells that give rise to a growing 
clone13 . Several factors contribute to the final cloning efficiency, including culture conditions 
(plating efficiency) and the precursor frequency of cells in the 'bulk' population capable of 
responding to the particular stimulus . As indicated in table 7.111, cloning efficiency was 
generally low in the current study; in the case of mitogen-stimulated cultures, this may reflect 
suboptimal culture conditions or inadequacies of the responder cells 13 . The low proportion of 
positive wells obtained when antigenic stimuli were used in the cloning of cells from gout 
synovium may be an indication of the low precursor frequency of these cells in the parent T cell 
lines, in addition to other factors . 
Limiting dilution cloning permits estimation of clonality according to the zero term of the 
Poisson distribution, F O = e-u, where F O is the fraction of negative cultures per total number of 
cultures, e the base of the natural logarithm and u the average number of precursor cells per 
culture6 . As clonality is defined as the growth of cells from a single precursor, u = l ; for u = 1, 
F0 = e-1 = 0.37. Thus clonality is likely (95% probability) when > 37% negative wells are 
obtained (see Table 7 .111), although this assumption may be compromised in settings of low 
plating efficiency1. 
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Table 7.111 
Limiting dilution cloning of T cells from synovium and circulation 
CELL SOURCE CLONING: STIMULUS Positive wells/ % Negative Cloning 
Cells/well total wells wells Efficiencyt 
AP 100 PHA 108/108 o* 100% 
(RA synovium) 50 PHA 108/108 o* 100% 
10 PHA 300/354 15 .3* 85% 
0.5 PHA 49/474 89.7t 20.7% 
vs 10 PHA 70/108 35* 64.8% 
(OA s_ynovium) 1 PHA 8/108 92 .5t 7.4% 
TS 10 PPD 7/108 93 .5t 6.5% 
(Gout synovium) 1 PPD 0/216 100 0% 
0.3 PPD 0/324 100 0% 
10 SK-SD 3/108 97 .2t 2.8% 
l SK-SD 0/216 100 0% 
0.3 SK-SD 0/324 100 0% 
10 HSP65 9/108 91.7t 8.3% 
l HSP65 0/216 100 0% 
0.3 HSP65 0/324 100 0% 
PL 10 PPD 45/600 92.5t 7.5% 
(Normal PBMNC) 10 Tettox 63/600 89.5t 10 .5% 
* As the probability of clonality is extremely low in these cultures, the tem1 culture efficiency may be more 
appropriate than cloning efficiency 
t Positive wells are likely to be monoclonal according to Poisson statistics 
t May be affected by minor errors in cell counting, due to the amplification effect of repeated dilutions; assumes 
'single hit' model even when> 1 cell per well was plated 
PHA - phytohaemagglutinin; PPD - purified protein derivative of Mycobacterium tuberculosis; SK-SD -
streptokinase-streptodomase; HSP65 - recombinant 65kDa heat shock protein of Mycobacterium bovis; Tettox -
tetanus toxoid. 
EXPANSION AND MAINTENANCE OF CLONES 
Growing cells were 'picked' when greater than 50% of the well surface was occupied by cells 
(usually between 7-12 days after cloning) using a 20µ1 rnicrotitre pipette and transferred to u-
bottomed 96-well microtitre plates . Re-stimulation was performed using irradiated autologous 
PBMNC as feeder cells (5 x 104 /well), rIL2 (lOOiu/ml) and antigen or mitogen at optimal 
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concentrations, in a final volume of 200µ1 of cloning medium. Autologous PBMNC were 
employed as the optimal source of feeder cells throughout these studies as preliminary 
experience with Epstein-Barr virus transformed lymphoblastoid cell lines (LCL) indicated 
inadequate function of these cells in soluble antigen-induced proliferation of T cell lines and 
clones (data not shown) . Growing cultures were fed by replacing 100µ1 of medium with fresh 
cloning medium containing rIL2 (lOOiu/ml) at day 3-4 following transfer and cells were 
resuspended regularly to avoid the formation of large clumps. At day 7 following transfer, cells 
were counted, seeded into new 96 well microtitre plates (I o5 /well) and re-stimulated with 
feeders and antigen or mitogen as indicated above. 
As the objective at this stage of culture was to obtain maximal cell numbers within relatively 
few passages, cultures were divided when confluent or near confluent, fed every 3-4 days as 
detailed above, and transferred to 24 well tissue culture plates, usually by the end of the second 
passage in rnicrotitre wells . Approximately 2.5 x 105 cells were seeded in each well of the 24 
well plate and stimulated with irradiated autologous PBMNC (105 per well), antigen or 
mitogen and rIL2, at concentrations indicated previously, in a final volume of 1ml. Cultures 
were resuspended regularly, fed every 3-4 days and passaged weekly . Once sufficient cells had 
been obtained, aliquots of clones were cryopreserved and the remainder of cells analysed as 
indicated below, or expanded further. Using these techniques, sufficient quantities of each clone 
(20 - 30 x l 06) were usually obtained within 4-6 weeks of cloning; additionally, it was possible 
to perform repeated functional studies on individual clones, previously cryopreserved at early 
passage, for over 2 years after initial cloning. 
CHARACTERISATION OF CLONES 
1. Phenotypic analysis 
Phenotypic analysis of the clones obtained was performed by flow cytometry, as described 
earlier (chapter 3 pg. 83) . As the objective of these studies was the investigation of CD4+ T 
cells, clones were initially screened for CD4 expression, and CD4 negative cultures, with one 
exception, excluded from further analyses . Only four CD4 negative cultures in total were 
identified (3 from patient AP (RA) and one from patient TS (gout)) . 
2. Proliferation 
T cell clones were screened for proliferative responses to rnitogen (PHA), a range of antigens 
(PHA, PPD, SK-SD, HSP65 and tetanus toxoid) and rIL2 . Assays were performed at least 3 
days after the clone had been fed with fresh rIL2 and 7 days after re-stimulation with feeders 
and antigen . All proliferation assays were perfom1ed in triplicate in u-bottomed microtitre wells 
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in cloning medium. Clones (5xl04/well) were stimulated by antigen or mitogen at optimal 
concentration in the presence of 2.5 x 104 irradiated autologous PBMNC but in the absence of 
rIL2 . Incorporation of 3tt thymidine (2µCi/well) (Amersham International) was measured 
over the last 8 hours of the 48h incubation. Wells with feeders and clone but no 
antigen/mitogen served as background controls; 3tt thymidine incorporation of feeders in the 
presence of antigen/mitogen but in the absence of the clones, was also determined to ensure 
effectiveness of the irradiating procedure. Results were expressed as either stimulation index 
(SI) (where SI = mean counts per minute in stimulated wells/mean counts per minute in 
background wells) or ficpm (mean counts per minute in stimulated wells - mean counts per 
minute in background wells). Data obtained from these assays are provided in chapter 5. 
3. Cytotoxicity 
Cytotoxic function of a selection of the clones was determined in a standard 15 h 51 CR release 
assay, as detailed in previous chapters . Both antigen-specific and lectin-dependent cytotoxic 
functions were investigated. Assays were performed in triplicate and usually at multiple 
effector to target ratios . Clones were used as effectors at day 2 or 3 following re-stimulation 
with feeders , antigen and rIL2, although similar levels of cytotoxocity at other time intervals 
after restimulation were demonstrated (chapter 4 pg. 105). Cytotoxicity assays were performed 
in complete medium, without the addition of rIL2 . Data obtained from these assays are 
provided in chapters 3,4 and 5. 
4. Cytokine production 
Cytokine profiles of a selection of the clones were determined as described in chapter 3. As for 
the proliferation assays, cytokine production of a clone was assayed at least 3 days following 
feeding the clone with fresh rIL2 and 7 days after re-stimulation with feeders and 
antigen/mitogen. Cytokine production in response to specific (antigen and autologous irradiated 
PBMNC) and non-specific stimuli (mitogen and autologous irradiated PBMNC or plastic 
adherent anti-CD3 and rIL2) were investigated. Where irradiated PBMNC were employed, 
background cytokine production by these cells alone, in the presence of the mitogenic or 
antigenic stimulus, was also determined. Cell supematants were harvested after 48h incubation, 
confirmed in the kinetics studies (chapter 4) as the optimal incubation period. Cytokine 
concentrations in the cell supematants was assayed using commercial kits , as described in 
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The studies described in the preceeding chapters were undertaken to address several aspects of 
the role of CD4+ T-cells in the immunopathogenesis of RA and identify potential novel 
therapeutic targets . In meeting the objectives of the study (as tabulated in chapter l ), the data 
obtained provide insight into potential pathogenetic mechanisms of RA that may have 
therapeutic relevance. 
2. Novelty of the approach 
The approach adopted in the studies was innovative in the following respects : (i) antigen-
induced proliferation and antigen-specific cytotoxicity of mononuclear cells from the synovial 
fluid and circulation of patients with RA and other arthritides were examined in parallel, 
permitting comparison of functions between cells from either compartment, and correlation 
with clinical parameters, (ii) antigen-specific cytotoxicity of mononuclear cells in the patient-
based studies was determined using short-term cell lines stimulated with antigen alone; an 
isolated previous report of antigen-specific T-cell mediated cytotoxicity in RA was based on 
IL-2 dependent lines and clones from the synovial compartment and did not include clinical 
correlations1, (iii) the in vitro effects of leukotrienes and prostanoids on CD4+ T-cell mediated 
cytotoxicity (either murine or human) have not previously been reported and neither have there 
been reports of the effects of leukotrienes on cytokine secretion by human CD4+ T-cell clones, 
(iv) the dissociation between proliferation/cytokine production and cytotoxicity of human 
CD4+ T-cell clones has not previously been demonstrated; in addition, the approach to defining 
the cellular regulation of these functions following a single inciting stimulus has not previously 
been adopted, (v) the investigation of mycobacterial antigen-reactivity of mononuclear cells 
from the site of pathology in RA and other arthritides was performed with patients drawn from 
a population where tuberculosis is endemic, and included a novel investigation of the kinetics of 
responses, and (vi) the studies of synovial T-cell reactivity to autologous synovial constituents 
used a novel application of the T-cell immunoblot technique and tissue explant culture 
techniques. 
3. Salient findings 
In the patient-based study reported in chapter 2, a positive linear relationship between PPD-
induced proliferation and PPD-specific cytotoxicity was confirmed in peripheral blood 
mononuclear cells (PBMNC) and synovial fluid mononuclear cells (SFMNC) of 20 patients 
with seropositive RA. Three subsets of RA patients were classified according to their SFMNC 
proliferative and cytotoxic responses to PPD. This distinction, based on SFMNC function, 
correlated with disease duration and therapy. Low or absent SFMNC proliferative and 
cytotoxic responses were associated with significantly longer disease duration. In patients with 
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shorter disease duration, moderate to high levels of both proliferation and cytotox.icity were 
associated with NSAID monotherapy. Intact proliferation but impaired PPD specific 
cytotoxic1ty was a feature of SFMNC from 5 out of 6 patients rece1vmg DMARDs and 
supplemental NSAID therapy. The potential mechanisms for these findings were explored. 
Dissociation of proliferation and cytotoxicity in normal PBMNC was not an in vitro effect of 
the DMARDs tested, but was suggested to be an effect of PGE2. Thus it was postulated that 
the specific impairment of SFMNC cytotoxicity despite intact proliferative responses may have 
been due to higher production of PGE2 by cells from the synovial compartment in patients 
receiving DMARDs and supplemental NSAID therapy, compared to patients receiving NSAID 
monotherapy. Support for this hypothesis was provided by (i) confirmation of higher PGE2 
production by CD 14+ synoviocytes from patients receiving DMARDs, and (ii) demonstration 
that the suppressive effects of synovial CD 14+ cell supematants on the cytotoxic function of a 
CD4+ T-cell clone may be abrogated by the generation of the supematants in the presence of 
the cycloxygenase inhibitor, indomethacin. Given the relatively small numbers of patients, 
conclusions about these data remain guarded and may require confirmation in a larger series . 
The mechanism of PGE2 inhibition of CD4+ T-cell cytotoxicity and the effects of this agent 
and other eicosanoids on CD4+ T-cell effector functions and phenotypic expression were 
examined (chapter 3). Studies were performed in vitro using PBMNC from normals and panels 
of clones generated from the synovium of patients with inflammatory synovitis and the 
circulation of a healthy control. PGE2 inhibition of antigen-specific cytotoxicity was 
demonstrated in bulk PBMNC effectors and in the clones. Misoprostol (PGEl analogue) and 
forskolin (cAMP agonist) displayed similar inhibitory effects on the clones, although the 
suppression mediated by misoprostol was directly dose-dependent. Inhibition of both binding 
and post-binding events by PGE2 was indicated by data from lectin-dependent and antigen-
specific cytotox.icity assays . Long-term culture of a clone in the presence of PGE2 did not 
inhibit the maintenance of cytolytic potential, as demonstrated in the lectin-dependent 
cytotoxicity assay, but suppressed antigen-specific cytotox.icity. Moderate but significant 
augmentation of cytotox.icity by LTB4 and L TC4 was demonstrated in the clones, although the 
effects of L TB4 were not titratable. Modulation of CD4+ T-cell cytotoxicity by the eicosanoids 
tested was mainly due to effects on calcium-dependent pathways of cytotoxicity. Reciprocal 
effects of PGE2 and leukotrienes on IFNy production by the clones was also found . 
In chapter 2, a positive linear relationship between antigen-induced proliferation and antigen-
specific cytotoxicity was demonstrated in bulk PBMNC and SFMNC. However, dissociation in 
these functions (proliferation in the absence of cytotox.icity) was observed in the SFMNC of a 
subset of patients and also shown to be an effect of PGE2 on normal PBMNC responses . These 
findings suggested that proliferation and cytotoxicity of CD4+ T-cells may be independently 
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regulated. This hypothesis was tested by measuring a range of morphologic, phenotypic and 
functional parameters of a panel of CD4+ T-cell clones as a function of time following a single 
initiating stimulus (chapter 4) . Dissociation of functions was noted, with maintenance of 
cytolytic potential independently of other parameters . Thus these findings provide evidence, at a 
clonal level, of the separate regulation and different kinetics of cytotoxicity in CD4+ T cells 
and that post activated CD4+ T-cells retain cytolytic potential irrespective of their size, 
activation status, cell cycle position or cytokine production. 
Previous reports have suggested that mycobacterial antigen reactivity of SFMNC in RA may 
have aetiological significance. In the current study, PBMNC and SFMNC proliferative and 
cytotoxic responses to PPD were indeed found in a subset of patients with RA, but also 
demonstrated in SFMNC and CD4+ T-cell clones from patients with non-rheumatoid 
inflammatory synovitis (chapter 5) . Studies of the kinetics of PPD induced proliferation in 
SFMNC and PBMNC from RA and control patients yielded similar results, supporting the 
contention that PPD reactivity in RA reflects the non-specific nature of the synovial T-cell 
inflitrate. In addition, the frequency of PBMNC reactivity to HSP65 of Mycobacterium bovis 
in PPD-responsive RA patients was significantly lower than that found in PPD-responsive 
healthy controls . Specific localisation of HSP65 reactive T-cells at the site of acute synovial 
inflammation was found in a patient with gout. 
Proliferation of synovial T-cell lines in response to a high molecular-weight component of 
autologous synovial membrane was found in patients with RA but not other arthritides ( chapter 
6) . The stimulatory fraction of synovium was shown to contain components of extracellular 
matrix proteins, including collagen and fibronectin . 
4. Immunopathogenetic relevance of this study 
The present paradigm of CD4+ T-cells in the immunopathogenesis of RA has focussed on the 
'helper' function of these cells, mediated by their release of cytokines2,3,4. However, the role of 
CD4+ T cells in the pathogenesis of the disease has been disputed, due to the paucity of T-cell 
derived cytokines in the rheumatoid synovial compartment and evidence suggesting that these 
cells are not activated, not progressing through the cell cycle, and small in sizes . Data from this 
study have highlighted the cytotoxic potential of rheumatoid synovial CD4+ T cells . In 
addition, investigation of the in vitro regulation of these cells indicated that small, post 
activated CD4+ T-cells retain maximal cytotoxic potential, independently of cytokine 
production and cell cycle progression. Taken together, these findings suggest that CD4+ T-cell 
mediated cytotoxicity (including target cell lysis and apoptosis) may be involved in the 
pathogenesis of RA. 
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The reciprocal modulation of CD4+ T-cell effector functions by prostanoids and leukotrienes 
B4 and C4 demonstrated in this study highlights a potential regulatory network between 
macrophage-lineage cells and CD4+ T-cells in the rheumatoid synovial compartment, and 
indeed between CD4+ T-cells and other cellular sources of eicosanoids . Although prostanoids 
are generally viewed as deleterious in RA, data from this study indicates the need for 
reappraisal of their function in the pathogenesis of RA. PGE2 may play an important role in 
the inhibition of cytotoxic effector function of CD4+ memory T-cells sequestered at a chronic 
inflammatory site. In addition, prostanoid inhibition of IFNy production by CD4+ T-cells, as 
shown in this study, may also be of benefit in the rheumatoid synovial compartment. 
Conversely, the immune stimulatory properties of LTB4 and LTC4 demonstrated in the current 
study support a role for these products of lipoxygenase metabolism in promoting the immuno-
inflammatory cascade in RA. 
Data from this study do not support a role for mycobacterial infection in the aetiopathogenesis 
of RA. The finding of a lower frequency of HSP65 reactivity among PPD-reactive RA patients 
compared to PPD-reactive healthy controls may be indicative of a failed regulatory T-cell 
response in the patients that may have contributed to the persistent local immune response. The 
sustained outgrowth of CD4+ T-cells from rheumatoid synovial explants and the demonstration 
of T-cell reactivity to a component of autologous synvoium supports the previous suggestion 
that the synovial compartment in RA represents a special environment that either induces or 
maintains a degree of T cell activation . 
5. Prospects for immunotherapy 
Given the potential role of CD4+ T-cells in the pathogenesis of RA, modulation of CD4+ T cell 
function has been a major objective of immunotherapeutic regimens to date6,7 . This study 
indicates the potential for modulation of CD4+ T-cell functions (including cytokine production 
and cytotoxicity) at the site of pathology in RA by therapeutic manipulation of local eicosanoid 
concentrations. Thus specific inhibition of 5 lipoxygenase metabolism, or L TB4/LTC4 
antagonism, in the rheumatoid synovial compartment may reduce the stimulatory effects of 
these eicosanoids on CD4+ T-cell functions . As reviewed in chapter 1, reduction in the 
leukotriene stimulus of cells of other lineage in the synovial compartment (including 
macrophage production of TNFa) may also be beneficial in RA. The in vitro 
immunosuppressive properties of prostanoids and the association of NSAID monotherapy with 
high levels of SFMNC cytotoxicity in patients with RA demonstrated in this study both suggest 
that cycloxygenase inhibition as the sole form of therapy in RA may remove the potentially 
protective effects of local prostanoids in the synovial compartment. In addition, the 
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immunosuppressive properties of the PGEl analogue misoprostol demonstrated in this study 
indicate its therapeutic potential in RA. 
The dissociation of CD4+ T-cell functions demonstrated in both bulk and clonal populations in 
the current study indicate the potential for selective modulation of effector mechanisms in these 
cells. Thus it may be possible to inhibit CD4+ T-cell mediated cytotox.icity independently of 
effects on cytokine production and thereby increase the specificity of the immunosuppression. 
Further elucidation of the nature of the high molecular-weight T-cell stimulus identified in the 
synovium of patients with RA may have therapeutic potential. Identification of a specific 
antigen within this synovial fraction may permit the therapeutic targeting of individual T-cell 
populations in RA. Alternatively, as suggested by the current study, confirmation that the 
stimulus is due to T-cell binding to components of extracellular matrix proteins may indicate 
the therapeutic potential of inhibiting such processes in RA. 
6. Future research 
The findings of the current study provide the rationale for further research incorporating in 
vitro and in vivo models, and perhaps early phase clinical trials . These studies include: 
(i) investigation of the potential contribution of CD4+ T-cell mediated cytotoxicity to joint 
destruction in animal models of inflammatory arthritis; these studies may include analysis 
of cytolytic and apoptotic cell death mechanisms, 
(ii) further definition of the in vitro effects of eicosanoids on CD4+ T-cell mediated 
cytotoxicity, including the modulation of fas/fas ligand expression and intracellular 
granzyrne/perforin contained within cytotoxic granules, 
(iii) characterisation of the high molecular weight T-cell stimulatory factor m rheumatoid 
synovium, as detailed in chapter 6, 
(iv) phase I clinical trials of 5 Iipoxygenase inhibitors and specific L TB4 antagonists in the 
treatment of patients with RA, and 
(v) early phase clinical trial to investigate the potential disease-modifying properties of the 
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